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1 | INTRODUCTION
In the 20 years since the Canadian Network for Mood and Anxiety 
Treatments (CANMAT) first published guidelines on the management 
of BD (BD),1 there has been an explosion of research on treatment of 
this illness. During this time period, CANMAT has strived to translate 
advances in research into international consensus on evidence- based 
clinical management; first by publishing 2005 guidelines accompanied 
by expert commentaries, then by providing updates in 2007,2 20093 
and 20134 in collaboration with the International Society for Bipolar 
Disorders (ISBD). The main objective of these publications was to syn-
thesize the wealth of evidence on the efficacy, safety, and tolerability 
of the range of interventions available for this complex and varied ill-
ness, with the goal of providing clear, easy to use recommendations 
for clinicians to improve outcomes in their patients.
Given that 13 years have elapsed since the publication of the last 
full edition in 2005, the objective of these 2018 CANMAT and ISBD 
Bipolar Disorder Management Guidelines is to provide a compre-
hensive, up-to-date review of research evidence on the treatment 
of various phases of BD, translated into clinical recommendations 
for evidence- based management. Updated principles related to di-
agnosis and management are also included, in response to signif-
icant changes made in the 5th edition of the American Psychiatric 
Association Diagnostic and Statistical Manual for Mental Disorders 
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously pub-
lished treatment guidelines for bipolar disorder in 2005, along with international com-
mentaries and subsequent updates in 2007, 2009, and 2013. The last two updates 
were published in collaboration with the International Society for Bipolar Disorders 
(ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the 
significant advances in the field since the last full edition was published in 2005, includ-
ing updates to diagnosis and management as well as new research into pharmacologi-
cal and psychological treatments. These advances have been translated into clear and 
easy to use recommendations for first , second, and third- line treatments, with consid-
eration given to levels of evidence for efficacy, clinical support based on experience, 
and consensus ratings of safety, tolerability, and treatment- emergent switch risk. New 
to these guidelines, hierarchical rankings were created for first and second- line treat-
ments recommended for acute mania, acute depression, and maintenance treatment in 
bipolar I disorder. Created by considering the impact of each treatment across all 
phases of illness, this hierarchy will further assist clinicians in making evidence- based 
treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperi-
done, risperidone, and cariprazine alone or in combination are recommended as first- 
line treatments for acute mania. First- line options for bipolar I depression include 
quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or 
adjunctive lamotrigine. While medications that have been shown to be effective for 
the acute phase should generally be continued for the maintenance phase in bipolar I 
disorder, there are some exceptions (such as with antidepressants); and available data 
suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole 
monotherapy or combination treatments should be considered first-line for those ini-
tiating or switching treatment during the maintenance phase. In addition to addressing 
issues in bipolar I disorder, these guidelines also provide an overview of, and recom-
mendations for, clinical management of bipolar II disorder, as well as advice on specific 
populations, such as women at various stages of the reproductive cycle, children and 
adolescents, and older adults. There are also discussions on the impact of specific psy-
chiatric and medical comorbidities such as substance use, anxiety, and metabolic disor-
ders. Finally, an overview of issues related to safety and monitoring is provided. The 
CANMAT and ISBD groups hope that these guidelines become a valuable tool for prac-
titioners across the globe.
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(DSM- 5).5 With increased research into various treatments for BD, 
the evidence ratings have also been modified to increase rigor; for 
instance, minimum sample sizes are now specified for randomized 
controlled trials (RCTs) at each level of evidence (Table 1).
As with previous editions of CANMAT guidelines, clinical support 
for efficacy was an important consideration in arriving at the final 
treatment recommendations (Table 2). Major conflicting data are ad-
dressed in blue text boxes (figures) to clarify the rationale for arriving 
at a specific level of evidence for efficacy.
In the current edition, an additional distinction is made between 
safety and tolerability, and a consensus rating is assigned to each 
medication on these two measures when used in both the acute 
and maintenance phase. Further, a rating is also assigned to each 
medication for its propensity to switch patients into mania or de-
pression (treatment-emergent switch). More information on these 
ratings can be found in the respective treatment sections, as well 
as in Section 8.
The final grading of recommendations into first, second, or third- 
line considers levels of evidence for efficacy, clinical support based 
on experience, and consensus ratings of safety, tolerability, and risk 
of treatment- emergent switch. In addition, hierarchical rankings were 
created and are listed in the tables for first and second line recom-
mendations for acute mania, depression and maintenance treatment 
in bipolar I disorder (BDI). This hierarchy was created by considering 
the impact of each treatment across all phases of illness (Figure 1). 
The rationale for the hierarchical approach is that BD is a chronic 
lifetime condition with recurrent mood episodes and subsyndromal 
mood symptoms, and most if not all patients will require maintenance 
treatment. Since treatments that are prescribed for an acute mood ep-
isode are usually continued into maintenance treatment, maintenance 
efficacy should be considered when choosing acute- phase treatments. 
Treatments that have demonstrated efficacy across the spectrum 
of the illness should thus be tried first before treatments that have 
demonstrated efficacy for only selective phases of the disorder. As an 
example, if two treatments are shown to be similarly effective in acute 
mania, and if only one of these treatments has demonstrated efficacy 
for maintenance treatment, the treatment with evidence for mainte-
nance would be placed higher in the hierarchical ranking.
Of note, when a treatment is listed as a monotherapy, that implies 
that it may be used on its own or in combination with other ongoing 
treatments, even if there are no specific studies demonstrating the ef-
ficacy of that combination. In this situation, the assumption is that the 
previous ongoing treatment was partially effective, and the addition of 
the new agent will provide benefits in either an additive or synergistic 
manner. In contrast, agents specifically listed as adjunctive therapy may 
have no evidence for efficacy as monotherapy, and/or may have safety 
concerns if prescribed as monotherapy (eg. antidepressants), and are 
only recommended for use in combination with other evidence- based 
agents.
As with previous editions, these guidelines also have a “not rec-
ommended” category which includes treatments that have clearly 
been shown to be ineffective in double- blind RCTs. Further, we have 
included another category called “no specific recommendation/agents 
that require further study” to list treatments with insufficient evidence 
or clinical experience to make a recommendation, or where there is a 
reason to believe that negative trials failed because of methodologi-
cal problems-especially when the results are inconsistent with what is 
expected based on the pharmacological properties of treatment and 
clinical experience. Inclusion in this category means the efficacy of 
these agents is unknown at this time.
As in previous editions, these guidelines are organized into eight 
sections (Table 3), including the Introduction. Foundations of man-
agement (Section 2) discusses the epidemiology of BD, screening 
and diagnostic considerations, the importance of monitoring risk for 
suicide, the chronic disease management model and patient- centred 
care (including shared decision making), as well the importance of 
incorporating psychoeducation and other psychosocial treatment 
TABLE  2 Definitions for line of treatment ratings
Line Evidence level
First Level 1 or level 2 evidence for efficacy plus 
clinical support for safety/tolerability and no 
risk of treatment- emergent switcha
Second Level 3 or higher evidence for efficacy plus 
clinical support for safety/tolerability and low 
risk of treatment- emergent switcha
Third Level 4 evidence or higher for efficacy plus 
clinical support for safety/tolerability
Not recommended Level 1 evidence for lack of efficacy, or level 2 
evidence for lack of efficacy plus expert 
opinion
aThe text will specifically note when lack of clinical support for safety/ 
tolerability or risk of treatment-emergent switch has impacted 
recommendations.
TABLE  1 Definitions for level of evidence ratings
Level Evidence
1 Meta- analysis with narrow confidence interval or replicated double- blind (DB), randomized controlled trial (RCT) that 
includes	a	placebo	or	active	control	comparison	(n	≥	30	in	each	active	treatment	arm)
2 Meta- analysis with wide confidence interval or one DB RCT with placebo or active control comparison condition 
(n	≥	30	in	each	active	treatment	arm)
3 At least one DB RCT with placebo or active control comparison condition (n = 10- 29 in each active treatment arm) or 
health system administrative data
4 Uncontrolled trial, anecdotal reports, or expert opinion
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strategies into treatment. Additional information on presentation 
and hierarchical rankings of treatment options for acute mania 
(Section 3) and depression (Section 4) are reviewed, and include 
descriptions of clinical features that may help direct treatment 
choices. The importance of long- term maintenance treatment and 
promotion of treatment adherence for mood stability, as well as hi-
erarchical rankings of treatment options are discussed in Section 5. 
An expert review of the available evidence for treatments of bipolar 
II disorder (BDII) and recommendations based on those findings are 
presented in Section 6. The management issues related to specific 
populations, including women at various stages of the reproductive 
cycle, children and adolescents, older adults, and those with psychi-
atric or medical comorbidity are each discussed in Section 7. Finally, 
the principles of medical monitoring and an overview of safety and 
tolerability concerns for recommended treatments are provided in 
Section 8.
For convenience and to avoid confusion, these guidelines also 
include a table of commonly used terms (with an explanation of the 
intended meaning) that may have overlapping definitions or criteria in 
the literature (Table 4).
These guidelines are intended for use by psychiatrists and primary 
care providers who care for patients with BD throughout the lifespan, 
supporting them to provide evidence- based assessment, treatment of 
acute symptoms, prevention of episode recurrence, and management of 
comorbidities. These guidelines are not meant to replace clinical judge-
ment or define standards of care. While designed with Canadian physi-
cians in mind, input from experts from the ISBD makes these guidelines 
applicable for practitioners from across the globe. As with previous 
publications, CANMAT will strive to publish regular updates to these 
guidelines, incorporating new knowledge useful for practising clinicians.
As not all medications included in these guidelines will be available 
in all countries, including Canada, clinicians are advised to follow the 




Bipolar disorder is a common and disabling mental illness with signifi-
cant morbidity and mortality. The estimates of prevalence of BD vary. 
The World Mental Health Survey Initiative reported total lifetime (and 
12- month) prevalence estimates of 2.4% (1.5%) across BDI, BDII and 
subthreshold BD subtypes. While the prevalence rates for each sub-
type varied across the nine countries studied, subthreshold BD was 
the most common at 1.4% (0.8%), followed by BDI at 0.6% (0.4%) and 
BDII at 0.4% (0.3%).6 While Canada was not included in this study, 
similar results were reported from the Canadian Community Health 
Survey- Mental Health, which found the lifetime prevalence of BDI 
was 0.87% and that of BDII was 0.67%.7
2.1.2 | Age of onset
Bipolar disorder frequently manifests in late adolescence and 
young adulthood, with an overall average age of onset of 25 years. 
Statistical models suggest the presence of three age of onset sub-
groups within BDI and these can be categorized into a large early- 
onset group (mean ± standard deviation (SD) 17.24 ± 3.20 years), 
and smaller middle- onset (23.93 ± 5.12 years) and late- onset 
(32.20 ± 11.96 years) groups, with the proportion of individu-
als falling into each category being 41.7%, 24.7% and 33.6% 
of the total sample, respectively.8 However, the ages of onset 
tend to differ somewhat depending upon the origins of sam-
ples analysed. For instance, a recent study showed that the 
TABLE  3 Sections
Section 1: Introduction
Section 2: Foundations of management
Section 3: Acute management of bipolar mania
Section 4: Acute management of bipolar I depression
Section 5: Maintenance therapy for bipolar I disorder
Section 6: Bipolar II disorder
Section 7: Specific populations
Section 8: Safety and monitoring
F IGURE  1 Hierarchical rankings of treatment recommendations: How were they arrived at? [Colour figure can be viewed at 
wileyonlinelibrary.com]
What are hierarchical rankings?
Hierarchical rankings of treatment opons are new to the 2018 Guidelines. They were created for first and second line treatment
recommendaons for acute mania, depression, and maintenance treatment of bipolar I disorder; and will further assist clinicians in making
evidence based treatment decisions.  
These orders were created by considering the efficacy of each treatment across all phases, as well as acute and maintenance safety and
tolerability and the risk for treatment emergent switch. Thus, for example if two treatments were shown to be similarly effecve in acute
mania, and if only one of these treatments has demonstrated efficacy for maintenance treatment, or had beer safety or tolerability, that
treatment would be placed higher in the hierarchical recommendaon.
When making treatment decisions, we recommend that agents listed higher in the hierarchy be tried first, unless there are paent-specific
reasons for choosing an agent lower in the order (such as paent preference, prior treatment non/response, or clinical features which favor
treatments lower in the ranking).   
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mean age of onset for a USA sample was 20 years, with ages 
of onset of 14.5 ± 4.9 years (63%), 26.5 ± 7.6 years (28.5%), 
and 39.5 ± 12.5 years (8.5%) for early- , middle- and late- onset 
groups, respectively; while a European sample showed a later 
mean age of onset of 29 years and a later onset in each of the 
three categories, with 19 ± 2.7 years (24.8%), 27.2 ± 6.3 years 
(50.7%), and 41.8 ± 10.7 years (24.5%) as the ages of onset for 
early, middle and late- onset groups, respectively.9 Those with an 
earlier age of onset tend to have a longer delay to treatment, 
greater depressive symptom severity, and higher levels of co-
morbid anxiety and substance use.10 While manic episodes can 
occur for the first time after the age of 50 years as a part of BDI, 
the possibility of organic mania should be considered and inves-
tigated in these cases.11
2.1.3 | Burden of illness
People living with BD experience substantial impairment, being symp-
tomatic with syndromal or subsyndromal symptoms, particularly those 
of depression, for approximately half of their lives.12,13 Patients are 
unable to maintain proper work role function approximately 30% or 
more of the time.14 Quality of life is reduced in both symptomatic and 
non- symptomatic patients when compared to healthy controls,15-17 
and several domains of functioning have been identified by patients 
as being of particular importance- including physical, sleep, mood, 
cognition, leisure, social, spirituality, finances, household, self- esteem, 
independence, identity, work, and education.18 For both psychosocial 
functioning and quality of life, impairments are more pronounced in 
patients with depressive symptoms,19-21 in those with more previ-
ous episodes/longer duration of illness,20,22 and in those with lower 
cognition.23
Consistent with these observations, the Global Burden of Disease 
Study attributed 9.9 million years lost to disability (YLD) to BD, mak-
ing it the 16th leading cause of YLD worldwide.24 The impact that BD 
has on young people is even greater, with  being the sixth leading 
cause of disability- adjusted life years among people aged 10- 24 years 
worldwide.25 The burden of this disease was further emphasized in 
a systematic review addressing cost of illness studies, with findings 
demonstrating that the worldwide annual costs per person with BD 
range from US $1904 to $33 090; higher per person costs associated 
with BDI, delayed or misdiagnosis, frequent psychiatric interventions, 
use of atypical antipsychotics, treatment non- adherence, poor prog-
nosis, relapse, and comorbidity.26
2.2 | Diagnostic assessment
2.2.1 | DSM- 5 diagnostic criteria
Bipolar disorder encompasses a spectrum of diagnostic subgroups 
primarily divided according to the severity of mood elevation expe-
rienced during acute episodes5 On this spectrum, BDI is placed at 
one pole due to the presence of threshold manic episodes in which 
features include inflated self- esteem, decreased need for sleep, pres-
sured speech, racing thoughts, distractibility, psychomotor agitation, 
and risky behaviour that leads to significant functional impairment, and 
may include psychotic features, and/or necessitate hospitalization. At 
the other end of the spectrum, cyclothymia is characterized by sub-
threshold presentation of hypomanic and depressive symptoms that, 
while chronic, do not meet diagnostic criteria for a major depressive 
episode or manic/hypomanic episode. BDII sits between the two con-
ditions with hypomanic episodes qualitatively like manic periods but, 
although distinct and observable, are not of a sufficient duration or 
severity to cause significant functional impairment, hospitalization, or 
psychosis. Individuals with BDII also experience threshold depressive 
episodes.
DSM- 5 has replaced the BD not otherwise specified (NOS) cate-
gory in DSM- IV with two new categories; other specified bipolar and 
related disorder and unspecified bipolar and related disorder. Also, 
DSM- 5 includes substance/medication- induced bipolar and related 
disorder and bipolar and related disorder due to another medical 
condition. For more detailed discussion of diagnostic categories, the 
reader is advised to consult DSM- 5 and recent Royal Australian and 
New Zealand College of Psychiatrists guidelines for treatment of mood 
disorders.27
TABLE  4 Clarifying overlapping terminology
Term Use
Mood stabilizer Use in the literature is inconsistent, and so this term will not be used in these guidelines
Divalproex Encompasses valproate, valpromide, valproic acid and divalproex sodium
Conventional 
antipsychotics
Include first- generation antipsychotics with high affinity for dopamine D2 receptors. Note these are referred to as dopamine 
receptor antagonists (D2) in the new neuroscience- based nomenclature
Atypical 
antipsychotics
Comprise second- generation antipsychotics with affinity for dopamine D2 and serotonin 5- HT2 receptors as well as those that 
have partial agonist effects at D2/D3 receptors. Note these are referred to as dopamine and serotonin receptor antagonists (D2 
and 5- HT2A), dopamine 2 partial agonists and serotonin receptor antagonists, and dopamine 2/3 partial agonists in the new 
neuroscience- based nomenclature
Recurrence Re- emerging episode(s) of mania or depression whether it be within the previous episode or a new episode. Note that, while the 
literature may use “relapse” and “recurrence”, respectively, inconsistencies in how they are applied and their irrelevance to 
treatment decisions mean we will use “recurrence” to refer to both
Maintenance Prophylactic therapy after stabilization of acute manic or depressive episodes
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2.2.2 | DSM- 5 specifiers for bipolar and 
related disorders
DSM- 5 also includes a range of specifiers that clinicians may use to 
further clarify the specific course, severity, and features of BDs. While 
a more detailed description can be found in the DSM- 5 manual, the 
available specifiers and their use across the spectrum are listed in 
Table 5. Many of these specifiers may also be used to guide treat-
ment decisions for acute mania (Section 3) and depression (Section 
4). Amongst these, the mixed features specifier, which has replaced 
mixed episodes, warrants consideration because of the multiple and 
complex presentations of mixed states it can give rise to. Furthermore, 
the nascency of this terminology has meant that treatment data are as 
yet sparse. DSM- 5 has added mixed features as a specifier during an 
episode of major depressive disorder (MDD) as well, which will prob-
ably pose some pragmatic diagnostic challenges and management di-
lemmas for clinicians.
2.2.3 | Staging bipolar disorder
The course of BD is heterogeneous but, on average, the risk of recur-
rence increases with the number of previous episodes.28 In addition, 
data examining the effect of episodes on the course of illness shows 
that the number of previous episodes is associated with increased du-
ration and symptomatic severity of subsequent episodes. Moreover, 
the number of episodes is associated with a decreased threshold for 
developing further episodes and with an increased risk of dementia 
in the long term.28 The progressive course of illness in patients with 
multiple episodes is called clinical progression and the biological basis 
of clinical progression is defined as neuroprogression.28,29
The concepts of clinical progression and neuroprogression have 
provided the basis for the development of staging systems in BD.30 
Overall, the staging models describe three broad clinical stages: (I) 
individuals at increased risk for developing BD due to family history 
as well as certain subsyndromal symptoms predictive of conversion 
into full- blown BD; (II) patients with fewer episodes and optimal func-
tioning in the interepisodic periods, and (III) patients with recurrent 
episodes as well as decline in functioning and cognition.31 So far, the 
heterogeneity intrinsic to BD has prevented the clinical use of stag-
ing systems.32 In addition, the field of staging is in its infancy and the 
ability of staging systems to guide prognosis and treatment is still to 
be determined. Overall, the model of staging has helped clinicians to 
appreciate the importance of early identification and treatment as well 
as illness trajectories in BD.33
2.2.4 | Screening and diagnosis of bipolar disorder
Due to frequent depressive onset, variable help seeking for hypomanic 
or manic periods, temporal instability of symptoms, and high rates of 
comorbidity; accurate the timely identification of BD can be difficult 
to achieve in many cases. Indeed, many individuals are not accurately 
diagnosed until up to 10 years after the onset of symptoms, with one 
to four alternate diagnoses typically being given prior to correct rec-
ognition and treatment34,35 This delay has important consequences, 
including inadequate initial treatment and worse prognosis in terms of 
episode recurrence and functional outcome.36,37
The most frequent misdiagnosis is that of MDD, as patients 
are more likely to present for the treatment of depressive symp-
toms and may not recall periods of hypomania or mania, or may 
not interpret them as being pathological. Recall and insight are 
particularly impaired during periods of acute depression, with pro-
nounced memory or concentration difficulties. There are several 
features of depression that may increase suspicion of bipolarity, 
and prompt more careful investigation, including earlier age of ill-
ness onset, highly recurrent depressive episodes, a family history 
of BD, depression with psychotic features, psychomotor agitation, 
atypical depressive symptoms such as hypersomnia, hyperphagia, 
and leaden paralysis, postpartum depression and psychosis, past 
suicide attempts, and antidepressant- induced manic symptoms or 
rapid cycling (Table 6) Given the recent change in DSM- 5 to allow 
the possibility of depression symptoms with subthreshold simulta-
neous hypomanic symptoms (mixed specifier), it is also important 
to explore if an individual is experiencing mixed symptoms.38,39 
Schizophrenia and other psychotic disorders are the second most 
TABLE  5 DSM- 5 specifiers for bipolar and related disorders
Specifier Manic episode Depressive episode Illness course
Anxious distress X X




Psychotic features X X
Catatonia X X
Peripartum onset X X
Seasonal pattern X
Remission X X
Current episode severity X X
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common misdiagnosis, occurring as the initial diagnosis in as many 
as 30% of patients.40
In addition to this under- diagnosis, there are also concerns that 
BD may be over- diagnosed in some circumstances.41 For instance, the 
symptoms of borderline personality disorder, substance use disorder 
(SUD) and attention deficit hyperactivity disorder (ADHD) overlap sig-
nificantly those of hypomania/mania, and some reports suggest that 
patients with these conditions often get misdiagnosed with BD. These 
conditions also are often comorbid with BD, which makes the diagno-
sis of this condition often challenging.42
Validated self- report instruments, such as the Mood Disorders 
Questionnaire (MDQ), may be used as a screening tool to flag patients 
for whom a more detailed assessment is needed. It is important to 
note, that such tools have poor sensitivity and specificity, especially in 
community or highly comorbid populations, and will thus have an ele-
vated risk of also flagging those with borderline traits.43 As such, tools 
such as the MDQ should be used only as an adjunct for screening clini-
cal populations and not for diagnostic or treatment planning purposes.
To improve the accuracy of diagnosis, it is important that clinicians 
strictly adhere to diagnostic criteria rather than relying on heuristics.44 
It is important to complete a careful psychiatric history, including in 
first- degree relatives, with attention paid to any suspected periods of 
increased activity, irritability, or other change in behaviours. Collateral 
information from friends and family members should be included 
wherever possible. Ongoing monitoring of symptoms, such as mood 
charting, can also help to detect bipolarity that may only become ap-
parent over time. Confirmation of the diagnosis can then be made 
more confidently when episodes are prospectively observed.
2.2.5 | Comorbidities and mimics
As described in Section 6, patients diagnosed with BD very commonly 
have one or more comorbid psychiatric diagnoses, with SUDs, im-
pulse control disorders, anxiety disorders, and personality disorders 
(especially cluster B disorders) particularly common.45 The presence 
of comorbidity increases the complexity of the illness and can make 
an accurate diagnosis even more difficult.
In addition to differentiating BD from other psychiatric diagnoses, 
alternative causes of mood symptoms, such as personality disorders, 
medical or neurological conditions, substance use, and medications 
must be considered in the differential diagnosis (Table 7).
2.3 | Suicide risk
It is important for clinicians to frequently monitor suicidal ideation 
and risk. Suicide is one of the leading causes of death in BD, with ap-
proximately 6%- 7% of identified patients with BD dying by suicide; 
thus, suicide risk is substantially higher in BD than in the general 
population (10.7 per 100 000 per year).46,47 The fatality of suicide 
attempts is also higher in BD than in the general population.48,49 
Worldwide, approximately 43% of patients with BD report suicidal 
ideation, 21% a plan, and 16% a suicide attempt within the past 
year.6 Men are at a higher risk of death by suicide, with an estimated 
rate of 0.366 per 100 person years, compared to 0.217 for women.47
As reviewed in the ISBD Task Force on Suicide in Bipolar 
Disorder,50 a number of sociodemographic and clinical risk factors 
need to be considered in determining the level of suicide risk (Table 8). 
Factors reported to be significantly associated with suicidal attempt 
include female sex, younger age of illness onset, depressive polarity 
of first illness episode, depressive polarity of current or more recent 
episode, comorbid anxiety disorder, comorbid SUD, comorbid cluster 
B/borderline personality disorder, first- degree family history of sui-
cide, and previous suicide attempts. Only male sex and first- degree 
family history of suicide have been significantly associated with sui-
cide deaths.50,51 The periods during and following hospital admission 
further represent times of particularly high risk, with 14% of suicides 
occurring during an inpatient stay and another 26% within 6 weeks of 
discharge.47,52
A comprehensive assessment for suicide risk should occur during 
all clinical interactions. Risk stratification using assessment tools is not 
sufficiently accurate for prediction of suicide risk in clinical use; in-
stead, clinical assessment should focus on modifiable risk factors that 
could be targeted to reduce the risk.53 The ISBD has developed clinical 
tips and patient information sheets (translated into several languages) 
that can be useful tools for clinicians, patients and families to develop 
a comprehensive approach to suicide prevention (http://www.isbd.
org/Files/Admin/Knowledge-Center-Documents/Suicide-Prevention-
Tip-Sheet.pdf).
TABLE  6 Features of depression that may increase suspicion of a bipolar vs unipolar illness
Feature Suggestive of bipolarity Suggestive of unipolarity
Symptomatology and 
mental state signs
Hypersomnia and/or increased daytime napping
Hyperphagia and/or increased weight
Other “atypical” depressive symptoms such as leaden paralysis
Psychomotor retardation
Psychotic features and/or pathological guilt
Lability of mood; irritability; psychomotor agitation; racing 
thoughts
Initial insomnia/reduced sleep
Appetite and/or weight loss
Normal or increased activity levels
Somatic complaints
Course of illness Early onset of first depression (<25 years)
Multiple	prior	episodes	(≥5	episodes)
Late onset of first depression (>25 years)
Long duration of current episode (>6 months)
Family history Positive family history of bipolar disorder Negative family history of bipolar disorder
Adapted from Mitchell et al.38 and Schaffer et al.39
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The association between various treatments and suicide risk 
has been reviewed by the ISBD Task Force and others, which 
suggest that lithium54 and, to a lesser extent, anticonvulsants may 
contribute to preventing suicide attempts and deaths; although more 
data are needed to determine their relative efficacies. There were lim-
ited data on both antipsychotics and antidepressant agents.47 As the 
most common method of suicide in this population is self- poisoning, 
the potential benefits of various treatments should be considered 
against their risk of toxicity and lethality. One small Canadian study 
indicated higher rates of lethal doses of antipsychotics (32%), opioids 
(29%), benzodiazepines (27%), carbamazepine (21%) and diphenhydr-
amine (15%) compared to lithium (3%) in 34 self- poisoning deaths.55
2.4 | Chronic disease management
Due to the chronic, relapsing and remitting nature of BD, a long- term, 
multidisciplinary approach to management is needed. The Chronic 
Disease Management Model56 outlines several important principles to 
enhance long- term care for these individuals and their families (Table 9). 
After basic clinical management, including attention to diagnosis, comor-
bidity, and medical health has been established, patient health education 
and pharmacotherapy should be the initial and foundational steps for 
all patients. Ideally, the patient will be connected to a health care team 
which includes at least one other health care professional (typically a 
nurse) in addition to the psychiatrist for psychoeducation, ongoing mon-
itoring, psychosocial support, and referral to community resources.57 
All patients should have access to a primary care provider to attend to 
mental and physical health needs. If the patient is stable and discharged 
to primary care, the mental health care system should provide support 
directly to the primary care provider with attention to continuity of 
care.58 Additional psychosocial treatments (described below) may also 
be selected to fit the specific needs and preferences of the patient.
A strong therapeutic alliance is central to improve treatment adher-
ence and outcomes.59,60 Providers should encourage individuals to ac-
tively participate in treatment planning, using a shared decision- making 
approach.61,62 Whenever possible, family members or key friends should 
be included as part of the care team. There is evidence that specialized, 
team- approach- based interventions combining pharmacotherapy and 
psychoeducation are more effective than standard community care.63
Regular, ongoing monitoring of mood symptoms and other mea-
sures related to the patient’s own individual recovery, such as sleep, 
cognition, functioning, and quality of life is encouraged.18 For many 
patients, daily recording of mood symptoms such as through a 
mood diary or National Institute of Mental Health (NIMH) Life Chart 
Method- Self Rating Scale can help identify early warning signs of re-
lapse, as well as outline relationships between mood and treatment or 
lifestyle factors such as diet, exercise, or stress.64 While many patients 
will agree with the value of completing a mood diary, and this strategy 
has been shown to improve treatment, regular completion can be a 
burden.65 Online solutions such as mobile apps may improve adher-
ence,66 such as the Self- Monitoring and Psychoeducation In Bipolar 
Patients smartphone app (SIMPLE) which provides weekly and daily 
mood tests, with reminders to take medication or see their doctor.67-69
2.5 | Dealing with stigma
Stigma is an important issue that will impact individuals with BD, as well 
as their family members, potentially preventing individuals from seeking 
TABLE  7 Differential diagnosis of bipolar disorder
Diagnosis Distinguishing features
Major depressive disorder or persistent depressive 
disorder
Manic or hypomanic episodes probed for and not present
Bipolar or related disorder due to another medical 
condition
Episodes are judged to be a consequence of a medical condition such as traumatic brain 
injury, brain tumours such as frontal lobe meningiomas, multiple sclerosis, stroke, Cushing’s 
disease or hyperthyroidism. Onset or exacerbation of mood coincides with that of the 
medical condition
Substance- or medication- induced mood disorder Episodes are judged to be a consequence of a substance such as an illicit drug, or a medica-
tion (stimulants, steroids, l- dopa or antidepressants) or toxin exposure. Episodes may be 
related to intoxication or withdrawal
Cyclothymic disorder Hypomanic symptoms do not meet the full criteria for a hypomanic episode, and depressive 
symptoms do not meet the criteria for a major depressive episode
Psychotic disorders (schizoaffective disorder, 
schizophrenia and delusional disorder)
Periods of psychotic symptoms in the absence of prominent mood symptoms. Consider onset, 
accompanying symptoms, pervious course and family history
Borderline personality disordera Instability of interpersonal relationships, self- image and mood, with marked impulsivity and a 
central theme of intense abandonment fears. Early onset and long- standing course. True 
euphoria and prolonged well- functioning intervals are extremely rare
Narcissistic personality disordera Grandiosity, need for admiration and lack of empathy of early onset. Grandiosity not 
associated with mood changes or functional impairments
Antisocial personality disordera Early onset of disregard for, and violation of, the rights of others, which does not occur only 
in the context of a manic episode
Adapted from Yatham et al. 20052
aCan occur comorbidly with bipolar disorder.
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or engaging in treatment or causing them to conceal their illness, reduc-
ing social support, functioning and quality of life.70 Linked to stereotypi-
cal negative attitudes that mental illness is due to personal weaknesses 
or decisions, or associated with violent or criminal behaviour, stigma 
can be perceived or experienced with interactions with others, includ-
ing health care providers, or internalized (self- stigma). Specific strate-
gies to reduce stigma, particularly self- stigma, by enhancing coping 
skills through improvements in self- esteem, empowerment, and help- 
seeking behaviour can improve outcomes in this population.71
2.6 | Psychosocial interventions
While pharmacotherapy is essential and forms the foundation for the 
successful treatment of BD, adjunctive psychosocial interventions 
may also be useful for acute depressive episodes, as well as in main-
tenance treatment to prevent relapse and to restore quality of life 
to the individual and family.72,73 No evidence exists, and hence there 
are no recommendations, for specific psychosocial interventions in 
acute mania. Positive evidence has been found for psychoeducation, 
cognitive behavioural therapy (CBT), family- focused therapy (FFT), in-
terpersonal and social- rhythm therapy (IPSRT), and peer support in 
the maintenance phase of BD and these interventions are included 
as recommended adjunctive treatment options. Additional studies are 
needed before conclusions can be drawn regarding other strategies 
such as family/caregiver interventions, dialectical behavioural therapy 
(DBT), mindfulness- based cognitive therapy (MBCT), cognitive and 
functional remediation, and online interventions (Table 10).
In general, provision of psychoeducation to all patients and fam-
ily members is recommended for prevention of relapse, particularly at 
illness onset, with selection of any additional psychosocial therapies 
based on individual concerns/presentations or deficits.
2.6.1 | Psychoeducation
Psychoeducation broadly includes provision of information about 
the nature of the illness, its treatments, and key coping strategies to 
the patient and family.74 Current psychoeducational models for BD 
teach skill development in detecting and managing prodromes of 
depression and mania, ongoing stress management, problem solv-
ing, how to diminish the effects of stigma and denial of the illness, 
and provide tips on enhancing medication adherence and develop-
ing healthy lifestyles (eg, minimizing the use of alcohol, tobacco, 
drugs, stimulants such as caffeine; getting regular exercise; and 
regulating sleep and wake times). A key goal is the creation of per-
sonalized coping strategies to prevent mood relapse.
Psychoeducation may be delivered individually or in group set-
tings. Empirical models of psychoeducation involve face- to- face inter-
action with a therapist, but new models are being tested that involve 
online tools, smartphone apps, and workbooks.75 Consistent with 
broader theories of learning, it is believed that psychoeducation is 
enhanced when it features active learning, with attention to monitor-
ing the development of understanding, active skill development, and 
homework between sessions. Peer support and group learning are also 
postulated to add efficacy to psychoeducation. Regardless of the type 
of model and content included, priority should be given to maximize 
the therapeutic alliance, convey empathy, and consistently monitor 
symptoms.76
TABLE  8 Summary of main factors associated with suicide 
attempt and suicide deaths in bipolar disorder (BD)
Variable







Older—higher ratio of 
deaths/attempts
Race Minorities—youth only
Marital status Single, divorced, single 
parents










































borderline or cluster B
Physical 
comorbidity



























Adapted from Schaffer et al.50
BMI, body mass index.
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Two models of psychoeducation, both delivered in group for-
mat to individuals who are well (euthymic), have published manu-
als and have substantial research support. These programmes, the 
Barcelona BDs Program77 (21 sessions over 6 months) and the Life 
Goals Program78 (phase I is six weekly sessions), also have tools 
to aid implementation with workbooks and handout materials, 
and both are first- line psychoeducational interventions based on 
level 2 evidence for the prevention of relapse. Individual psycho-
education based on these manuals would probably be effective, 
and when individual trials utilizing several different approaches 
to psychoeducation are combined in a meta- analysis, individual 
psychoeducation of at least five sessions would still be a first- 
line intervention for relapse prevention, based on level 2 evi-
dence.75,79,80 One large study demonstrated that the six- session 
Life Goals Program psychoeducational intervention was equiva-
lent in relapse prevention to 20 sessions of individual CBT, at far 
lower cost,81 with probable shared mechanisms.82 Furthermore, 
that study demonstrated that integration of best practices in med-
ication and psychotherapy simultaneously produced striking over-
all improvement in course of illness.83 Psychoeducation does not 
have any significant evidence of utility in either acute depressive 
or manic episodes.
2.6.2 | Cognitive behavioural therapy
CBT in BD is supported by several published manuals and typi-
cally is given in 20 individual sessions over 6 months, often with 
additional booster sessions. Despite evidence of efficacy for CBT 
for MDD and psychosis, the results of CBT trials for BD have been 
mixed. One large RCT supports it use for acute bipolar depression84 
in a trial that compared the efficacy of up to 30 (mean 14) CBT 
sessions against those of FFT, IPSRT, and a three- session control 
intervention, but it was not possible to identify whether the ben-
efits came from changes in the medications prescribed or the psy-
chosocial treatments. Efficacy of CBT in relapse prevention was 
observed in one RCT,85 but not in another larger RCT, at least in 
patients who had multiple mood episodes.86 From meta- analyses, 
effects on either depressive symptoms or on relapse remain uncer-
tain due to important methodological problems and study selection 
factors.87-89 A promising new direction in CBT has been established 
by a pilot study of “recovery- focused CBT” where 33 subjects re-
ceived the novel CBT intervention, with evidence of reduction of 
relapse in the intervention group.90 Group CBT in euthymic pa-
tients with BD is also a new direction and has shown to increase 
time in remission.91
In MDD, CBT, interpersonal psychotherapy (IPT) and behavioural 
activation have been explored in multiple RCTs and in general dis-
play similar efficacies.92 Based on this and the findings of the study 
by Miklowitz and colleagues in acute bipolar depression,84 CBT is still 
recommended as an adjunctive second- line treatment for acute bipo-
lar depression (level 2). The recommendation is also second-line for 
maintenance treatment (level 2) for patients with fewer episodes and 
less severe form of illness. No evidence exists, and hence no recom-
mendation is made, for CBT in mania.
TABLE  9 The chronic disease management model
Self- management support Empower and prepare patients to manage their health and health care
Use effective self- management support strategies that include assessment, 
goal setting, action planning, problem solving, and follow- up
Decision support Promote clinical care that is consistent with scientific evidence and patient 
preferences
Embed evidence- based guidelines into daily clinical practice and share this and 
other information with patients to encourage their participation
Use proven provider education materials
Community Encourage patients to participate in effective community programs
Form partnerships with community organizations
Delivery system design Provide clinical care and self- management support that patients understand 
and that fits with their cultural background
Ensure regular follow- up by the care team, with defined tasks for different 
team members
Provide clinical case management services for complex patients
Clinical information systems Provide timely reminders for providers and patients
Facilitate individual patient care planning
Share information with patients and providers to coordinate care
Health system Measure outcomes and use information to promote effective improvement 
strategies aimed at comprehensive system change
Develop agreements that facilitate care coordination within and across 
organizations
Adapted from Wagner.56
     |  107YATHAM eT Al.
2.6.3 | Family- focused therapy
FFT93 presumes that outcomes in BD may be enhanced with the sup-
port and cooperation of family or significant others, particularly in fam-
ilies characterized by high levels of expressed emotion. FFT focuses on 
communication styles between patients and their families or marital 
relationships, with the goal of improving relationship functioning, and 
is delivered to the family and patient in 21 sessions over 9 months.
For acute bipolar depression in adults, an intensive FFT (up to 30 
sessions; mean 14) out- performed a three- session control condition,94 
although this study was limited by the caveats identified for CBT and 
IPSRT. Given that the original creation of FFT targeted factors related 
to depression, it may have specific antidepressant activity, which is 
also suggested by reduced depression relapse in maintenance stud-
ies. For relapse prevention, four significant RCTs of varying sizes have 
been conducted, delivered to a mixed audience of young adults and 
adolescents.95 In these studies, FFT demonstrated efficacy in reduc-
ing recurrence of new episodes of depression, but not mania. Overall, 
FFT is recommended as adjunctive second- line treatment for acute 
depression (level 2) and for maintenance (level 2). No evidence exists, 
and hence no recommendation is made, for FFT for mania.
2.6.4 | Interpersonal and social rhythm therapy
IPSRT expands on the IPT focus on grief, interpersonal role tran-
sition, role dispute, and interpersonal deficits by including regula-
tion of social and sleep rhythms, specifically targeted to the bipolar 
population. It is typically delivered in 24 individual sessions over 
9 months.96,97
Few controlled trials of IPSRT have been conducted, with lim-
ited evidence of acute efficacy. The first, large trial98 showed no ef-
fect of IPSRT compared to a control condition but did show benefit 
for reduction of relapse and improved occupational functioning. An 
acute bipolar depression study84 showed intensive IPSRT (up to 30 
sessions; mean 14) out- performed a three- session control condition, 
but it is impossible to state whether the performance was related to 
the intensity and number of sessions, changes in medication use, or 
specific attributes of IPSRT. Two small studies failed to demonstrate 
specific benefits of IPSRT compared to control conditions.99,100 Other 
open studies have shown some pre- post benefits in very small sam-
ples.101-103 Again, since many psychosocial treatments for bipolar dis-
order share common core elements that may be psychoeducational, 
it is possible that the relapse prevention aspects of psychoeducation 
may also result from IPSRT interventions, mediated by the same ther-
apeutic processes.104
Overall, IPSRT is recommended as an adjunctive third- line treat-
ment for acute depression and for maintenance, based on limited (ef-
fect size and small sample size) level 2 evidence in each phase. No 
evidence exists, and hence no recommendation is made, for IPSRT for 
mania.
2.6.5 | Peer interventions
Peer interventions, such as peer groups or one- on- one support, are 
an important strategy believed to reduce self- stigma and isolation in 
BD, and to help improve engagement in treatment.105 Some caution 
is needed when applying this strategy, however, as there may be risks 
if the peers delivering the intervention are not adequately trained or 
supported, and if they promote a viewpoint that does not support 
treatment compliance or promotes substance use.
Reviews of peer interventions for persons with serious mental 
illnesses, usually incorporating a small but significant number of in-
dividuals with BD, have demonstrated modest evidence from RCTs 
and other controlled studies suggesting that there are important im-
provements in self- efficacy and reduction in self- stigma.106-109 The 
largest peer intervention study involving BD allocated 153 individuals 
to attend 21 weekly group psychoeducation events, with another 151 
assigned to attend 21 weekly group peer support events. The two pro-
grammes achieved similar outcomes in terms of time to relapse, and 
increased knowledge about BD, although psychoeducation was more 
acceptable to the subjects and worked more effectively at preventing 
relapse in a subset of people with fewer previous episodes.110





Psychoeducation (PE) First-line (Level 2) Insufficient evidence
Cognitive behavioural therapy (CBT) Second-line (Level 2) Second-line (Level 2)
Family- focused therapy (FFT) Second-line (Level 2) Second-line (Level 2)
Interpersonal and social rhythm therapy (IPSRT) Third-line (Level 2) Third-line (Level 2)
Peer support Third-line (Level 2) Insufficient evidence
Cognitive and functional remediation Insufficient evidence Insufficient evidence
Dialectical behavioural therapy (DBT) Insufficient evidence Insufficient evidence
Family/caregiver interventions Insufficient evidence Insufficient evidence
Mindfulness- based cognitive therapy (MBCT) Insufficient evidence Insufficient evidence
Online interventions Insufficient evidence Insufficient evidence
aSee text for specific definitions of type of therapy and number of sessions needed (“dose of psychosocial intervention”) corresponding to this recommen-
dation and evidence.
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A significant source of peer support is emerging from online 
resources, particularly through the websites of peer advocacy or-
ganizations such as the Depression and Bipolar Support Alliance 
(http://www.dbsalliance.org/site/PageServer?pagename=peer_
landing), the Mood Disorders Association of Ontario (https://www.
mooddisorders.ca/), the research and advocacy group CREST.BD 
(http://www.crestbd.ca/), MoodSwings (www.moodswings.net.
au/), and Revivre (http:/wwww.Revivre.org). YouTube is also emerg-
ing as an important source of peer support, along with other social 
media.111,112
Overall, peer interventions receive a third- line treatment recom-
mendation (level 2) as an adjunctive maintenance therapy.
2.6.6 | Other psychosocial interventions
Various other approaches have been tried in BD, with a variety of 
aims, modalities, and outcome targets. None of the other interven-
tions have been specifically targeted for bipolar depression or for 
mania. Some have been designed in part to reduce episode recur-
rence, but none have been successful in providing substantial evi-
dence of efficacy. Because CANMAT recommendations are for the 
treatment of acute depression and mania, and maintenance treat-
ment to prevent them, we do not make specific recommendations 
regarding these treatments. However, some of these approaches have 
been helpful in ameliorating some important symptoms in individuals 
with BD, (such as residual mood symptoms or anxiety) and so we will 
describe them briefly.
Although somewhat like FFT, family/caregiver interventions con-
stitute a distinctly different psychosocial intervention in that the in-
tervention is given to the family/caregiver, not the person with BD, 
and evidence exists that such interventions improve clinical outcomes 
in the patient.75,113 Clinical wisdom and common practice, however, 
support the importance of family or caregivers being included in at 
least some sessions with the patient (particularly for psychoeduca-
tion), both to reduce symptom burden on the individual with BD and 
to reduce burnout and emotional burden on the caregiver. Validated 
caregiver resources are available online, such as www.bipolarcaregiv-
ers.org.114
DBT, which includes distress tolerance training, has several small 
studies showing its utility in the reduction of some depressive symp-
toms and suicidality.75
One RCT of MBCT involving 95 patients did not demonstrate any 
difference in relapse prevention compared to a treatment- as- usual 
group, but did reveal fewer anxiety and depressive symptoms in the 
MBCT arm.115 Coupled with the findings of other smaller studies, this 
suggests that MBCT may have a role to play in anxiety reduction in 
BD.75,116
While not reviewed here, given that individuals with BD may have 
histories of childhood abuse and comorbid personality disorders, and 
experience various sequelae such as shame or conflict due to be-
haviours experienced during acute bipolar episodes, all of these may 
rightly be a target for psychosocial intervention in a very individualized 
manner.
2.6.7 | Cognitive and functional remediation
Functional impairment as well as cognitive deficits are found in many 
individuals with BD, not just during an acute episode but even be-
tween episodes, prompting the evaluation of various psychosocial 
and biological strategies to address these problems. One intervention, 
functional remediation (FR), involves a 21- session group intervention 
over 6 months. In a large RCT, FR was shown to have a substantial im-
pact on functioning, in comparison to treatment as usual.117 Coupled 
with the results of other small studies involving other interventions, 
these findings suggest that there is considerable hope in addressing 
cognitive and functional deficits in BD.118 Computer- based cognitive 
remediation, though, may show positive effects on cognition but not 
on functioning.119
2.6.8 | Online and digital strategies
Modern trends to rely on the internet and apps, along with access 
problems in mental health, have led to the study of various online 
tools and mobile phone apps.120 Such strategies also build on strong 
traditions of self- monitoring and self- management developed for-
mally in traditional psychoeducational interventions. In reviews, such 
internet and mobile health interventions have shown good adherence 
to validated psychological health principles, good acceptability to pa-
tients, ease of access, and ease of use. However, research is mostly 
limited to pilot studies and the relatively few larger studies have not 
shown unequivocal benefit.68,121
3 | ACUTE MANAGEMENT OF 
BIPOLAR MANIA
3.1 | Presentations of mania
DSM- 55 made a change to “criterion A” for mania which now requires 
a distinct period of abnormally and persistently elevated, expansive, 
or irritable mood and abnormally and persistently increased activity or 
energy present most of the day, nearly every day for at least 1 week 
(or less time if hospitalization is necessary). In addition, a diagnosis of 
a “manic episode” requires at least three (or four if the mood is only 
irritable) of the following symptoms: inflated self- esteem or grandios-
ity, decreased need for sleep, more talkative than usual or pressure 
of speech, flight of ideas or subjective experience that thoughts are 
racing, distractibility, increased goal- directed activity or psychomotor 
agitation, or excessive involvement in activities with a high potential 
for painful consequences. The mood disturbance must lead to marked 
impairment in functioning, require hospitalization, or be accompanied 
by psychotic features.
Unlike DSM- IV, DSM- 5 allows a diagnosis of BDI in patients with 
major depression whose mania emerges during treatment (eg, during 
medication or electroconvulsive therapy [ECT]) and persists at a fully 
syndromal level beyond the physiological effect of the treatment.
DSM- 5 has eliminated the categorical “mixed episode” specifier, 
replacing it with the more dimensional “mixed features”. DSM- 5 also 
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includes other specifiers that can accompany a manic episode: anx-
ious distress, rapid cycling, mood- congruent or mood- incongruent 
psychotic features, catatonia, peripartum onset, and seasonal pattern 
(Table 5). The utility of several of these specifiers in selecting treat-
ment options for mania is discussed later in this section (see “Clinical 
features that help direct treatment choice”).
3.2 | Management of agitation
Agitation is common in mania, and is particularly frequent in patients 
who have mixed features.122 Defined in DSM- 5 as “excessive motor 
activity associated with a feeling of inner tension”,5 agitation can 
manifest as pacing or fidgeting in mild cases to uncooperative, threat-
ening, or aggressive behaviours in severe cases. Severe symptoms of 
agitation require prompt attention in order to reduce distress, mitigate 
potentially dangerous behaviour, and allow for an assessment and 
evaluation of underlying manic symptoms.123
A key step in treating agitation is preventing it, or at least mitigat-
ing its severity, by rapidly treating the causative manic episode. When 
addressing agitation in patients with BDI, clinicians need to be aware 
that akathisia may present as agitation and, therefore, this must be 
excluded before implementing the general principles of management 
of acute mania described in step 1 (see “Pharmacological treatment 
of manic episodes”). Since agitation in this context is a manifestation 
of mania, it is assumed that effective interventions for treating mania 
that have rapid onset of efficacy would be effective in reducing agita-
tion. Therefore, if the patient is agreeable to taking oral medications, 
antimanic agents with rapid onset of efficacy should be considered 
first.
When agitation persists despite administration of antimanic 
treatments, additional rapidly acting pharmacotherapy may often be 
needed. The evidence for specific efficacy of various agents in short- 
term treatment of agitation is summarized in Table 11. Some of these 
agents are either not available or rarely used in North America (eg, 
midazolam and promethazine). We further note that the dose ranges 
in Table 11 are based on the doses studied in the trials, and would 
probably be appropriate in most situations. However, a comprehen-
sive evaluation of the agitated patient is necessary (ie, medical con-
ditions, treatments, drugs, intoxication, etc.) to determine a safe and 
adequate dose.
As can be seen from Table 11, the highest level of evidence avail-
able in short- term treatment of agitation for oral formulations of any 
agent is level 3, and level 2 for intramuscular (IM) or inhaled formula-
tions. In this context, it is important to remember that the absence of 
evidence does not constitute lack of efficacy. Indeed, clinical expe-
rience suggests that agitation in many patients with acute mania re-
sponds well to the oral medications. Thus, a loading dose of divalproex, 
oral formulations of atypical antipsychotics, conventional antipsychot-
ics such as haloperidol or loxapine, and/or benzodiazepines such as 
lorazepam may be appropriate. If a patient indicates willingness to take 
oral treatment but there is a suspicion that the patient might “cheek” 
the medication, then either orally dispersing tablets (ODT), those that 
rapidly melt, oral liquid, or oral inhalation forms should be considered. 
In countries where inhaled loxapine is available, this could be consid-
ered if there are no contraindications.
If oral preparations are ineffective or if the agitation is severe 
and if the patient is refusing oral medications, or when oral ther-
apy cannot be safely or reliably administered, then IM formulations 
should be considered.124 Because of the strength of evidence for 
efficacy in alleviating agitation in this population, aripiprazole IM 
(level 2),125,126 lorazepam IM (level 2),125,127 loxapine inhaled (Level 
1)128,129 and olanzapine IM (level 2)127,130-133 are recommended as 
the first- line option. Sublingual asenapine (level 3),134 haloperidol IM 
(level 3),131,135,136 haloperidol IM + midazolam IM (level 3),131,137 hal-
operidol IM + promethazine IM (level 3),131,137,138 risperidone ODT 
(level 3),136 and ziprasidone IM (level 3)131,137,139 are recommended 
as a second- line treatment. Haloperidol per os (PO) (level 4),140,141 
loxapine IM (level 4) (clinical opinion), quetiapine PO (level 4),141 
and risperidone PO (level 4)140 are included as third- line options 
(Table 11).
3.3 | Pharmacological treatment of manic episodes
There are a range of strategies that have been investigated for use in 
mania; including lithium, divalproex, other anticonvulsants, typical and 
atypical antipsychotics, and other agents and therapies. These treat-
ments have been evaluated using the criteria for strength of evidence 
for efficacy (Table 1) as well as safety and tolerability (Section 8). The 
evidence for efficacy and the recommendations for treating acute 
mania are summarized in Table 12.
As stated previously, the first and second- line agents are listed hi-
erarchically taking into consideration not only their efficacy for acute 
mania but also their efficacy in preventing mania or depression, treating 
acute bipolar depression, safety/tolerability and the risk of treatment- 
emergent switch. The implication of this hierarchical recommendation 
is that those listed higher up in the table should be considered first 
before moving on to the next on the list, unless other factors such 
as history of previous non- response or patient’s preferences preclude 
such strategy in a given patient.
Monotherapy and combination therapy are listed separately 
as first- line treatments for acute mania in Table 12. This does not 
mean that all monotherapy agents should be tried first before 
considering combination therapy for acute mania. We suggest 
that the treating clinician make a decision as to whether to treat 
a given patient with monotherapy or combination therapy. That 
decision is typically based on the rapidity of response needed 
(eg, combination treatments tend to work faster), whether the 
patient had a previous history of partial response to monother-
apy, severity of mania, tolerability concerns with combination 
therapy, and willingness of the patient to take combination ther-
apy. Once a decision is made whether to treat the patient with 
monotherapy or combination therapy, then hierarchy related 
to monotherapy or combination therapy could be followed. We 
also suggest that clinicians evaluate the efficacy and tolerabil-
ity at the end of weeks 1 and 2 and modify treatment options 
accordingly.
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3.3.1 | Step 1: review general principles and assess 
medication status
Examination of a patient presenting in a manic state should include 
an immediate assessment for risk of aggressive behaviour, violence 
and safety threat to others, suicide risk especially in those with mixed 
features, degree of insight and the ability to adhere to treatment, 
comorbidity (including substance use that may be aggravating or 
contributing to clinical presentation), and availability of a psychoso-
cial support network. A physical examination with laboratory inves-
tigations (described in Section 8) should be conducted, but may be 
deferred for patients who are uncooperative. Results of the overall 
assessment should be used to establish the most appropriate treat-
ment setting (eg, ambulatory or inpatient).
Before initiating pharmacological treatment for a manic episode, 
it is imperative to rule out symptoms secondary to drugs of abuse, 
medications, other treatments, or a general medical or neurological 
condition (although, even in these cases, symptomatic treatment 
may be applied on a short- term basis). Steps should be taken to rule 
out any other factors that may be perpetuating symptoms such as 
prescribed medication, illicit drug use/abuse or an endocrine dis-
order. Any patients presenting with mania who have been taking 
antidepressants should have these medications discontinued. If 
there is a previous diagnosis of BD, it is appropriate to immediately 
commence antimanic agents. If this is the first emergence of manic 
symptoms, clinicians are advised to confirm the diagnosis of BD by 
monitoring patients for a period of time after antidepressant dis-
continuation and obtain collateral information to confirm whether 
symptoms remain and antimanic treatment is necessary. Patients 
should also be supported to discontinue stimulant use, including caf-
feine and alcohol. Current and prior therapies should be assessed, 
including appropriateness of medications, dosing, and trough serum 
levels (where indicated), as well as past response; and this should 
be used to direct subsequent therapeutic choices. Attention should 
be paid to managing withdrawal symptoms that may occur in manic 
patients with histories of substance abuse.
When the symptoms of mania have remitted, behavioural and ed-
ucational strategies should be applied to promote ongoing medication 
adherence, reduce residual symptoms, help identify early signs of re-
lapse, and support functional recovery (see Section 2).
3.3.2 | Step 2: initiate or optimize therapy and 
check adherence
It is recommended that, for all patients (including those who are un-
treated as well as those receiving a non- first- line treatment), therapy 
be initiated with one of the available first- line monotherapy or com-
bination treatments.
First- line monotherapy
Approximately 50% of patients will respond to monotherapy with 
significant improvement in manic symptoms within 3- 4 weeks.142 
TABLE  11 Level of evidence and recommendations for short- term pharmacological management of agitationa
Level of 
recommendation Agent Formulation Level of evidence
Dose range of studiesb
Single dose Max/24 h
First-line Aripiprazole IM 2 9.75 mg 15 mg
Lorazepam IM 2 2 mg IM
Loxapine Inhaled 1 5 mg 10 mg
Olanzapine IM 2 2.5 mg 10 mgc
Second-line Asenapine Sublingual 3 10 mg
Haloperidol IM 3 5 mg 15 mg
Haloperidol + midazolam IM 3 2.5 mg (haloperidol) + 
7.5 mg (midazolam)
5 mg (haloperidol) + 15mg 
(midazolam)
Haloperidol + promethazine IMe 3 2.5 mg (haloperidol) + 
25 mg (promethazine)
5 mg (haloperidol) + 50 mg 
(promethazine)
Risperidone ODTe 3 2 mg 4 mg
Ziprasidone IMe 3 2 mg 20 mg
Third-line Haloperidol POd 4 5 mg 15 mg
Loxapine IM 4 N/A
Quetiapine POd 4 Mean (SD) = 486.7 (317.2) mg/day
Risperidone POe 4 2 mg
aSee text for recommendations about use of oral antipsychotics and divalproex. IM, intramuscular; ODT, orally disintegrating tablet; PO, per os.
bDoses are reported as per studies.
c26.3% received two or three 10 mg injections.
dAssessed 2 h after the dose.
eDoses are not specifically for bipolar disorder but included schizophrenia or other diagnoses.
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Lithium (level 1), quetiapine (level 1), divalproex (level 1), asenapine 
(level 1), aripiprazole (level 1), paliperidone (level 1 for doses >6 mg), 
risperidone (level 1), and cariprazine (level 1) are all recommended as 
first- line treatment options. Overall, these agents show comparable 
efficacy (Cohen’s d 0.32- 0.66; small to medium effect size).143
Although they have comparable efficacy for treating acute mania, 
we recommend that the agents listed first in the text and placed higher 
in Table 12 be tried first, in the order listed, unless there are patient- 
specific reasons for choosing an agent lower down in the order (see 
“Clinical features that help direct treatment choices”). For instance, 
lithium should be considered first for acute mania unless there are 
specific reasons not to, such as mixed features, comorbid substance 
use or previous non- response to lithium.
Carbamazepine, olanzapine, ziprasidone and haloperidol also have 
level 1 evidence for efficacy but they are downgraded to second- line 
options due to safety/tolerability risks with these agents.
First- line combination therapy
Combination therapy with the atypical antipsychotics quetiapine 
(level 1), aripiprazole (level 2), risperidone (level 1), or asenapine (level 
2) and lithium or divalproex is also recommended as first- line treat-
ment options with greater efficacy than monotherapy with lithium 
or divalproex alone, especially in those with higher index severity.144
In general, combination therapy is preferred to mood stabilizer 
monotherapy because clinical trials suggest that on average about 
20% more patients will respond to combination therapy.142,145,146 
There is also some evidence to suggest the benefit of combination 
therapy compared to atypical antipsychotic monotherapy, although 
there are fewer trials. Specifically, lithium plus quetiapine showed su-
periority to quetiapine alone.147 While there is also level 1 evidence 
for olanzapine combination therapy over olanzapine monotherapy, 
this is downgraded to second-line due to tolerability/safety concerns 
with olanzapine.
The decision to treat with one or a combination of available first- 
line agents should be informed by current and prior medication use, 
with treatment previously shown to be successful in managing symp-
toms preferred. Safety and tolerability factors for each medication and 
clinical features predictive of better response (see “Clinical features 
that help direct treatment choices”) should also be considered. In gen-
eral, combination therapy is associated with more adverse events than 
monotherapy. Whenever possible, options should be discussed with 
the patient and/or their caregiver and their preferences considered 
prior to treatment selection.
If symptoms are not controlled using monotherapy or combination 
therapy with first- line agents, dosing should be optimized, issues of 
non- adherence identified and addressed, and consideration given to 
possible substance use (Section 4) prior to adding or switching ther-
apies (Step 3). Given that almost all antimanic agents separated from 
placebo within 1 week, some therapeutic response is expected with 
antimanic agents within 1- 2 weeks. If no response is observed within 
2 weeks with therapeutic doses of antimanic agents, and other con-
tributing factors for non- response are excluded, then switch or add- on 
strategies should be considered.
3.3.3 | Step 3: add on or switch therapy (alternate 
first- line agents)
If therapy with one or a combination of the first- line agents (lithium, 
divalproex and/or an atypical antipsychotic) at optimal doses is inad-
equate or not tolerated, the next step is to switch to or add on an al-
ternate first- line agent. An exception is that, despite level 1 evidence 
for monotherapy with paliperidone and ziprasidone, we do not 
recommend combination therapy with these agents due to lack of 
evidence for additional efficacy (see “No specific recommendation/
agents that require further study” below). Because there are multiple 
first- line agents with substantial efficacy data and relative safety and 
tolerability, the use of second- and third- line agents is only recom-
mended after unsuccessful trials of multiple first- line strategies.
3.3.4 | Step 4: add on or switch therapy (second- line 
agents)
Second-line
In patients who are inadequately responsive to first- line agents, 
second- line choices include monotherapy with olanzapine (level 1), 
carbamazepine (level 1), ziprasidone (level 1), and haloperidol (level 
1)143 or combination therapy with olanzapine plus lithium or dival-
proex (level 1). While each of these strategies has strong support for 
their efficacy, as indicated above, safety and tolerability concerns 
relegate them to second- line options. Although widely used in clini-
cal practice, the combination of lithium and divalproex is also recom-
mended as a second- line choice, as evidence supporting its efficacy is 
limited to uncontrolled trials (level 3).148-151
ECT is also recommended as a second- line option (level 3)152 and, 
although the number of controlled trials is limited, there is evidence to 
suggest that up to 80% of patients will show marked clinical improve-
ments.153 Brief pulse therapy with two or three treatments per week 
has been used. Bifrontal electrode placement is preferred over bitem-
poral as it is associated with faster treatment response and fewer cog-
nitive side effects.154-156
When all first- line agents have failed, the hierarchy should be ap-
plied to second- line agents as well. Hence, olanzapine, which is high-
est in the hierarchy amongst second- line agents, should be first choice 
before moving down the list in Table 12.
3.3.5 | Step 5: add on or switch therapy (third- line 
agents)
Third-line
Agents recommended as third- line options for treatment of acute mania 
include monotherapy with chlorpromazine (level 2),157 monotherapy 
with clonazepam (level 2),158 monotherapy or adjunctive therapy with 
clozapine (level 4),159-162 and monotherapy with tamoxifen (level 2).143 
Tamoxifen is downgraded because of the risk of uterine cancer and the 
lack of clinical experience despite evidence for efficacy. Combination 
treatments with carbamazepine or oxcarbazepine (level 3),163 haloperi-
dol (level 2),144,164 or tamoxifen (level 2)165 plus lithium or divalproex are 
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also included as third-line. Repetitive transcranial magnetic stimulation 
(rTMS) in the right prefrontal cortex at 110% motor threshold (level 
3)166 can also be considered in combination with pharmacotherapy.
The third- line agents should only be used if a patient has not re-
sponded to adequate trials with all first and second- line agents alone 
and in combination. Given that the evidence is very limited for third- 
line agents, it was not possible to list them in any hierarchical order 
and they are thus listed alphabetically (Table 13).
3.3.6 | Agents not recommended for the 
treatment of acute mania
Antimanic efficacy has not been demonstrated for allopurinol (level 1 
negative),167 eslicarbazepine/licarbazepine (level 2 negative),168 gabap-
entin (Level 2 negative), lamotrigine (level 1 negative),143 omega- 3 fatty 
acids (level 1 negative),169 topiramate (level 1 negative),143 valnoctamide 
(level 2 negative),170,171 or zonisamide (level 2 negative)172 (Table 13).
3.3.7 | No specific recommendation/agents that 
require further study
Trials with paliperidone (level 2 negative) and ziprasidone (level 2 neg-
ative) adjunctive therapy to lithium or divalproex showed lack of ef-
ficacy.144 This is surprising given that all other atypical antipsychotic 
agents that showed efficacy in monotherapy have also been shown to 
offer additional benefit when combined with lithium or divalproex. It is 
likely that methodological problems have contributed to failure in these 
studies; hence, further studies are needed before specific recommen-
dations can be made about the use of these combinations for mania.
Studies of olanzapine (level 2 negative) 173 or risperidone (level 3 
negative)174 plus carbamazepine have been negative, although this is 
probably due to enzyme- inducing effects of carbamazepine. While 
this may be overcome by dosing adjustments, because such interac-
tions are unpredictable and effective doses have not been established, 
we are unable to provide a specific recommendation.
Nutraceuticals such as branched chain amino acids (level 3),175 
folic acid (level 2),176 and l- tryptophan (level 3),177 as well as other 
experimental agents such as medroxyprogesterone (level 3),178,179 me-
mantine (level 4),180 mexiletine (level 4),181 levetiracetam (level 4)182 
and phenytoin (level 3),183 have all shown indications of efficacy when 
used adjunctively with other antimanic agents, as have glasses that 
block blue light (level 3).184 Larger controlled trials are needed, how-
ever, before a recommendation for their use in mania can be made. 
While an initial small RCT did not show anti- manic efficacy for ver-
apamil,185 there is some evidence that it may work as an adjunctive 
therapy (level 4)186 or as monotherapy in women (level 4).187 Larger 
studies are needed before a conclusion can be made.
3.3.8 | Clinical features that help direct 
treatment choices
Clinical features, including DSM- 5 specifiers, may assist in making 
treatment choices between first and second- line treatment options.
In general, lithium is preferred over divalproex for individuals who 
display classical euphoric grandiose mania (elated mood in the ab-
sence of depressive symptoms), few prior episodes of illness, a mania- 
depression- euthymia course,188-190 and/or those with a family history 
of BD, especially with a family history of lithium response. Divalproex 
is equally effective in those with classical and dysphoric mania. 
Further, divalproex is recommended for those with multiple prior 
episodes, predominant irritable or dysphoric mood and/or comorbid 
substance abuse or those with a history of head trauma.188,191-195 
Because of its teratogenic potential, however, caution should be ex-
ercised when prescribing divalproex to women of childbearing age. 
Patients with specific factors such as a history of head trauma, comor-
bid anxiety and substance abuse, schizoaffective presentations with 
mood- incongruent delusions, or negative history of bipolar illness in 
first- degree relatives may respond to carbamazepine.196
Combination therapy with lithium or divalproex and an atypical 
antipsychotic is recommended when a response is needed faster, in 
patients judged at risk, who have had a previous history of partial acute 
or prophylactic response to monotherapy or in those with more severe 
manic episodes.145
Anxious distress
Symptoms of anxiety frequently co- occur during a manic episode, and 
are a predictor of poor outcome; including greater severity of manic 
symptoms,197 a longer time to remission,197,198 and more reported 
side effects of medication.198 There have been no studies specifically 
examining the efficacy of any agents in reducing symptoms of anxiety 
during a manic episode, although these symptoms do tend to improve 
concurrently with mood disturbance. Post hoc analyses suggest that 
TABLE  13 Additional agents evaluated for use in acute mania
Agent Level of evidence




Haloperidol + Li/DVP Level 2
rTMS Level 3
Tamoxifen Level 2
Tamoxifen + Li/DVP Level 2
Not recommended Allopurinol Level 1 negative
Eslicarbazepine/licarbazepine Level 2 negative
Gabapentin Level 2 negative
Lamotrigine Level 1 negative
Omega- 3 fatty acids Level 1 negative
Topiramate Level 1 negative
Valnoctamide Level 2 negative
Zonisamide Level 2 negative
DVP, divalproex; Li, lithium; rTMS, repetitive transcranial magnetic 
stimulation.
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divalproex, quetiapine, and olanzapine may have specific anxiolytic 
benefits199 and carbamazepine may be useful as well.196
Mixed features
Depressive symptoms co- occur alongside mania in 10%- 30% of 
cases,200,201 with studies suggesting mixed features are indicative of 
a more severe and disabling course, as well as a higher rate of sui-
cide.201,202 Evidence supports the preferential use of atypical antip-
sychotics and divalproex in these cases, with combination therapy 
frequently required.195,203 Atypical antipsychotics such as asenapine, 
aripiprazole, olanzapine and ziprasidone have been shown to be equally 
effective in treating manic symptoms in those with classical mania as 
well as in mixed mania or in manic patients with mixed features.196,204,205
Psychotic features (mood congruent or incongruent)
At least half of manic episodes are characterized by the presence of 
psychosis,206 and theories suggest that it is a nonspecific feature which 
improves alongside underlying manic symptoms.207 While the progno-
sis for patients experiencing mood- congruent psychotic features may 
not differ from those with an absence of psychotic symptoms, limited 
evidence does suggest that those with mood- incongruent features 
have a more severe illness with poorer long- term prognosis.207-212 
There is no evidence of superiority of any first- line monotherapy 
treatment in comparison to other monotherapy options in treating pa-
tients with psychotic features. Similarly, there is no evidence that any 
first- line combination therapy of lithium or divalproex plus an atypi-
cal antipsychotic is more effective than other first- line combination 
therapy.174,193,213,214 However, clinical experience suggests that the 
combination of lithium or divalproex plus an atypical antipsychotic 
is more appropriate for manic patients with mood- incongruent psy-
chotic features (ie, other than grandiose delusions). Similarly, in pa-
tients where the diagnostic possibility of schizoaffective disorder with 
manic symptoms is considered, either use of an atypical antipsychotic 
or combination of an atypical antipsychotic with a mood stabilizer is 
more appropriate.
Rapid cycling
Rapid cycling, or a course of illness that includes four or more mood 
episodes a year, affects up to one- third of patients with BDI.215-218 
Hypothyroidism, antidepressant use and substance abuse are often 
associated with rapid cycling; thus assessing thyroid function and dis-
continuation of antidepressants, stimulants, and other psychotropic 
agents that are contributors to cycling are imperative. Consideration 
should be given to gradually withdrawing substances in order to pre-
vent withdrawal, but this needs to be balanced against the severity of 
mood cycling and the need for rapid mood stabilization. As there is 
no evidence for the superiority of any first- line treatment in address-
ing acute manic symptoms in patients with a rapid cycling course,219 
appropriate pharmacotherapy should be selected primarily based on 
effectiveness in the maintenance phase, if known (see Section 5). It is 
likely that combinations of mood- stabilizing drugs may be more often 
necessary than monotherapies when rapid cycling is present,220 but 
triple mood stabilizer therapy has not demonstrated superiority to 
double mood stabilizer therapy in a single RCT,221 although methodo-
logical weaknesses probably limited interpretability of the findings.
Seasonal pattern
While some individual patients may show a seasonal pattern, Canadian 
data are mixed as to whether episodes of mania or depression in BD 
follow a consistent seasonal variation.222 There is no evidence for the 
superiority of any agent in patients with an observed seasonal pattern 
of manic episodes.
4 | ACUTE MANAGEMENT OF 
BIPOLAR DEPRESSION
4.1 | Presentations of bipolar depression
The DSM- 5 criteria for bipolar depression are unchanged from 
DSM- IV. Depression is characterized by a minimum of 2 weeks of 
depressed mood and/or anhedonia and at least four other symptoms 
that include changes in sleep, appetite/weight, energy, psychomotor 
activity, concentration, thought content (guilt and worthlessness), 
and suicidal intent. For many patients with BD, the depressive polar-
ity is often more pervasive and more debilitating than manic states, 
with estimates that depressed mood accounts for up to two- thirds of 
the time spent unwell, even with treatment.12,223,224 Subsyndromal 
depressive symptoms, which persist despite treatment, are particu-
larly common and a major source of functional impairment in these 
patients.225-229 They should be treated aggressively.
DSM- 5 includes several specifiers that may accompany depressive 
episodes: anxious distress, mixed features, rapid cycling, melancholic 
features, atypical features, mood- congruent or mood- incongruent 
psychotic features, peripartum onset, and seasonal pattern (Table 5). 
The utility of several of these specifiers in selecting treatment options 
for depression is discussed later in this section (see “Clinical features 
that help direct treatment choices”).
4.2 | Diagnostic and treatment challenges
4.2.1 | Misdiagnosis and delayed diagnosis
Patients with depression occurring in the context of BD are fre-
quently misdiagnosed as having MDD, since the presence of mania 
or hypomania (particularly mild or moderate episodes which do not 
require hospitalization) may be challenging to establish retrospec-
tively. This is especially true in the absence of a comprehensive 
diagnostic interview or collateral information, as patients may often 
lack basic knowledge of what hypomania/mania is, and/or have lim-
ited insight into these symptoms; and thus may not disclose this 
information unless specifically asked. Alternatively, patients who 
will ultimately present with hypomanic or manic episodes may only 
have experienced episodes of depression. Thus, clinicians must be 
vigilant for a diagnosis of BD, and routinely ask for symptoms of 
a previous manic/hypomanic episode in every patient presenting 
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with a major depressive episode. A diagnosis of MDD should be 
made only after excluding the possibility of  BD.
In addition to overt manic/hypomanic symptoms, there are nu-
merous features that increase the likelihood of a diagnosis of BD 
in depressed individuals. These include earlier age of illness onset 
(before 25 years), brief, highly recurrent depressive episodes, a 
family history of BD, depression with psychotic features, atypical 
features such as reverse vegetative symptoms of hypersomnia and 
hyperphagia, leaden paralysis, psychomotor agitation, postpartum 
depression or psychosis, and antidepressant- induced irritability, 
manic symptoms or rapid cycling38,39 (Table 6).
Individuals with depression who are at high risk for BD, par-
ticularly those with a strong family history of BD, should be 
closely monitored for emergence of manic or mixed symptoms. 
Consideration should also be given to applying the BD depression 
treatment recommendations amongst those at very high risk, rather 
than risk potential iatrogenic effects of antidepressant monother-
apy, although this recommendation is based on clinical experience 
as there is a lack of sufficient research addressing this issue. As 
discussed in Section 2, there are also several useful psychosocial 
interventions, such as individual and family psychoeducation and 
FFT, that have been shown to have some benefit in this population.
4.2.2 | Suicide risk
Principles related to management of suicidal ideation and risk (see 
Section 2 and47) are of utmost importance during depressive epi-
sodes, as >70% of suicide deaths and suicide attempts in patients 
with BD occur during this phase.230,231 Depressive episodes with 
mixed features are a particularly dangerous period associated 
with even higher short- term risks of suicide attempts or death.232 
Overall, it is imperative for clinicians to review risk factors (Table 9) 
and determine an appropriate treatment setting to address any 
safety issues. All patients at risk should be encouraged to develop 
and share a written safety plan listing coping strategies and sources 
of support which may be applied during times of crisis. As described 
in Section 2, the most common method of suicide in this population 
is self- poisoning, and so potential benefits of various treatments 
should be considered against their risk of toxicity and lethality. One 
study found that there were fewer deaths due to lethal lithium lev-
els compared to carbamazepine, and that opioids and benzodiaz-
epines were the most common medication classes ingested at lethal 
levels—noteworthy given the lack of efficacy of these agents in the 
disorder.55
4.2.3 | Cognitive and functional impairment
Part of the impact of acute and subsyndromal depressive symptoms 
on functional impairment is thought to be mediated through cogni-
tive performance, which is both subjectively and objectively impaired 
in bipolar depression and linked to poor psychosocial function.233-236
Because of the important link between cognition and function-
ing,237 attention should be paid to avoiding treatments that may 
further exacerbate cognitive difficulties238 (see Section 8). Although 
evidence for their efficacy is limited, cognitive enhancement therapies 
can be considered experimental in this population.72,239,240
4.3 | Psychological interventions for acute bipolar 
I depression
While pharmacotherapy is essential and forms the foundation for 
successful treatment of BD, adjunctive psychosocial interventions 
may also be useful for acute depressive episodes. As described in 
Section 2, there are no first- line psychosocial treatment options for 
acute bipolar depression. Selecting between second- line options 
such as CBT (level 2) and FFT (level 2), as well as the third- line op-
tion IPSRT (level 3), should be based on individual strengths and 
needs.
4.4 | Pharmacological treatment for acute 
bipolar depression
Lithium, anticonvulsants, atypical antipsychotics, and other agents 
such as antidepressants have all been investigated for efficacy in man-
aging bipolar depression. These treatments have been evaluated using 
the criteria for strength of evidence for efficacy (Table 1) as well as 
safety and tolerability (Section 8). Recommendations are summarized 
in Table 14.
4.4.1 | Step 1: review general principles and assess 
medication status
Examination of a patient presenting in a depressed state should in-
clude an assessment of the nature and severity of depression and 
associated symptoms, risk of suicide/self- harm behaviour, ability 
to adhere to a treatment plan, availability of a psychosocial sup-
port network, and functional impairment. Laboratory investigations 
(described in Section 8) should also be completed. Results of the 
overall assessment should be used to establish the most appropriate 
treatment setting (eg, ambulatory or inpatient), with consideration 
given to management of safety risks. Before initiating pharmacolog-
ical treatment for a depressive episode, it is imperative to rule out 
symptoms secondary to alcohol/drug use, medications, other treat-
ments, or a general medical condition. Patients should be supported 
to discontinue stimulant use and limit nicotine, caffeine, drug, and 
alcohol use. Course of illness and treatments used in current and 
prior episodes should be assessed, including past response to and 
tolerability of specific medications and doses, and used to direct 
subsequent therapeutic choices. Consideration should be given to 
restarting medications if their recent discontinuation appeared to 
coincide with a depressive relapse.
Psychoeducation and other psychosocial strategies should also 
be offered alongside pharmacological treatment to promote ongoing 
medication adherence, reduce residual symptoms and suicidal be-
haviour, help identify early signs of relapse, and support functional 
recovery (see Section 2).
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4.4.2 | Step 2: initiate or optimize therapy and 
check adherence
It is recommended for all patients that pharmacotherapy be initiated 
with one or more of the available first- line agents. The choice of agent 
or agents to manage an acute bipolar depressive episode should be 
discussed with the patient and their supporters (as appropriate) and 
take into account current and prior medication use and response, per-
sonal preference, and the safety and tolerability of each agent, as well 
as clinical features that may influence prognosis (see “Clinical features 
that help direct treatment choices”).
First-line
Quetiapine (level 1),241-243 lithium (level 2),244-246 lamotrigine (level 
2)242,247,248 and lurasidone (level 2)249 are all recommended as first- 
line treatment options with evidence for efficacy as monotherapy.
Lurasidone (level 1)249,250 and lamotrigine (level 2)251,252 are also 
recommended as first- line adjunctive treatments (Figure 2). Although 
quetiapine and lithium have not been assessed for efficacy as adjunc-
tive treatments for acute bipolar depression, clinicians may choose to 
apply this combination in patients who experience depression when 
optimized on one of either of these medications.
Recommendations as to which first- line treatment should be consid-
ered first are outlined in our hierarchy. We recommend that the agents 
listed first in the hierarchy be tried first, in the order listed, unless there 
are patient-specific reasons for choosing an agent lower down in the 
order, such as previous history of response/ non-response or clinical 
features (see Clinical features which help direct treatment choices). For 
instance, if a patient presents with an acute bipolar depressive episode 
and is not taking any treatment and has not been treated for this epi-
sode, that patient should be commenced on quetiapine monotherapy 
if there is no previous history of non- response or tolerability concerns 
with quetiapine. However, if a patient had been taking lithium and ei-
ther had a breakthrough acute bipolar depressive episode or did not 
respond to monotherapy with lithium, then lurasidone or lamotrigine or 
quetiapine add- on or switch to quetiapine monotherapy or lurasidone 
monotherapy might be more appropriate in that order, given that lur-
asidone and lamotrigine adjunctive therapies have demonstrated effi-
cacy in lithium non- responders. Similarly, in non- responders to lithium 
monotherapy, adjunctive lamotrigine could be another option.
F IGURE  2 Lithium and lamotrigine as first-line agents for bipolar I depression: Summary of evidence [Colour figure can be viewed at 
wileyonlinelibrary.com]
Why are lithium and lamotrigine recommended as first-line agents for bipolar depression? 
Reconciling conflicng data
Lithium
In the only large double blind placebo controlled trial conducted to date, lithium was not more effecve than placebo for treang acute
bipolar depression(254). So, how does one jusfy recommending lithium as a first-line agent?  
The mean serum lithium levels in this study was only 0.61 mEq/L and this may account for lack of efficacy as a previous study demonstrated
that lithium monotherapy was as effecve as lithium plus paroxene in those with serum lithium levels of ≥0.8 mEq/L (247). 
Further, several small crossover trials demonstrated significantly higher response rates to lithium than placebo in paents with acute
bipolar depression (245). As well, the STEP-BD study suggested that mood stabilizers which include lithium are as effecve as mood
stabilizers plus andepressants in treang acute bipolar depression, although the durable recovery rate was modest, and there was no
sub analysis focusing on lithium versus other anmanic drugs (246). Thus, the findings of these studies jusfy a Level 2 rang of efficacy
for lithium. 
Given that lithium also has clearly demonstrated efficacy in prevenng mood episodes and in treang acute mania, our hierarchical
ranking thus jusfies lithium as an important first-line agent for bipolar depression, and based on overall evaluaon of available studies,
it is our opinion that a trough lithium serum level of 0.8-1.2 mEq/L would be needed for clinical effecveness.
Lamotrigine
Lamotrigine monotherapy was not superior to placebo in four double blind placebo controlled trials of acute bipolar depression on the
primary outcome (254). However, a meta-analysis conducted on the response rates from these studies as well as a BDII trial showed
superiority of lamotrigine (248). Moreover, methodological issues with the trials likely led to the effect of lamotrigine being
underesmated-including the relavely low final dose (200 mg in most trials, which is lower that usually used in clinical pracce) (255)
and short trial duraon (8 weeks in most trials) which, coupled with the slow traon of lamotrigine, resulted in parcipants being on
the final dose for only a short period (around two weeks). Further, lamotrigine was superior to placebo on Montgomery–Åsberg
Depression Rang Scale (MADRS) in one of the studies (249), and changes in symptoms on this scale have since been used to demonstrate
the efficacy of other agents for acute bipolar depression. Finally, the addion of lamotrigine to lithium (253) was superior to adding placebo
to lithium and there was a trend for superiority of addion of lamotrigine to queapine vs placebo add on (252) in treang bipolar
depression. It is likely that these beneficial effects are due to the direct effect of lamotrigine and not due to pharmacokinec interacon
between lamotrigine and concomitant medicaons. Furthermore, trial design issues, especially the fact that the six-week dose traon
phase took up most of the 8 week trials, is likely to compromise efficacy signals. Lastly, the short and long-term tolerability of lamotrigine
is a major benefit. Taken together, we believe these data jusfy at least a Level 2 rang for lamotrigine for acute bipolar depression.
In addion to this Level 2 rang for bipolar depression, lamotrigine also has demonstrated efficacy in maintenance treatment and an
excellent tolerability profile-features which qualify it to be a first-line treatment for bipolar depression.
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Clinicians are advised to appropriately dose these medications 
for an adequate period of time before concluding lack of efficacy. 
Clinical trials have shown that there is no difference in efficacy be-
tween quetiapine 300mg and 600mg daily doses. Lower doses of 
quetiapine have not been studied in clinical trials for bipolar depres-
sion. Therefore, clinicians are advised to consider a target dose of 
300 mg/day for quetiapine. For lithium, we suggest that serum lith-
ium levels should be maintained between 0.8 and 1.2 meq/L, while 
for lamotrigine, the target should be a minimum of 200 mg/day.
4.4.3 | Step 3: add on or switch therapy (alternate 
first- line agents)
Across several different medications for bipolar depression, early im-
provement (after 2 weeks) has been found to be a reasonable predic-
tor of overall response, whereas lack of early improvement is a more 
robust predictor of non- response.255 Lamotrigine is the exception to 
this rule, given a necessary slow titration initiating the medication. In 
the case of non- response, dosing should be optimized and issues of 
non- adherence identified and addressed (see Section 2) prior to ad-
justing treatment strategies.
When determining whether an agent should be switched or an-
other first- line agent be added on to any current treatment, the ef-
fectiveness of each of the medications needs to be understood in 
the context of all the goals of managing BD. It is often the case that 
a medication may be selected to address several goals; for instance, 
lithium could be added for acute depression with intent to also bol-
ster anti- manic prophylaxis. In this scenario, if lithium is ineffective 
in the individual patient for an acute bipolar depression but is also 
being used over the long term for anti- manic prophylaxis, then an 
“add- on” intervention should be the next treatment for the acute 
bipolar depression. If, for instance, the anti- manic prophylaxis is 
already being fully provided by an atypical antipsychotic, then the 
new medication could replace lithium via a switch strategy. Decision- 
making must also address efficacy for comorbid conditions, as well 
as tolerability concerns. In principle, all things being equal, a switch 
is preferred over add- on to limit the degree of polypharmacy, but 
the clinical reality is that medications may be helpful for some but 
not all components of the illness, and using rational polypharmacy 
via add- on treatments is often required. For situations in which pa-
tients experience a depressive episode while already receiving an 
adequately dosed antidepressant, strong consideration should be 
given to discontinuing or switching the class of antidepressant, un-
less clear benefits are apparent in reducing the severity or frequency 
of depressive episodes. Switch of medications should be done in an 
overlap and taper manner unless there is medical necessity for abrupt 
discontinuation.257
All first- line options should be tried in adequate doses for an ade-
quate duration of time before considering second- line options either 
as an add- on or switch strategy.
4.4.4 | Step 4: add on or switch therapy (second- line 
agents)
Second-line
In patients who are inadequately responsive to first- line agents, mono-
therapy with divalproex (level 2)242,258 is included as a second- line option.
Adjunctive use of antidepressant therapy (selective serotonin re-
uptake inhibitors [SSRIs] or bupropion) with lithium/divalproex or an 
atypical antipsychotic may also be considered as a second- line add- on 
treatment. While some individual studies have failed to demonstrate 
the efficacy of adjunctive antidepressant therapy, a recent meta- 
analysis (level 1) supports efficacy, albeit with a small effect size.259
This is a key aspect of decision- making regarding antidepressants, 
since historically much of the focus has been on risk of manic switch or 
rapid cycling, with an underappreciation of the relatively weak efficacy 
data. This new appreciation, exemplified by the small benefit seen in 
the above meta- analysis, led to the change from the last CANMAT 
guidelines, which previously gave add- on SSRI/bupropion antidepres-
sants a first- line recommendation. As per the ISBD Antidepressant 
Task Force recommendations,260 antidepressants should ideally be 
avoided, or used cautiously if necessary, in patients with a history of 
antidepressant- induced mania or hypomania, current or predominant 
mixed features, or recent rapid cycling. Patients and caregivers (as ap-
propriate) should receive education regarding early warning symptoms 
of mood switching or cycle acceleration, and antidepressants should 
be discontinued if these emerge. Antidepressant monotherapy should 
NOT be used for the treatment of BDI depression.
ECT (level 3) is also a second- line treatment, and should be consid-
ered particularly for treatment- refractory patients and those for whom 
a rapid treatment response is needed, such as those with severe de-
pression with imminent suicidal risk, catatonia or psychotic depression, 
F IGURE  3 Armodafinil and modafinil as third-line agents for bipolar I depression: Summary of evidence [Colour figure can be viewed at 
wileyonlinelibrary.com]
Why are armodafinil and modafinil third-line treatments for bipolar I depression? 
Armodafinil adjuncve therapy was assessed in three double blind randomized controlled trials.  Of these, one was posive (270) but in the
other two studies, it failed to separate from placebo on the primary efficacy measure (286, 287) although in one of the trials several
secondary outcomes were posive (288). Furthermore, in a fourth trial, there was also suggeson of efficacy based on some secondary
measures (289). Therefore, although two trials were negave on the primary efficacy measure, based on one posive trial and some posive
secondary outcomes in two trials, this was given a Level 4 rang (expert opinion), and recommended as a third-line.
Although modafinil has been shown to be efficacious in the only trial (269), it was also recommended a third-line in light of the three negave
trials for armodafinil.
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and/or when a rapid response is important for medical stabilization. 
Data support efficacy for brief pulse right unilateral placement, al-
though there are insufficient data to guide the decision of unilateral 
or bilateral placement for bipolar depression.261 Additional second- 
line options include cariprazine, with efficacy demonstrated through 
a large RCT262 and a pooled analysis of a failed RCT and a positive 
RCT263 (level 2), although there is less clinical experience supporting 
its use. Olanzapine- fluoxetine combination (level 2)264,265 is effective 
and is also recommended as a second- line option.
Similar to the approach for treatment of a manic episode, multiple 
first- and second- line agents and combinations should be trialled be-
fore considering initiating third- line agents in step 5.
4.4.5 | Step 5: add on or switch therapy (third- line 
agents)
Third-line
Third- line options are listed alphabetically in Table 15. In patients 
who fail to respond to multiple first- and second- line agents, third- 
line choices include monotherapy with carbamazepine (level 2)242 or 
olanzapine (level 1).242
Agents that may be applied adjunctively include aripipra-
zole (level 4),266,267 armodafinil (level 4)268,269 (Figure 3), asenap-
ine (level 4),270 levothyroxine (level 3),271,272 modafinil (level 2)268 
(Figure 3), and pramipexole (level 3).273,274 rTMS targeted at the left 
or right dorsolateral prefrontal cortex (level 3)275 may also be used 
in addition to medication. Other classes of antidepressants such as 
serotonin- norepinephrine	reuptake	inhibitors	[SNRIs]	and	monoamine	
oxidase inhibitors [MAOIs] could be used adjunctively but clinicians 
need to ensure adequate anti- manic prophylaxis in such situations, as 
SNRIs and MAOIs have a higher propensity than other antidepressants 
to induce manic switch and cause mood destabilization (level 2).276-278
Ancillary treatments such as adjunctive eicosapentaenoic acid (EPA) 
(level 2),169,279,280 N- acetylcysteine (level 3),281 and light therapy (level 
3),282 including bright light delivered midday (level 3),283 are also rec-
ommended as third- line treatment options to use adjunctively to other 
medications. There may be additional benefits to using light therapy in 
combination with total sleep deprivation (level 2), although there is lit-
tle clinical experience with this technique. While there is evidence from 
several small studies that intravenous ketamine (level 3)284 is a highly 
effective and fast- acting antidepressant, due to its invasive nature, short 
duration of effect, and lack of long- term safety data, it has been relegated 
to a third- line treatment, with recommendations that it be reserved for 
patients with severe symptoms or significant suicidal ideation for whom 
other treatments have been unsuccessful. In clinical situations that priori-
tize rapidity of response to treatment, ketamine may be considered earlier 
in the treatment order, although clinicians need to be aware that the data 
for efficacy are limited and the effects do not appear to last longer. Further, 
there are case reports of manic switch, but the clinical trial data have not 
provided any confirmatory evidence.284 Also, clinicians need to be aware 
of potential abuse of ketamine, especially in domiciliary use situations.285
4.4.6 | Agents not recommended for the 
treatment of acute bipolar depression
Antidepressants should not be used as monotherapy in patients with 
BDI depression, as available trials do not support their efficacy and 
there are concerns about their safety in terms of mood switching 
(level 2 negative).260,289-291
Aripiprazole monotherapy failed to separate from placebo in two 
bipolar depression trials.292 Although the pooled analysis reported sep-
aration,293 the mean difference in Montgomery–Åsberg Depression 
Rating Scale (MADRS) change score was only 1.12 points, which is not 
clinically meaningful and it is thus not recommended (level 1 negative). 
Ziprasidone monotherapy or adjunctive therapy (level 1 negative),242,294 
lamotrigine in combination with folic acid (level 2 negative),251 and mife-
pristone (adjunctive) (Leve 2 negative)295 are also not recommended 
due to evidence for lack of antidepressant efficacy (Table 15).
4.4.7 | No specific recommendation/agents that 
require further study
There are insufficient data to make a recommendation regarding the 
use of aspirin (adjunctive) (level 3 negative),296 celecoxib (adjunctive) 
TABLE  15 Additional agents evaluated for use in acute bipolar I 
depression
Agent Level of evidence
Third-line Aripiprazole (adj) Level 4
Armodafinil (adj) Level 4










Levothyroxine (adj) Level 3
Modafinil (adj) Level 2
N- acetylcysteine (adj) Level 3
Olanzapine Level 1





SNRI/MAOI (adj) Level 2
Not recommended Antidepressant 
monotherapy
Level 2 negative
Aripiprazole Level 1 negative
Lamotrigine +  
folic acid
Level 2 negative
Mifepristone (adj) Level 2 negative
adj, adjunctive; MAOI, monoamine oxidase inhibitor; SNRI, serotonin and 
norepinephrine reuptake inhibitor.
120  |     YATHAM eT Al.
(level 3 negative),297 gabapentin (monotherapy) (level 3 negative),298 
leviteracitam (adjunctive) (level 3 negative),299 lisdexamfetamine (ad-
junctive) (level 3 negative),300 memantine (adjunctive) (level 3),301 
pioglitazone (adjunctive) (level 3),302,303 riluzole (level 4 negative),304 
and risperidone (adjunctive) (level 3).305 Although adjunctive therapy 
with pregnenolone separated from placebo at week 6, the change in 
depressive symptoms was not significantly different from week 8 to 
week 12 between the two groups (level 2).306
4.5 | Clinical features that help direct 
treatment choices
There are limited data on predictors of treatment response in bipolar 
depression. However, clinical features of a depressive episode includ-
ing DSM- 5 specifiers may assist clinicians in choosing among recom-
mended treatment options.
Need for rapid response
Amongst the first- line options recommended, quetiapine and lurasi-
done have separated from placebo in clinical trials at as early as week 
1.249,307,308 Thus, these medications may be preferable when a rapid 
response is required, for example in patients who are at increased risk 
of suicide or who have medical complications, including dehydration. 
While ECT is recommended as a second- line option, this may also be 
used earlier when a rapid response is imperative. Second- line options 
such as cariprazine and olanzapine- fluoxetine have also separated 
from placebo at as early as week 1 and may also be considered when 
a rapid response is desirable, but this needs to be balanced against the 
potential side effects. Lamotrigine administration requires slower ti-
tration due to the risk of skin rashes, Stevens- Johnson syndrome, and 
toxic epidermal necrolysis, and is thus not ideal for patients requiring 
a rapid response. Lamotrigine, however, is well tolerated, and there 
is some evidence that its effectiveness may be more pronounced 
in patients experiencing depressive cognitions and psychomotor 
slowing.309
Previous treatment response
Adjunctive antidepressant use may be appropriate in those with 
prior antidepressant response if there was no history of treatment- 
emergent switch.310
Anxious distress
Symptoms of anxiety are often experienced during a depressive epi-
sode, and are predictive of more persistent depressive symptoms311 
and increased suicidal ideation.312 A pooled analysis of two double- 
blind RCTs demonstrated that quetiapine is more effective than pla-
cebo in relieving symptoms of anxiety co- occurring alongside bipolar 
depression,313 and olanzapine- fluoxetine combination has also been 
shown to be effective.314 In a post hoc analysis, lurasidone was ef-
fective in improving depressive as well as anxiety symptoms in 
patients with MDD who had mixed features and anxiety.315 The an-
xiolytic effects of divalproex, risperidone, and lamotrigine appear to 
be limited.199,316
Mixed features
Many patients with bipolar depression will also experience at least 
subsyndromal hypomanic or manic features, and this presentation is 
associated with more severe depressive symptoms, as well as a higher 
rate of substance use and cardiovascular disease.317 For many of these 
patients, combination therapy will be necessary to adequately address 
symptoms.318 Pooled analysis indicates that atypical antipsychotics 
show a class effect in alleviating mixed features in bipolar depression, 
with olanzapine- fluoxetine combination, asenapine, and lurasidone all 
demonstrating efficacy.319 Lurasidone has further been shown to have 
efficacy in treating both depressive and hypomanic symptoms in MDD 
with mixed features.320 The ISBD Task Force recommends avoiding an-
tidepressants in patients with mixed features260 and the CANMAT/
ISBD group concurs with this recommendation.
Melancholic features
No specific studies assessed the predictive ability of melancholic fea-
tures; however, clinical experience suggests that ECT is very effective 
in this population.
Atypical features
There is some evidence for efficacy of tranylcypromine in patients 
with anergic bipolar depression.321 However, given the risks of poten-
tial manic switch, this agent should only be used in conjunction with 
lithium or divalproex or an atypical antipsychotic. Clinicians also must 
consider adverse events of this agent related to its interactions with 
food and other medications.
Psychotic features (mood congruent or incongruent)
Up to 20% of inpatients experience psychosis in the context of an 
acute bipolar depressive episode.322 The relative efficacy of various 
medications to treat these features in this phase of illness has not been 
examined, although clinical experience suggests that ECT and antipsy-
chotics are highly effective for this population.
Rapid cycling
As described in Section 3, hypothyroidism, antidepressants and sub-
stance abuse may be associated with rapid cycling, thus making as-
sessment of thyroid function and discontinuation of antidepressants, 
drugs of abuse, stimulants, and other psychotropic agents imperative. 
As there is no evidence to support any specific agent to treat acute 
depression during a rapid cycling phase, appropriate pharmacotherapy 
should be selected based on effectiveness in the acute and mainte-
nance phases. Lithium, divalproex, olanzapine, and quetiapine all ap-
pear to have comparable maintenance efficacies in these patients.219 
In contrast, lamotrigine did not separate from placebo in maintenance 
treatment in patients with rapid cycling BDI.323 Antidepressants are 
not recommended, as they have been shown to destabilize patients, 
even with concurrent mood stabilizer use.324
Seasonal pattern
While some individual patients may show a seasonal pattern, Canadian 
data are mixed as to whether episodes of mania or depression in BD 
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follow a consistent seasonal variation.222 There is no evidence for the 
superiority of any agent in patients with an observed seasonal pattern 
of manic episodes.
5 | MAINTENANCE THERAPY FOR 
BIPOLAR DISORDER
5.1 | Need for long- term strategies
Almost all individuals with BD require maintenance treatment to pre-
vent subsequent episodes, reduce residual symptoms, and restore 
functioning and quality of life. There is increasing evidence to suggest 
that, for a subgroup of patients, BD may be a neuroprogressive disease 
in which recurrences are associated with reductions in brain grey and 
white matter volumes, worsening cognitive impairment, a decrease in 
inter- episodic recovery and functioning, a higher rate and severity of re-
lapse, and a reduced rate of treatment response to both pharmacother-
apy and psychotherapy.325 It is therefore important that comprehensive 
treatment be initiated even after a first episode.63 Effective maintenance 
treatment, early in the course of illness, has been shown to reverse cog-
nitive impairment and preserve brain plasticity, particularly in those who 
remain episode free,326,327 and may therefore lead to improved prog-
nosis and minimization of illness progression.328 There are preliminary 
data suggesting that, after a first episode, lithium might be superior to 
quetiapine in both volumetric and cognitive outcomes.329,330
With treatment, 19%- 25% of patients will experience a recurrence 
every year, compared to 23%- 40% of those on placebo.331 Risk factors 
for recurrence include younger age of onset,332 psychotic features,212 
rapid cycling,331 more (and more frequent) previous episodes,333 comor-
bid anxiety,334 and comorbid SUDs.335 Persistent subthreshold symp-
toms also increase risk for subsequent mood episodes,334,336,337 and the 
presence of residual symptoms should therefore be an indicator of a need 
for further treatment optimization. Availability of psychosocial support 
and lower levels of stress are also protective against recurrence.337,338
5.2 | Treatment adherence
Concordance between clinician and patient views of illness and treat-
ment is a crucial determinant of adherence,339 and reinforces the need 
for a collaborative approach to the treatment alliance.340 Asking about 
adherence behaviour and attitudes in a non- judgemental manner and 
exploring the reasoning behind poor adherence are important parts of 
treatment,341 as up to half of patients do not take their medications 
as prescribed.342-344 Unrecognized treatment non- adherence can lead 
physicians to believe that the patient is non- responsive, resulting in 
unnecessary dose increases (especially problematic for drugs with a 
narrow therapeutic index), medication switches, or adjunctive medi-
cations.341 Treatment withdrawal may precipitate recurrence; 50%- 
90% of patients discontinuing lithium experience a recurrence within 
3- 5 months,345,346 with rapid lithium discontinuation associated with 
greater recurrence risk than gradual discontinuation.347 Withdrawal 
of other mood stabilizers also predicts recurrence.348,349 Risks for 
hospitalization, suicide, and lost productivity are also increased 
with non- adherence or discontinuation.350-352 A variety of patient , 
disorder , and treatment- related risk factors for non- adherence or 
partial adherence are outlined in Table 16.353
Meta- analyses suggest that interventions aimed at engaging pa-
tients in treatment may more than double adherence compared to 
treatment as usual or other control groups.354 Brief psychoeducational 
interventions focusing specifically on medication adherence can be in-
tegrated into clinical practice.354 Flexible and collaborative engagement 
to address individual risk factors for non- adherence is recommended 
to optimize acceptability of pharmacological therapies.353,355-357
5.3 | Psychosocial interventions for 
maintenance therapy
Although pharmacotherapy is the foundation of maintenance treatment in 
BD, it is often insufficient to prevent recurrence. Over the last two decades, 
several controlled trials have examined the efficacy of adjunctive psychosocial 
treatments in reducing recurrence. On average, adjunctive psychosocial treat-
ments reduce recurrence rates by about 15%. Therefore, adjunctive psycho-
social interventions are an important component of management of BD and 
should be offered for all patients.
As described in more detail in Section 2, psychoeducation is the 
only first- line psychosocial intervention for the maintenance phase 
(level 1), which should be offered to all patients. Additional second- line 
options such as CBT (level 2) and FFT (level 2), and third- line options 
such as IPSRT (level 2) and peer support (level 2) should be offered 
based on individual strengths and needs.
TABLE  16 Risk factors for partial adherence or non- adherence to medication
Sociodemographics Male, younger age, low level of education, single
Psychological Poor insight, lack of awareness of disease, negative attitude to treatment, fear of side effects, negative attitude to 
medication, low overall life satisfaction, low cognitive functioning
Comorbidity Alcohol or cannabis use, obsessive compulsive disorder
Social No social activities, work impairment
Chronology Younger age of onset, current inpatient status, hospitalization or suicide attempt in past 12 months
Disease characteristics Mixed episode, rapid cycling, delusions and hallucinations, greater severity of illness, BDI diagnosis, higher number of 
episodes
Treatment- related factors Side effects of medications, inadequate efficacy of medication, use of antidepressants, low treatment doses
Adapted from Leclerc et al.353
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5.4 | Efficacy ratings for pharmacological agents 
used as maintenance therapy: importance of 
naturalistic and cohort studies
Evidence from RCTs is at the core of the recommendations in these 
guidelines. Nonetheless, RCTs are not the only source of clinically 
useful information, particularly when evaluating maintenance ther-
apy. RCTs offer relatively limited follow- up time- frames while, for 
some patients, maintenance therapy may extend across decades. 
Furthermore, new medications are often assessed in studies with an 
enriched design (including only patients who have responded to the 
medication under study in the acute phase), limiting the generalizabil-
ity of positive findings to patients who responded to the medication 
acutely.
Useful data can be obtained from large, often whole- population 
databases constructed from electronic medical records or electronic 
patient registries with large numbers of patients that would be diffi-
cult to obtain in RCTs. In some instances, they allow comparisons of 
multiple treatments.358-360 These large numbers make it possible to 
evaluate differences in rates of rare events such as less common side 
effects or suicide.361,362
Patient cohorts followed in a specific setting provide another 
source of informative data. Their main advantage usually is the length 
of observation, in some instances reaching several decades.363-365 This 
comes at the cost of generalizability, in terms of both patient selection 
and non- random treatment allocation.
5.5 | Pharmacological treatments for 
maintenance therapy
As in earlier sections, pharmacological treatments for maintenance 
therapy have been evaluated using the criteria for strength of evi-
dence for efficacy (Table 1) as well as safety and tolerability (Section 
8). Results are summarized in Table 17.
5.5.1 | Step 1: review general principles and assess 
medication status
Many agents recommended for management of acute manic or de-
pressive episodes have prophylactic efficacy. Generally, medications 
that have been found to be effective in the acute phase should be con-
tinued during the maintenance phase. However, there are exceptions 
to this: the efficacy of adjunctive antidepressant therapy has not been 
examined systematically in large double- blind placebo- controlled tri-
als; hence, long- term antidepressant use is not recommended, espe-
cially in light of the concerns about potential risk of manic/hypomanic 
switch and mood instability. However, in the subgroups of patients 
who have responded to combination treatment and are stable, pre-
liminary evidence suggests that withdrawal of antidepressants may 
contribute to destabilization.366
Clinical trials have shown that many atypical antipsychotics 
are effective in preventing relapse of mood episodes; with many 
agents, this efficacy is related to prevention of manic episodes but 
not depressive episodes. However, many of these trials have been 
conducted in patients with an index manic episode and, given that 
the polarity of an index episode predicts the polarity of relapse, de-
pressive relapse rates in placebo groups in such studies have been 
low- compromising the statistical power to test the efficacy of these 
agents in prevention of depressive relapses. Thus, the efficacy of 
many of these agents in preventing depressive relapses remains 
unknown.
For patients who are currently not receiving or responding to 
pharmacological treatment, a careful history including details of 
clinical course, response (or lack thereof) to previously used med-
ications, and family history should be collected. Other variables to 
be considered include psychiatric comorbidity (including substance 
use), the predominant illness polarity, and the polarity of the most 
recent episode.
Ongoing clinical monitoring, including medication blood levels 
as appropriate, is also a crucial part of maintenance treatment that 
should be used to support enhanced medication adherence, detection 
of early symptoms of recurrence, and monitoring of side effects (see 
Section 8).
5.5.2 | Step 2: initiate or optimize therapy and 
check adherence
The choice of agent or agents used in maintenance treatment should 
be discussed with the patient and their caregivers (as appropriate) 
and, based on knowledge of current and prior medication use and re-
sponse, safety and tolerability of each agent, predominant episode po-
larity, and clinical features that may influence prognosis (see “Clinical 
features that help direct treatment choices”). As with treatment for 
mania and acute depression, we recommend that treatment choices 
for maintenance treatment of BD should follow the hierarchy listed 
in Table 17 unless patient preference or other considerations such as 
previous response/non- response, tolerability or predominant polar-
ity justify other choices. Similarly, as a general rule, if a patient has 
been treated for an acute mood episode and responded to a first- line 
maintenance treatment, we recommend continuing that treatment for 
maintenance even if lower down in the hierarchy. As an example, if a 
patient responded to asenapine in an acute manic episode, asenapine 
should be continued, even if it is lower down in the hierarchy for main-
tenance treatment. It may be necessary to lower the dose to some 
degree once in maintenance treatment as patients often experience 
greater side effects once out of the acute episode.
There is evidence that the risk of recurrence is reduced when an 
antipsychotic is combined with lithium/divalproex. When a combina-
tion therapy of an atypical antipsychotic with lithium/divalproex was 
used to treat acute mania, continuing the atypical antipsychotic for 
the first 6 months following response offered clear benefit in reducing 
risk of mood episode recurrence (level 2),367 but the benefits beyond 
6 months remain uncertain. Therefore, clinicians are advised to re- 
evaluate risks and benefits after 6 months of sustained response to 
determine whether maintenance combination therapy with an atypical 
antipsychotic is justified.
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First-line
Lithium (level 1),368,369 quetiapine (level 1),369,370 divalproex (level 
1) 369,371,372 (Figure 4) and lamotrigine (level 1)369,373 monothera-
pies have the best combination of clinical trials, administrative data, 
and clinical experience to support their use as first- line therapies 
for maintenance treatment of BD. Recent data suggest that asenap-
ine (level 2)374 is effective in preventing both manic and depressive 
episodes, and thus is recommended as a first- line treatment. Finally, 
aripiprazole oral (level 2)375,376 or once monthly (level 2)377 is also rec-
ommended as a first- line monotherapy in view of its efficacy in pre-
venting any mood or manic episode as well as its safety/tolerability 
profile, although it has not been shown to be effective in preventing 
depression.
Additional combination therapies included as first- line include 
quetiapine adjunctive therapy with lithium/divalproex (level 1),378,379 
which has demonstrated efficacy in preventing any mood, manic or 
depressive episode. Aripiprazole plus lithium/divalproex (level 2)380 
should also be considered as a first- line option.
For patients who experience a recurrence or who remain symp-
tomatic while on a first- line agent or a combination, dosing should be 
optimized and issues of non- adherence identified and addressed prior 
to moving to step 3.
5.5.3 | Step 3: add on or switch therapy (alternate 
first- line agents)
If therapy with one or a combination of the first- line agents at opti-
mal doses is inadequate or not tolerated, the next step is to switch 
to or add on an alternate first- line agent. Because there are multiple 
first- line agents with substantial efficacy data and relative safety and 
tolerability, the use of second- line agents is only recommended after 
unsuccessful trials of multiple first- line strategies.
5.5.4 | Step 4: add on or switch therapy (second- line 
agents)
Second-line
Although olanzapine (level 1)381,382 is effective in preventing any 
mood, manic or depressive episode, it is considered second- line 
treatment because of safety issues such as metabolic syndrome. 
Biweekly long- acting injectable risperidone monotherapy (level 1)383 
or adjunctive therapy (level 2)384 has demonstrated efficacy in pre-
venting any mood or manic episode, but had no clear efficacy in de-
pressive episode prevention in these trials. Further, there was a trend 
for superiority of oral risperidone adjunctive therapy at 6 months in 
preventing any mood episode and in preventing mania but not de-
pression.367 Carbamazepine (level 2) has not been assessed in any 
large placebo- controlled trials, but active comparator trials support 
its efficacy.385 Paliperidone (level 2) was more effective than placebo 
TABLE  18 Additional agents evaluated for use in maintenance 
treatment of bipolar I disorder
Agent Level of evidence
Third-line Aripiprazole + lamotrigine Level 2
Clozapine (adj) Level 4
Gabapentin (adj) Level 4
Olanzapine + fluoxetine Level 2
Not recommended Perphenazine Level 2 negative
Tricyclic antidepressants Level 2 negative
adj, adjunctive.
F IGURE  4 Divalproex as a first-line maintenance therapy for bipolar I disorder: Summary of evidence  
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
Why is divalproex recommended as a first-line maintenance treatment for bipolar I disorder? 
In the only large double-blind placebo controlled RCT of divalproex monotherapy (373), it was not more effecve than placebo in
prevenng relapse of mood episodes i.e. me to any mood episode. However, in this trial, lithium which has been shown in many other
studies to be effecve in relapse prevenon, was also found to be no more effecve than placebo. Thus, these results suggest that this trial
was a failed trial and not a negave trial.  
Most modern studies of maintenance therapy use enriched design, meaning that those that responded in acute phase to the medicaon
being tested are randomized to connuaon of the same drug or replacement with placebo. This pracce to a large extent mirrors clinical
pracce as clinicians are likely to connue the medicaon that worked in the acute phase for maintenance treatment. Interesngly, in the
divalproex RCT, some but not all paents that were randomized into the double-blind phase were divalproex responders. In a post-hoc
analysis of this study, in this enriched subgroup of paents that responded to divalproex during the acute phase and randomized to
connuaon of divalproex vs switch to placebo, divalproex was more effecve in prevenng relapse of mood episodes compared with
placebo. 
Further, divalproex was superior to placebo on a number of other secondary efficacy measures such as lower rates of disconnuaon for
any mood episode or a depressive episode. Surprisingly, there was also a trend for superiority of divalproex relave to lithium in me to
any mood episode. Other RCTs have shown that divalproex is as effecve as lithium (221) in prevenng relapse of mood episodes. 
As well, two meta-analysis have concluded that divalproex is effecve in prevenng relapse of mood episodes (370, 372),  and a populaon
based cohort study in the UK showed that there were no differences in efficacy between divalproex, queapine and olanzapine in the
maintenance treatment of bipolar disorder (359).
Taken together, we believe these efficacy data support our raonale for a Level 1 rang. This along with clinical experience, real world
cohort data, and safety, jusfy our recommendaon of divalproex as a first-line maintenance treatment. 
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in preventing any mood or manic episode but less effective than 
olanzapine.386
Ziprasidone oral adjunctive therapy (level 2)387 has been shown 
to be effective in preventing any mood or manic episode, although 
there are conflicting (positive and negative) data for acute treatment 
(see Sections 3 and 4). There was a trend for superiority of lurasidone 
adjunctive therapy in preventing any mood episode (but not manic or 
depressive episodes individually) in a controlled trial with significant 
separation from placebo in preventing mood episodes in those with an 
index depressive episode.388 Thus, lurasidone adjunctive therapy may 
be appropriate for those who responded to this medication during an 
index depressive episode.
5.5.5 | Step 5: add on or switch therapy (third- line 
agents)
Third-line
Third- line agents are listed alphabetically in Table 18. There was 
a trend for superiority of adjunctive aripiprazole with lamotrigine 
(level 2)389 compared to lamotrigine monotherapy in preventing 
mania; thus, this combination may provide additional prophylaxis for 
patients on lamotrigine monotherapy in preventing manic relapses. 
Clozapine (level 4)162 and gabapentin (level 4)390 may also be useful 
adjunctive treatments for those who incompletely respond to first- 
or second- line therapies. The olanzapine/fluoxetine combination ap-
pears to maintain mood stability over a 6- month period in patients 
with bipolar depression who respond acutely to this combination 
(level 2).391
5.5.6 | No specific recommendation/agents that 
require further study
We do not provide specific recommendations for the use of caripra-
zine, as there is currently only evidence for efficacy in acute manic 
and depressive episodes262,392 and not yet for maintenance treatment 
(level 4). While a small RCT suggests a lack of efficacy for flupenthixol 
as maintenance treatment, larger studies are needed before definite 
conclusions can be drawn (level 3 negative).393 Likewise, oxcarbaz-
epine adjunctive therapy requires further evaluation (level 4).394-396 
No recommendation is made for topiramate as there is an absence of 
controlled data supporting its efficacy in maintenance (level 4 nega-
tive), and a lack of efficacy in acute mania381; however, its use may be 
indicated as it has efficacy for many syndromes that are often comor-
bid with BD (Section 7).
5.5.7 | Agents not recommended for 
maintenance treatment
Perphenazine is not recommended for maintenance based on evidence 
that patients treated with perphenazine and a mood stabilizer follow-
ing an episode are more likely to have emergent depressive symptoms 
or intolerable side effects, compared to those maintained on the mood 
stabilizer alone (level 2 negative).397 Tricyclic antidepressant mono or 
adjunctive maintenance therapy is not recommended due to an in-
creased risk of manic switch (level 2 negative)398-400 (Table 18).
5.5.8 | Clinical features that direct treatment choices
Clinical trials tell us how efficacious one drug is in comparison with 
another (or placebo) in groups of patients. To determine the degree 
of long- term response in an individual patient requires a different 
evaluation and may take a considerable amount of time. Few pa-
tients manage a lifetime of BD with monotherapy—most will re-
quire short- or long- term combination therapies to address acute or 
subsyndromal symptoms as well as to reduce rates of recurrence. 
Some,359,401,402 but not all,403,404 reports suggest that long- term 
treatment becomes less effective with longer duration of untreated 
illness, an argument for finding an effective treatment as early as 
possible.
In most instances, it is difficult to differentiate nonspecific cor-
relates of good prognosis of the illness from factors specific to the 
response to a particular mood stabilizer. Available data come mostly 
from naturalistic/cohort studies and few randomized trials.405 
Nevertheless, several tentative predictors are emerging from the 
available data.
Factors associated with overall good prognosis of BD include 
good treatment adherence, lack of early adversity, intermediate age 
at onset, good social support, and the absence of spontaneous rapid 
cycling406,407 or features of a personality disorder.408
In general, lithium is the gold standard for maintenance treat-
ment, as it is effective in preventing both manic and depressive 
episodes (magnitude of prophylactic efficacy greater against mania 
vs depression) and appears to have a degree of anti- suicidal ef-
fects.352,369,409-413 Patients who respond well to lithium treatment 
usually have an episodic remitting pre- treatment clinical course, a 
family history of BD (especially BD responsive to lithium), low rates 
of comorbidity (especially anxiety and substance abuse disorders), 
and a pattern of mania- depression- euthymia in biphasic episodes, 
as well as a typical clinical presentation.414-416 Responsiveness may 
also be a familial trait, with a study showing that patients who have 
a lithium- responsive relative have a 67% likelihood of also being lith-
ium responsive, versus 35% of those without a responsive relative.417 
Among biological measures, lack of electroencephalogram (EEG) ab-
normalities, higher brain lithium concentration, increased N- acetyl 
aspartate and lower myo- inositol peaks on magnetic resonance 
spectroscopy, as well as several variants in candidate gene studies, 
may predict response,418 but these studies require confirmation. 
Response to lithium in particular seems to be quite specific, as shown 
in a study of neurons derived from induced pluripotent stem cells. 
The neurons from people with BD were hyperexcitable and their ac-
tivity was selectively modified by in vitro lithium in accordance with 
clinical response.419
Responders to lamotrigine have a predominantly depressive polar-
ity as well as comorbid anxiety.420,421 Lamotrigine monotherapy is not 
appropriate for patients with frequent manic episodes, as it has limited 
efficacy in preventing mania.
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Quetiapine has been shown to be effective in preventing manic, 
depressive and mixed episodes in patients with index manic, de-
pressive and mixed episodes, and thus may be particularly valuable 
in those with mixed features.422 Asenapine appears to be effective 
in preventing both mania and depression, although the magnitude of 
prophylactic efficacy is greater for mania relative to depression. In a 
randomized open trial of carbamazepine versus lithium, responders to 
carbamazepine were more likely to have an atypical illness, BDII or 
schizoaffective disorder.405
Data to differentiate anti- psychotic medication responders from 
non- responders are lacking.
Overall, some of these possible predictors can have clinical utility, 
but not all are practical. For instance, it is difficult to evaluate a pre- 
treatment course in patients who started their treatment after one or 
two episodes (practice recommended by most treatment guidelines), 
and biomarkers are intriguing but lack sufficient replication and are 
not readily available.
In patients with a history of a rapid cycling course, as indicated in 
previous sections, factors associated with rapid cycling must be ad-
dressed. These include discontinuation of stimulants and antidepres-
sants and treating hypothyroidism if present. With regard to treatment 
options, the evidence suggests that monotherapy with a single mood 
stabilizer is often ineffective and patients may require a combination 
of mood stabilizers to achieve mood stability.
Treatment- refractory bipolar disorder
Treatment refractoriness may be related to non- adherence to oral 
medications, failure to optimize evidence- based oral medication ther-
apy/therapies, comorbidities complicating therapeutic response or 
true resistance to pharmacotherapy. Clinicians are advised to make a 
comprehensive assessment to determine factors responsible for treat-
ment refractoriness. Adequate doses of first and second- line agents 
should be employed for an adequate period of time (eg, this is typi-
cally individualized based on the previous course of mood episodes in 
each patient) to assess prophylactic response. Comorbidities should 
be addressed with pharmacological or psychological strategies as ap-
propriate. While genotyping for cytochrome P450 enzymes such as 
2D6 and 3A4 which metabolize most psychotropic drugs is not rou-
tinely recommended, clinicians are advised to consider this in patients 
with refractory BD who have not responded to high doses of various 
first , second , and third- line treatments or their combinations in order 
to exclude the possibility of ultra rapid metabolic status contributing 
to poor response.
In patients who are non- adherent, psychosocial strategies such 
as psychoeducation should be used to improve treatment adher-
ence. If ineffective, long- acting injectable medications should be 
offered. Risperidone long- acting injectable monotherapy383 or 
adjunctive therapy (level 2)384 once every 2 weeks or aripiprazole 
once- monthly injectable monotherapy (level 2)377 has been shown 
to be effective in preventing relapse of mood episodes in patients 
with BD.
There is a dearth of clinical trial data to inform treatment options 
for management of patients with refractory BD. Clozapine adjunctive 
therapy has been shown to be effective in reducing symptoms and 
total medication use in treatment- resistant patients.162
6 | BIPOLAR I I  DISORDER
6.1 | Presentation of bipolar II disorder
BDII is a distinct disorder from BDI, with a similar Canadian preva-
lence (0.67% compared to 0.87% for BDI).7 The diagnosis of BDII 
requires one or more episodes of hypomania, one or more episodes 
of depression, and an absence of manic episodes. The DSM- 5 cri-
teria for hypomania are similar to those for mania, with symptoms 
being uncharacteristic of the individual, observable by others, and 
lasting at least 4 consecutive days. In contrast to mania, they can-
not be severe enough to cause marked impairment or require hos-
pitalization, and there must be an absence of psychosis. Further, 
DSM- 5 has added a mixed feature specifier to hypomania as well. 
The diagnosis of BDII is generally stable over time, although there 
may be a higher risk of conversion to BDI early in the illness, sug-
gesting that BDII may be a risk factor or prodrome of BDI in some 
patients.423
TABLE  19 Strength of evidence and treatment recommendations 
for acute management of bipolar II depression
Recommendation Agent Level of evidence
First-line Quetiapine Level 1
Second-line Lithium Level 2
Lamotrigine Level 2




Third-line Agomelatine (adj) Level 4
Bupropion (adj) Level 4
Divalproex Level 4
EPA (adj) Level 4
Fluoxetinea Level 3












Not recommended Paroxetine 2 negative
adj, adjunctive; ECT, electroconvulsive therapy; EPA, eicosapentaenoic 
acid.
aFor patients with pure depression (non- mixed).
bFor patients with depression and mixed hypomania.
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Although hypomania is, by definition, less severe than mania, 
the disability associated with BDII is comparable to that associated 
with BDI,14,424 and the economic burden of BDII is up to four times 
greater.425,426 This is because patients with BDII spend as much time 
symptomatic as those with BDI, with mood symptoms predominantly 
in the depressive phase.427,428 Rates of attempted and completed 
F IGURE  5 Lithium as a second-line agent for bipolar II depression: Summary of evidence.  
BDI, bipolar disorder type I; BDII, bipolar disorder type II; BDNOS, bipolar disorder not otherwise specified; RCT, randomized controlled trial 
[Colour figure can be viewed at wileyonlinelibrary.com]
Why is lithium recommended as a second-line agent for bipolar II depression? 
Reconciling conflicng data
In a 16-week double blind RCT, lithium was as effecve as sertraline and lithium + sertraline combinaon (427) which qualifies lithium for
Level 2 evidence. Addional supporng data come from a single-blinded trial which showed that lithium was as effecve as lamotrigine in
treang BDII  depression over 6 weeks (445). However, neither of these studies had a placebo arm. Posive placebo-controlled data come
from 4 small placebo-controlled crossover studies conducted in the 1960s and 1970s, in which lithium was effecve in a mixed sample of
BDI and BDII depressed paents (446-449). Results were reported separately for BDII in 2 of the studies and were idencal to BDI
(pooled response rate = 65% for both) (446).   
In contrast, in the only modern a placebo-controlled parallel group study, lithium was not superior to placebo in BDII depression (254).
Further, lithium was less effecve than venlafaxine in a 12-week RCT (450).  
A potenal explanaon might have to do with trough serum lithium levels. Lithium levels ranged from 0.8-1.3 mEq/L, and were oen at the
high end of that range in the older placebo-controlled RCTs while in the negave placebo-controlled RCT, the mean serum lithium level was
lower (<0.61 mEq/L in the combined BDI + BDII sample, not reported separately for BDII). Thus, the opmal serum level for treang bipolar
II depression is unclear. However, based on the placebo-controlled BDII trials, as well as placebo-controlled studies in BDI (247), a serum
level of 0.8-1.2 mEq/L appears most likely to be beneficial.   
In addion to the evidence for efficacy in acute depression, lithium also has efficacy in prevenng mood episodes in BDII (400, 452-454).
Therefore, in balance, we believe the evidence, though mixed, jusfies recommending lithium as a second-line agent for BDII depression. 
F IGURE  6 Antidepressants for bipolar II depression: What is their role?  
BDI, bipolar disorder type I; BDII, bipolar disorder type II; ISBD, International Society for Bipolar Disorders; MDD, major depressive disorder; 
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
Should andepressants be used in bipolar II depression?
Addressing the controversy
The queson of whether, and if so when and how, to use andepressants in BDII remains controversial due to concerns regarding both
safety (parcularly the possibility of hypomanic switch, mixed symptoms, and increased cycling) and efficacy. 
With respect to safety, a meta-analysis that compared rates of andepressant-associated mood elevaons in BDII, BDI, and MDD
reported that they were significantly less frequent in BDII than BDI, and occurred almost exclusively into hypomania rather than mania
(454).  Switch rates were low even during andepressant monotherapy and with andepressants associated with high switch rates in BDI
(tricyclics, venlafaxine). An ISBD task force report on andepressants also concluded that their risk-benefit rao was more favorable in
BDII (261, 449). 
The issue of efficacy is less clear due to limited evidence. RCTs have shown that sertraline monotherapy was as effecve as lithium and
lithium+ sertraline combinaon, and that venlafaxine monotherapy was more effecve than lithium, sufficient for level 2 evidence for
these agents. In a RCT of BDI and BDII paents, bupropion was shown to be as effecve as sertraline and venlafaxine (277). Open-label
data also suggest efficacy for fluoxene, and there are maintenance data for venlafaxine and fluoxene in prevenng relapses. These
posive findings should be balanced against the fact that paroxene and bupropion were not beer than placebo for acute depression in
paents taking concomitant mood stabilizing medicaons. Moreover, it is important to bear in mind that 1) there are no placebo-controlled
acute-phase trials of andepressant monotherapy in BDII, 2) many andepressants have not been studied at all (and we do not believe it is
warranted to extend posive findings from sertraline/venlafaxine -or for that maer negave findings from paroxene/bupropion -to
“andepressants” generally), 3) the exisng trials enrolled people with pure (non-mixed) depression, and their efficacy/safety in the
broader spectrum of BDII paents is unclear, and 4) many of the exisng trials have significant weaknesses, including one or more of:
low dosing of the andepressant; sub-therapeuc dosing of comparator medicaons; and lack of replicaon. 
All of this makes it parcularly difficult to make evidence based recommendaons regarding andepressants in BDII. We have restricted
our recommendaons to the specific agents that have been studied, and we recommend bupropion, sertraline,and venlafaxine
monotherapy as second-line treatments; and fluoxene as third-line. We further recommend that any andepressant, especially in
monotherapy, be reserved for paents with pure depression and avoided in those with mixed symptoms or a history of andepressant-
induced hypomania (261). Whether andepressants should also be avoided in paents with rapid cycling is unclear, since some studies
report poorer outcomes in rapid-cycling paents (455) while others do not (450, 456-458). Paents prescribed andepressants must be
educated regarding early-warning signs of hypomania and carefully monitored for them. Finally, there is a pressing need for further studies
of other andepressants in BDII, in both monotherapy and combinaon therapy.
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suicide are similar in BDI and BDII, with approximately one- third of pa-
tients with BDII attempting suicide over the course of their illnesses429 
and one in twenty- five completing suicide.430
6.2 | Pharmacological treatment of bipolar II disorder
6.2.1 | General considerations for interpreting 
recommendations
The treatment of BDII has been understudied relative to BDI. This 
is probably due to the long- standing but discredited impression of 
BDII as a less severe form of BD. The number of RCTs in BDII is sub-
stantially smaller than that in BDI, and those studies that do exist are 
frequently under- powered. It also remains common for trials to enrol 
patients with both BDII and BDI without reporting results separately, 
making it difficult to determine if there are clinically meaningful differ-
ences in treatment response between the two illnesses. This is impor-
tant because, while clinical experience and the results of many studies 
suggest that response to mood stabilizers and antipsychotics is similar 
in BDII and BDI, there are enough exceptions to suggest this should 
not be taken for granted.248,405,431 This is also the case for antidepres-
sants, which may have a more favourable risk- benefit ratio in BDII 
(reviewed below). Therefore, in formulating our recommendations, 
studies that enrolled patients with both BDII and BDI but did not 
report results for BDII separately are assigned level 4 status (expert 
opinion) if the proportion of patients with BDII was less than 50%.
The relative paucity of large, methodologically sound clinical trials 
in BDII creates challenges in formulating evidence- based guidelines. 
As will be seen, there are fewer treatments with high- quality evidence 
in BDII compared to BDI and fewer first- line treatment recommenda-
tions. The limitations of the evidence base necessitate an awareness 
of the nuances of the available studies, and a greater reliance on clin-
ical experience. We thus have endeavoured to be clear in outlining 
the rationale for selecting first , second , and third- line treatments for 
hypomania, depression, and maintenance treatment of this important 
illness. There is clearly a pressing need for adequately powered trials 
in BDII across all illness phases.
6.2.2 | Acute management of hypomania
The general principles for assessing mania apply to hypomania. 
For some patients, hypomania causes no to minimal functional im-
pairment and may even be associated with brief periods of above- 
normal functioning. However, prolonged, relatively severe, or mixed 
or irritable hypomania may be impairing.423 Treatment should in-
clude discontinuing agents that can worsen or prolong symptoms, 
including antidepressants and stimulants, and initiating appropriate 
pharmacotherapy.
Unfortunately, many standard medications for mania, including 
lithium and most atypical antipsychotics, have not been studied in 
hypomania. There are four placebo- controlled trials that investigated 
divalproex (level 4),432 N- acetylcysteine (level 4),433 and quetiapine 
(level 4)434,435; and one open- label study of risperidone (level 4)436 in 
acute hypomania. The studies generally suggested efficacy but all had 
significant weaknesses, including one or more of: (i) small sample sizes, 
(ii) mixed samples with BDI, BDII, and BD NOS; (iii) mixed samples 
with hypomania and mania, and (iv) positive findings on some but not 
all outcomes. The small numbers of patients and mixed samples mean 
F IGURE  7 Lamotrigine as a second-line agent for bipolar II depression: Summary of evidence  
BDI, bipolar disorder type I; BDII, bipolar disorder type II; RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
Why is lamotrigine a second-line recommendaon for bipolar II depression?
Reconciling conflicng data
Lamotrigine monotherapy was studied in two trials in BDII depression: one in which 221 BDII paents received 200 mg/day or placebo for
8 weeks, and a second in which 206 BDI or BDII paents (N = 84 with BDII) received 100–400 mg/day for 10 weeks (254). Both produced
negave results. A meta-analysis confirmed that lamotrigine was not superior to placebo in BDII depression, although it did separate from
placebo in BDI (248). Several methodological shortcomings likely resulted in the studies underesmang the drug’s effect, including 1) a
slow traon which resulted in subjects being on the target dose for a short me, 2) a target dose lower than that oen used in clinical
pracce and in successful maintenance studies (255, 324), and 3) higher placebo response rates. In contrast, a single-blind RCT with a
relavely high dose (final peak dose=300mg) and a longer duraon (16 weeks) found that lamotrigine monotherapy was as effecve as
adequately-dosed lithium (mean final serum level=1.1 mEq/L) in N=98 BDII paents (445). Two large RCTs in BDI+BDII and a 12-week
open-label trial in paents with BDI+BDII+BDNOS also reported that adjuncve lamotrigine was effecve, but did not report results
separately for BDII (252, 253). Finally, lamotrigine has robust efficacy in prevenng depressive relapse in BDI and BDII (324, 459). 
Taking all of these factors into consideraon we recommend lamotrigine as a second-line treatment, parcularly for paents who can
tolerate a slow traon and delayed effect.
TABLE  20 Strength of evidence and treatment recommendations 
for maintenance treatment of bipolar II disorder
Recommendation Agent Evidence level
First-line Quetiapine Level 1
Lithium Level 2
Lamotrigine Level 2
Second-line Venlafaxine Level 2




Other antidepressants Level 3
Risperidonea Level 4
aPrimarily for prevention of hypomania.
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that even the placebo- controlled trials only met criteria for level 4 ev-
idence (Table 1).
These methodological limitations, coupled with the lack of clin-
ical trial evidence for many medications, make it difficult to make 
specific suggestions for the treatment of hypomania. Clinical experi-
ence suggests that all anti- manic medications are also efficacious in 
hypomania. Thus, when hypomania is frequent, severe, or impairing 
enough to require treatment, clinicians should consider mood stabi-
lizers such as lithium or divalproex and/or atypical antipsychotics. N- 
acetylcysteine may also be of benefit, but further studies are needed.
6.2.3 | Acute management of bipolar II depression
The general principles for assessing depression in patients with BDI 
apply to those with BDII. First , second , and third- line treatment 
options are listed below and shown in Table 19. Specific consid-
erations regarding each treatment are highlighted in the relevant 
sections.
First-line
Quetiapine is the only recommended first- line treatment for BDII de-
pression (level 1). Pooled analyses of five identically designed trials 
demonstrated that quetiapine was superior to placebo, and moreo-
ver was equally effective for acute depression in BDI and BDII.243,437 
The latter finding must be reconciled with the fact that quetiapine 
beat placebo in only three of the five individual trials in patients 
with BDII, compared to all five in patients with BDI.253,290,438-440 
This is probably because the smaller sample of BDII patients—only 
about half as many patients with BDII as BDI were enrolled in each 
of the trials—provided less statistical power for BDII. Finally, open- 
label studies also suggest efficacy for adjunctive quetiapine (level 
4).441,442
Second-line
Second- line treatments include lithium, ideally at a serum level of 
0.8- 1.2 mEq/L (level 2) (Figure 5), and the antidepressants sertra-
line (level 2) 426 and venlafaxine (level 2),443,444 mainly for patients 
with pure (non- mixed) depression (Figure 6). Lamotrigine (level 
2) is also recommended as a second- line agent despite conflict-
ing evidence, with the rationale for this provided in Figure 7. ECT 
(level 3)261 can also be considered second-line and is a good option, 
particularly for treatment refractory patients and those in need of 
rapid response.
Third-line
The third- line options include monotherapy with divalproex (level 
4)258,459,461,462-466 fluoxetine (mainly for patients with pure depres-
sion) (level 3)467-469 tranylcypromine (level 3),278 or ziprasidone (solely 
for patients with depression and mixed hypomania) (level 3).470,471 
Adjunctive agomelatine (level 4),472 bupropion (level 4)276 eicosa-
pentaenoic acid (EPA) (level 4),473-475 N- acetylcysteine (level 4),476 
pramipexole (level 3),274 or thyroid hormones (level 4)272 may also be 
considered.
Intravenous ketamine (level 3)477,478 has rapid onset of efficacy 
and may be considered for patients who are refractory to first and 
second-line treatments, as well as for those in need of rapid response.
No specific recommendation/agents that require further study
A number of agents do not have sufficient data to warrant specific recom-
mendations for BDII depression, including cranial electrotherapy stimu-
lation (CES),479 dextromethorphan + quinidine,480 light therapy,481-485 
lisdexamfetamine (adjunctive),300 olanzapine,486 pioglitazone,302 ad-
junctive pregnenolone,306 celecoxib,297 levetiracetam,487 adjunctive 
lisdexamfetamine,300 s- adenosylmethionine,488-490 acetyl- l- carnitine + 
alpha- lipoic acid,491 adjunctive modafinil,268 rTMS,275,492,493 and 
memantine.494
Not recommended
Based on negative placebo- controlled data, we do not recommend 
paroxetine (level 2 negative).245
6.2.4 | Maintenance treatment
Maintenance treatment is important to prevent relapse, reduce sub-
syndromal symptoms, and improve quality of life. As with BDI, se-
lection of an agent should be informed by acute phase treatment. 
Recommended agents and their evidence ratings are listed in Table 20.
First-line
Monotherapy with quetiapine (level 1),495 lithium (level 2),399,450,452 
and lamotrigine (level 2)323 are first- line options.
Quetiapine. In two 52- week maintenance studies, patients with 
BDII who achieved remission from depression with quetiapine mono-
therapy continued it or switched to placebo.495 A pooled analysis 
reported that patients treated with quetiapine had a significantly 
longer time to relapse into any mood episode (hazard ratio [HR] 
0.33, or a 67% reduction in the risk of relapse) and into depression 
(HR 0.28 or a 72% risk reduction). Time to relapse into hypomania 
was not significantly greater (HR 0.65 or a 35% risk reduction). The 
latter finding may be related to the low base rate of hypomania, 
which occurred in only 10% of all study participants. Quetiapine was 
at least as effective in BDII as in BDI, for which the risk reductions 
were 42% for any relapse, 48% for depression, and 30% for mania. 
Adjunctive quetiapine was also studied in a 6- month single- blind trial 
which randomly assigned patients with either BDI or BDII to lithium 
or quetiapine added to treatment as usual. They were equally effec-
tive in preventing relapse.453 Results were not presented separately 
for BDII, but BDII patients responded better to both treatments than 
did BDI patients.
Lithium. In three placebo- controlled RCTs conducted in the 1970s 
and 1980s (duration = 11- 25 months), lithium decreased the frequency 
and/or severity of hypomanic and depressive episodes.399,450,452 Serum 
lithium levels were 0.8- 1.2 mEq/L. A number of active comparator 
studies also support lithium. As noted above, lithium was as effective 
as quetiapine in preventing relapse in a 6- month single- blind trial.453 A 
20- month study comparing lithium and divalproex in rapid cycling BDI 
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+ BDII found the two drugs to be equally effective in preventing re-
lapses.496 The authors noted that findings were similar for BDII and BDI, 
but results were otherwise not reported separately for BDII. In a 2.5- 
year study in BDII + BD NOS, lithium and carbamazepine were equally 
effective on most outcomes, although a numerical advantage favoured 
carbamazepine for reducing clinical plus subclinical recurrence.405 In 
contrast, head- to- head comparisons with antidepressants (reviewed 
below) found that lithium was not as effective in preventing depressive 
relapse as fluoxetine or venlafaxine.469,497 This may be explained by the 
mean lithium levels, which were 0.7 mEq/L in both studies, while the 
fluoxetine trial was also enriched for fluoxetine responders.
Long- term naturalistic data also provide strong support for lithium. 
In a 6- year study of patients with either BDI or BDII (39% with BDII), 
lithium reduced time in hypomania/mania by 61% and time in depres-
sion by 53% in the entire sample, compared with the period before lith-
ium treatment was initiated.498 The authors noted that the proportion of 
time with mood symptoms was significantly lower for BDII than for BDI.
Lamotrigine. In a 6- month placebo- controlled RCT of lamotrigine 
monotherapy in rapid cycling BDI + BDII, post hoc analysis showed that 
significantly more lamotrigine- treated than placebo- treated patients 
with BDII were stable without recurrence into any mood episode,323 
although lamotrigine was not superior to placebo in BDI. In a large 52- 
week RCT in BDI + BDII, adjunctive lamotrigine was superior to pla-
cebo for improving depression severity and remission rates. However, 
results were not presented separately for BDII.251 Open- label trials 
and retrospective chart reviews also support lamotrigine.248,499-502
Second-line
Monotherapy with venlafaxine (level 2) or fluoxetine (level 3) are 
second- line options.
Venlafaxine. In a small 6- month RCT in patients with BDII who re-
sponded acutely to venlafaxine or lithium without hypomanic switch, 
there was a trend for lower rates of relapse into depression for patients 
treated with venlafaxine. Further, the rate of sustained response was 
significantly greater in those who continued venlafaxine compared to 
those who continued lithium.497 No hypomanic episodes occurred in 
either group.
Fluoxetine. In a 50- week RCT, the mean time to relapse into depres-
sion was significantly longer for fluoxetine than for lithium or placebo. 
Patients had responded acutely to open- label fluoxetine, making the 
sample enriched for fluoxetine response. Hypomanic episodes occurred 
in a similarly low frequency in the three groups.469 In a separate small 
6- month placebo- controlled trial, there was a statistical trend for lower 
relapse rates with fluoxetine compared to placebo.503 Finally, a post 
hoc analysis of a large 12- month placebo- controlled trial found that re-
sponse rates to fluoxetine were similar in BDII and MDD.468 However, 
it did not report whether fluoxetine was superior to placebo in BDII.
Third-line
Divalproex (level 4),504 carbamazepine (level 3),405 escitalopram (level 
3),505 other antidepressants (level 3),454 and risperidone (mainly for pre-
vention of hypomania) (level 4)436 may be considered as third- line options.
No specific recommendation/agents that require further study
There are insufficient data to make a recommendation regarding 
olanzapine.506
7 | SPECIFIC POPULATIONS
7.1 | Management of bipolar disorder in women at 
various stages of the reproductive cycle
7.1.1 | Pre- conception, psychoeducation and 
contraceptive counselling
The importance of pre-conception counselling  should be raised with 
all women of child bearing age. It should be provided for all patients at 
least 3 months prior to considering pregnancy or immediately for those 
already pregnant. The issues most frequently raised are fear of adverse 
TABLE  21 US Food and Drug Administration (FDA) classification 


























aFDA has replaced these risk categories in 2015 with Pregnancy and 
Lactation Labeling Final Rule (PLLR). SEE TEXT FOR DETAILS.
bAdapted from ACOG Committee on Practice Bulletins–Obstetrics878: US 
Food and Drug Administration Rating. A = controlled studies show no risk; 
B = no evidence of risk in humans; C = risk cannot be ruled out (human 
data lacking, animal studies positive or not done); D = positive evidence of 
risk (benefit may outweigh risk). The “m” subscript is for data taken from 
the manufacturer’s package insert.
cHale TW and Rowe HE.879 Lactation risk categories are listed as follows: 
L1, safest; L2, safer; L3, moderately safe; L4, possibly hazardous; L5, 
contraindicated.
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effects of medications on the fetus, fear of illness recurrence, and ge-
netic transmission to offspring.507 Other important topics to review 
include the effect of BD on risk for gestational hypertension, antepar-
tum haemorrhage, induction of labour, caesarean section, instrumen-
tal delivery, preterm delivery, and neonatal size.508,509 Discussion of 
modifiable risk factors is critical in pre- conception management of BD. 
For instance, pregnant women with BD are more often overweight, 
more often smoke tobacco during pregnancy, have poorer diet quality, 
and present more often with a history of drug and alcohol misuse in 
pregnancy.509 Modification of these risk factors may have a significant 
positive impact on outcomes for both the mother and child.
Decisions should be made collaboratively on whether medications 
should be continued, discontinued, or switched; and whether any dos-
age changes are needed. Conventional antipsychotics and risperidone 
may need to be discontinued to increase the likelihood of conception, 
as these medications often increase serum prolactin levels and thus 
interfere with ovulation and decrease fertility.510 For women who wish 
to have a medication- free pregnancy, it might be appropriate to have 
one or more psychotropic medications gradually tapered off prior to 
conception provided they have been clinically stable for a minimum 
of 4- 6 months and are considered at low risk of relapse. Information 
regarding potential teratogenic effects of different psychotropic med-
ications, as well as limitations of the scientific evidence, should be 
discussed and carefully considered. The decision to stop medications 
pre- conceptually should ideally occur only after careful individualized 
risk- benefit analysis for a given patient.511-513 If pharmacotherapy is 
required, monotherapy at minimum effective dose is recommended 
whenever possible.514,515
Contraceptive counselling, including emphasis on its effectiveness 
in reducing the likelihood of unintended pregnancies, should be in-
cluded as part of a comprehensive treatment plan for women with BD.
Several anticonvulsants, including carbamazepine, topiramate, 
and lamotrigine, can affect the pharmacokinetics of oral contracep-
tives and some might significantly reduce the effectiveness of oral 
contraceptives, and this should be considered when making treatment 
decisions.516,517 Oral contraceptives might also have effects on the ef-
ficacy of lamotrigine via reduction in lamotrigine levels.516
While folic acid supplementation is protective against sponta-
neous spina bifida, there is not enough evidence to indicate that 
folic acid, even in high doses, protects against spina bifida following 
the use of anticonvulsants.518 In addition, Health Canada recom-
mends that “Valproate products (valproic acid, divalproex sodium) 
should not be used in female children, in female adolescents, in 
women of childbearing potential and pregnant women unless al-
ternative treatments are ineffective or not tolerated because of 
its high teratogenic potential and risk of developmental disorders 
in infants exposed in utero to valproate.” Health Canada also rec-
ommends that women of childbearing potential must use effec-
tive contraception during treatment and be informed of the risks 
associated with the use of valproate products during pregnancy, 
and in women planning to become pregnant every effort should 
be made to switch to appropriate alternative treatment prior to 
conception.519
Regardless of treatment decisions made prior to or following 
conception, it is also important to work with the patient to develop 
and agree upon a monitoring schedule and treatment plan to be im-
plemented should clinically significant symptoms emerge. Education 
about the risks of psychotropic medications is critical, and careful dis-
cussion is needed regarding the magnitude of risks and benefits and 
limitations with the data. It is important to acknowledge the patient’s 
desire to do what is right for the child and support the decision made. 
Whenever appropriate, involve partners in the discussion and review 
the decision and supporting evidence for it directly or through educa-
tional materials.520
7.1.2 | Screening for bipolar disorder during 
pregnancy and postpartum
All women with depressive symptoms should be screened for BD 
during pregnancy and the postpartum period.521,522 Standardized 
screening tools such as the Mood Disorder Questionnaire alone or in 
conjunction with the Edinburgh Postnatal Depression Scale are use-
ful.521-524 Importantly, screening should be followed by a clinical in-
terview to confirm or exclude a diagnosis of BD. Women should also 
be assessed for other psychiatric disorders that commonly co- occur 
with BD, such as anxiety disorders or obsessive compulsive disorder 
(OCD).525
7.1.3 | Pharmacological management of bipolar 
disorder during pregnancy
Given the complexity of the risks faced by women with BD in preg-
nancy and puerperium, it is good clinical practice to encourage liai-
son between the mental health and obstetrics/gynecology teams. A 
longitudinal study conducted in a tertiary care centre found a high 
risk of recurrence during pregnancy: 85% of pregnant women with 
BD who discontinued a mood stabilizer and 37% of those who were 
maintained on one or more mood stabilizers experienced a mood 
episode—predominately depressive or mixed—during pregnancy. For 
nearly half of the patients, recurrence occurred in the first trimester, 
with the median time for recurrence for those abruptly discontinuing 
treatment being 2 weeks, compared to 22 weeks for those who were 
gradually tapered off.511 However, studies from primary care, as well 
as obstetric centres, found low rates of relapse or hospitalizations in 
pregnancy.526
The hierarchies presented throughout these guidelines should be 
followed for management of the various phases of BD, with consid-
eration given to specific risks associated with the use of each med-
ication using the most up- to- date information available from the 
US Food and Drug Administration (FDA) website (http://www.fda.
gov/ForConsumers/ByAudience/ForWomen/WomensHealthTopics/
ucm117976.htm).
Table 21 includes a brief overview of medications commonly 
used in BD and the risk categories. This list should not be viewed 
as complete or comprehensive. Further, the FDA has replaced these 
risk categories in 2015 with Pregnancy and Lactation Labeling Final 
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Rule (PLLR) with narrative sections and subsections. For instance, for 
pregnancy, the information for each medication is provided using the 
following subheadings: Pregnancy exposure registry, Risk summary, 
Clinical considerations, and Data. The last three subsections apply 
to medication risks during lactation. The FDA has not finalized and 
published the data for all medications as of completion date of these 
guidelines (February 2018), and new data appear to suggest that 
risks may have been overestimated for some medications such as 
lithium.527 Thus clinicians are strongly advised to use all the current 
data, including the FDA PLLR information if available, in collaboration 
with patient and family members to make final treatment decisions.
Wherever possible, psychosocial strategies should be preferred 
over medications in the first trimester as this period holds the high-
est risk for teratogenicity. When medications are deemed necessary, 
preference should be given to monotherapy using the lowest effective 
dose.
Each pregnancy should be closely monitored and appropriate 
screening tests (eg, foetal ultrasound if lithium is used in the first 
trimester) should be performed.528 Divalproex should be avoided 
during pregnancy due to elevated risk of neural tube defects (up to 
5%), even higher incidences of other congenital abnormalities, and 
evidence of striking degrees of neurodevelopmental delay in chil-
dren at 3 years of age and loss of an average of nine IQ points.529-531 
Because of changes in physiology in the second and early third tri-
mesters, such as increased plasma volume, hepatic activity, and renal 
clearance, patients may require higher doses of medications towards 
the later part of the pregnancy. Prenatal vitamins, including high- 
dose (5 mg/day) folic acid, are also recommended, preferably even 
before conception and continuously through pregnancy; and prepa-
rations containing choline have recently been recommended as pos-
sibly preventive of the later development of schizophrenia.532 While 
it is important to note that folic acid may reduce the effectiveness of 
lamotrigine,251 the anti- teratogenic effects of folate may outweigh 
the potential for this loss of effectiveness. However, recent concerns 
have been raised regarding a potential association between very 
high plasma levels of maternal folate and risk of autism spectrum 
disorders.533
7.1.4 | Pharmacological management of bipolar 
disorder during the postpartum period
The postpartum period is a time of elevated risk for recurrence, with 
66% of women who were medication free during pregnancy and 23% 
of those on treatment experiencing a mood episode following the de-
livery.534 The risk of postpartum relapse is highest in women who also 
experienced a mood episode during pregnancy and those who are not 
on prophylactic treatment.535 Despite the high prevalence of postpar-
tum episodes, there is a dearth of studies investigating the efficacy of 
medications during this period. There is evidence of efficacy of benzo-
diazepines, antipsychotics, and lithium for postpartum mania,535 and 
quetiapine for postpartum bipolar depression (level 4).536 There are 
no studies of psychotherapy in the acute or preventative treatment of 
bipolar postpartum depression.537
Patients should be encouraged to initiate or optimize maintenance 
treatment as soon after giving birth as possible, with preference given 
to medications that have previously been shown to be successful. 
Near delivery, close monitoring is essential for early detection and 
management of symptoms that might signal onset of a mood or psy-
chotic episode.538 If an acute mood episode emerges in the postpar-
tum period, the hierarchies for non- postpartum episodes should be 
followed, but, because most psychotropic medications are excreted in 
breast milk, treatment choice should take into consideration safety in 
breastfeeding when applicable.
The FDA website mentioned in the previous section as well as 
Table 21 also include information on lactation. The FDA PLLR should 
be consulted for further information about medication risks, as many 
are secreted in milk, if breastfeeding is being considered.
The potential risks and benefits of taking medications while breast-
feeding should be discussed with the patient. Education about early 
recognition of drug toxicity and requirement for ongoing monitoring of 
infants is also critical.539 A recent systematic review suggested queti-
apine and olanzapine as preferred choices for breastfeeding, consider-
ing their relatively lower infant dosages.540 The impact of medication on 
the infant can be reduced by scheduling medication administration after 
breastfeeding.541
Replacing or supplementing breast milk with formula can also be 
considered. Although there are many benefits to breastfeeding, associ-
ated sleep disruption may increase the risk of mood episodes in women 
with BD. If possible, bottle feeding at night by the woman’s partner or 
a support can be beneficial to allow the woman to maintain a better 
sleeping schedule. In women with postpartum psychosis or mania, 
breastfeeding may be more risky, and therefore may not be indicated, 
as the mother may be too disorganized to safely breastfeed.542
As childbirth can be a trigger for first onset of hypomania/mania in 
women with MDD, antidepressants should be used cautiously, espe-
cially in women with a family history of BD.543 Women with first onset 
of depression in the postpartum period or those who have recurrence 
of depression during the early postpartum period, may also be at a high 
risk of switching to BD following treatment with antidepressants.537
7.1.5 | Impact of the menstrual cycle on symptoms
Despite the paucity of large, well- designed research studies exam-
ining the impact of the menstrual cycle on mood symptoms in BD, 
accumulating evidence suggests that hormonal changes can impact 
the course of illness. Several case reports and prospective studies 
suggest that women who experience premenstrual symptom exac-
erbation are more likely to have a highly symptomatic and relapse 
prone illness.544,545 One of the largest studies (n = 1099) found that 
women who met DSM- 5 provisional criteria for premenstrual dys-
phoric disorder (PMDD) had an earlier illness onset, more comorbid 
Axis I disorders, a higher number of hypomanic/manic and depres-
sive episodes, and higher rates of rapid cycling.546 In this study, 
there was a closer gap between BD onset and age of menarche in 
women with comorbid PMDD, which suggests that sensitivity to 
endogenous hormones may influence the onset and the clinical 
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course of BD. Premenstrual syndrome (PMS) and PMDD also occur 
more frequently in women with BD.547,548 Importantly, an accurate 
diagnosis of comorbid PMDD in women with BD is made during 
euthymia, with a minimum of 2 months of prospective symptom 
charting.549
7.1.6 | Menopause
For many women, stress and hormonal changes associated with 
the transition to menopause may increase or trigger mood symp-
toms.550-552 A post hoc analysis of the prospective Systematic 
Treatment Enhancement Program for Bipolar disorder (STEP- BD) 
study showed increased rates of depressive, but not manic episodes 
during menopause transition.553 However, due to the paucity of clini-
cal trials in this area, more data are needed before treatment recom-
mendations can be made.554
7.2 | Management of bipolar disorder in children and 
adolescents
7.2.1 | Presentation and diagnosis
As the following section comprises only a brief overview of the epide-
miology, phenomenology, and differential diagnosis of BD in children 
and adolescents, the reader is referred to more detailed reviews for 
further information.555-560
Between one- third (community samples) and two- thirds (clinical 
samples) of patients with BD experience their first mood episode 
during childhood or adolescence, with an earlier onset related to a 
more severe illness characterized by increased symptom burden and 
comorbidity.561,562 In contrast to the controversies of as recently as 
a decade ago, there is now far greater consensus in the field that, 
although there are developmental differences in the manner in 
which symptoms manifest themselves, the actual diagnosis of BD 
in children and adolescents should be made based on the same set 
of symptoms as applied to adults.563 When defined rigorously ac-
cording to DSM- 5 criteria, the course of illness in childhood and 
adolescence is characterized by eventual high rates of symptomatic 
recovery, but also high rates of recurrence, even in the context of 
naturalistic treatment.564 While the concepts of “over- diagnosis” 
and “over- treatment” in pediatric BD have received substantial at-
tention,565 representative population studies demonstrate that ad-
olescent BD is characterized by low rates of treatment, alongside 
high rates of suicidality and comorbidity.566,567 Risks of incorrectly 
diagnosing and treating BD in a child or adolescent should thus be 
carefully weighed against the risk of incorrectly or not diagnosing or 
treating,568 keeping in mind that the duration of treatment delay has 
been shown to be an independent risk factor for a poor outcome in 
adulthood.569
Distinguishing early- onset mania or hypomania from other psy-
chiatric disorders is important as there is a high level of symptomatic 
overlap for multiple conditions including but not limited to ADHD, 
oppositional defiant disorder (ODD), disruptive mood dysregulation 
disorder (DMDD), substance abuse, personality disorders and general-
ized anxiety disorder555,570 (Table 22). The discrete episodes of mania/
hypomania and the non- overlapping symptoms can facilitate accurate 
diagnosis. When a comorbidity is present, such as ADHD, overlapping 
symptoms (eg, distractibility and hyperactivity) should only count to-
wards a diagnosis of mania or hypomania if they intensify during in-
tervals of elation or irritability. Notably, ADHD is an ongoing condition 
whereas BD is episodic, and decreased sleep, hypersexuality, hallucina-
tions or delusions, and homicidal or suicidal thoughts and actions occur 
with childhood mania, but are rare or absent in uncomplicated ADHD.
It is important to note that, while chronic irritability with episodic be-
havioural outbursts or rages can be seen in multiple paediatric psychiat-
ric disorders (including emerging personality disorders, substance abuse, 
TABLE  22 Differential diagnosis of manic symptoms in children and adolescents
Symptom Bipolar mania hypomania Attention deficit hyperactivity disorder Oppositional defiant disorder
Elation Episodic, prolonged, pathological (inappropri-
ate to context or uncharacteristic), 
associated with change in functioning, 
“travels”	with	≥3	other	manic	symptoms
If present, not clearly episodic or 
pathological
If present, not clearly episodic or 
pathological
Irritability Episodic, prolonged, pathological, associated 
with	change	in	functioning,	“travels”	with	≥4	
other manic symptoms
Can be an associated feature, related to 
stimulant rebound, or due to a 
comorbid illness (eg, ODD)
Diagnostic criterion, lacks distinct 
prolonged episodes, does not “travel” 
with other manic symptoms
Sleep Reduced need for sleep (ie, significantly less 
sleep than usual without increased daytime 
fatigue or somnolence); change must be 
mood- related
Insomnia (ie, difficulty falling asleep); can 
be an associated feature or associated 
with stimulants, but need for sleep is 
unchanged
Not a symptom or common character-
istic; may defy bedtime rules or 
routine
Grandiosity Distinct uncharacteristic increase in 
confidence or self- importance; change must 
be mood- related
Not a symptom or common 
characteristic
Defiance toward authority figures is 





Episodic; if comorbid ADHD is diagnosed, 
then distinctly “worse than usual” change 
must be mood- related
Diagnostic criteria, nonepisodic Not prominent or episodic
ADHD, attention- deficit hyperactivity disorder; ODD, oppositional defiant disorder (Adapted from Goldstein and Birmaher 2012555).
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ODD, pervasive developmental disorders, and major depressive episodes), 
such irritability and explosiveness are not sufficient to make a diagnosis, 
even when severe. The recent DSM- 5 diagnosis DMDD—which includes 
chronic irritability as a defining feature—lists BD as an exclusion criterion. 
However, the DMDD phenotype is evident in about 25% of adolescents 
with episodic BD, and is associated with factors such as greater family 
conflict and ADHD comorbidity.571 Classical BD and chronic irritability 
are therefore not mutually exclusive, the nonspecific nature of the latter 
notwithstanding.
A significant minority of children or youth with MDD will even-
tually go on to develop BD, with an average rate of 28% being re-
ported.572,573 Risk factors for switch to mania following a depressive 
episode include a family history of mood disorders, emotional and 
behavioural dysregulation, subthreshold manic symptoms, cyclothy-
mia, atypical depression and psychosis.572 A recent meta- analysis sug-
gested that the most potent predictors were family history, an earlier 
age of onset and the presence of psychotic symptoms.574 There is an 
increased prevalence of BD among offspring of parents with BD.575-
577 Although there is no uniform strategy for managing depression (or 
ADHD, anxiety, etc.) in the child of a parent with BD, increased caution 
is warranted when prescribing antidepressant or stimulant medica-
tions as these have the potential to precipitate mania/hypomania.578 
Patients and their parents should be informed of the potential switch 
risk and close monitoring for treatment- emergent manic/hypomanic 
switch should be instituted.
Self- report and/or parent- reported questionnaires can be informa-
tive and can raise the index of suspicion for BD.579 However, scores on 
such questionnaires as the Child Behaviour Checklist (CBCL) “dysregu-
lation phenotype”, previously described as “BD phenotype”, have poor 
capacity for differentiating BD from other complex and severe symp-
tomatic presentations.580 Questionnaires can be used as screeners, but 
do not substitute for a thorough diagnostic evaluation. Longitudinal 
rating by parents may be most helpful in diagnosis and assessment of 
treatment response. An online program for weekly parental ratings (of 
depression, anxiety, ADHD, oppositional behaviour, and mania) of chil-




The general principles for managing adults with BD also apply to 
children and youth. In youth, themes of comorbidity and tolerabil-
ity are accentuated. Comorbid ADHD is more common in children 
and adolescents as compared to adults with BD. Moreover, ADHD 
symptoms often do not improve following mood stabilization, and 
may require concurrent ADHD treatment. In addition, due to ele-
vated risk for accelerated atherosclerosis and early cardiovascular 
disease in this population, cardiovascular risk factors should also be 
assessed regularly and intervention implemented. Lifestyle manage-
ment including attention to diet, substance use, smoking and physi-
cal activity should be implemented alongside any psychological or 
pharmacological interventions.582 Relatedly, children and adoles-
cents are more susceptible than adults to the metabolic side effects 
of psychiatric medications, particularly the atypical antipsychotics 
that are considered first- line treatments.583 Taken together, these 
distinguishing features underscore the importance of ensuring that 
polypharmacy, as often required, is judicious and informed by a bal-
ance of factors including mood symptom burden, global functioning, 
and physical health.
Acute management of mania
First-line. Lithium (level 1),583-585 risperidone (level 1),584,586 aripipra-
zole (level 2),587 asenapine (level 2),588 and quetiapine (level 2)583,589 
are recommended as first- line options. Risperidone may be preferable 
to lithium for non- obese youth, and youth with ADHD.584
F IGURE  8 Treatments for pediatric bipolar depression: Summary of evidence [Colour figure can be viewed at wileyonlinelibrary.com]
Reconciling the paucity of RCT data with abundant clinical experience in determining level of
recommendaon for treatment of pediatric bipolar depression 
Aside from lurasidone, which has posive RCT data (597) alongside good tolerability, opons include either treatments with substanal
tolerability concerns (olanzapine-fluoxene combinaon) or treatments with no RCT data (eg. lithium, lamotrigine) or without posive
RCT data (eg.queapine). In this instance, clinical experience combined with tolerability consideraons and adult data informed the
ranking of recommendaons.   Lithium and lamotrigine have not been tested in RCTs in pediatric bipolar depression. However, there is
abundant clinical experience with these agents in treang depression in the pediatric group alongside posive open trials. Further, these
agents are recommended for treang acute bipolar in adult populaons, and they have good tolerability. Thus, despite lack of RCT data,
they are recommended as second-line agents for treang acute bipolar depression in pediatric populaon. 
In terms of queapine, of the two negave RCTs (601, 602), one had a dose range of 300-600 mg/day but was limited to 32 parcipants
and had a 67% placebo response rate. The other study was dosed at only 150-300 mg/day and had a 55% placebo response rate. One can
argue that the queapine studies have been failed, rather than truly negave, studies. Therefore, given its demonstrated efficacy in adult
bipolar depression and methodological problems in studies of pediatric bipolar depression and based on clinical experience, it is
recommended as a third-line opon. 
Ulmately, treatment decisions in general, but parcularly in the context of empirical uncertainty, should be informed by a thorough
discussion of comparave risks and benefits of compeng opons. Risk-benefit raos may differ across paents depending on factors
such as BD subtype, comorbid anxiety, and sleep disturbance.
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Second-line. Due to safety and tolerability concerns, olanzapine 
(level 2)590 and ziprasidone (level 2)591 should be considered second- 
line options. Quetiapine adjunctive therapy (level 3)592 is also recom-
mended as a second- line treatment.
Third-line. Despite low response rates in two RCTs, a long history 
of use among adults with BD, combined with positive findings in open- 
label studies are grounds for considering divalproex as a third- line op-
tion for youth who do not respond to or tolerate first or second- line 
agents (level 4).593
Not recommended. Oxcarbazepine was not superior to placebo in a 
large RCT (level 2 negative).594
Acute management of bipolar depression
The data in paediatric samples are very limited, and complicated by ex-
tremely high placebo- response rates in RCTs. These recommendations 
are therefore to a greater extent informed by clinical experience and stud-
ies in adults than the above acute mania recommendations (see Figure 8).
First-line. A recently published RCT found that lurasidone was 
superior to placebo (level 2)595 in improving depressive symptoms 
in children and adolescents with acute bipolar depression; however 
there is comparatively little clinical experience in this population. 
Nevertheless, given its efficacy and clinical experience in adult bipolar 
depression, lurasidone is recommended as a first- line treatment.
Second-line. Although lithium and lamotrigine were recom-
mended as first- line agents for bipolar depression in adults, there 
are only open- label data for lithium (level 4)596 and lamotrigine (level 
4)597 in children and youth. Despite limited RCT data, there is, how-
ever, substantial clinical experience with these agents as they are 
widely used in clinical practice. For this reason, together with the 
strength of evidence in adults, lithium and lamotrigine are recom-
mended as second- line, rather than third- line agents (see Figure 8).
Third-line. There is a positive RCT of olanzapine- fluoxetine com-
bination among youth with bipolar depression (level 1)598; however, 
metabolic concerns regarding olanzapine, and limited clinical expe-
rience with olanzapine- fluoxetine combination in youth lead to the 
positioning of this option as third-line. Despite negative findings in 
paediatric samples, quetiapine (level 2 negative)599,600 is also recom-
mended as third-line for this population due to the abundance of 
evidence from adult studies combined with substantial clinical experi-
ence. There are also several methodological concerns with the studies 
done in pediatric samples (see Figure 8).
Despite limited knowledge regarding the precise risks of 
antidepressant- induced mania in youth with BD, observational 
pharmaco- epidemiology studies support the conclusion that antide-
pressants should be used with caution in BDI and BDII, and in com-
bination with mood- stabilizing medication (level 4).578,601
Not recommended. A large RCT found that oxcarbazepine was not 
superior to placebo (level 2 negative)594 although it was effective in 
the youngest group of patients but not the older adolescents.
Maintenance treatment
The data in paediatric samples are very limited. These recom-
mendations are therefore informed by clinical experience and 
studies in adults to a greater extent than the above acute mania 
recommendations.
First-line. Preferred maintenance treatment options for this popu-
lation are aripiprazole (level 2),602,603 lithium (level 2)604 and divalproex 
(level 2).604,605 However, it should be noted that follow- up duration for 
the aripiprazole study was only 30 weeks, and the sample size in the 
18- month maintenance study of lithium vs divalproex was only 30 par-
ticipants. It is important to note that few patients continued to do well 
upon the switch to either lithium or divalproex monotherapy and the 
majority re- responded when the combination was reinstated. Further, 
other studies have also suggested the efficacy of combination therapy 
(eg, risperidone plus lithium or divalproex584 and lithium plus divalproex 
or carbamazepine606) to achieve and maintain remission. Adjunctive la-
motrigine	may	also	be	considered	for	those	aged	≥	13	years	(level	2).607
Second-line. No treatments with level 3 or higher evidence are 
available to recommend as second- line options for maintenance.
Third-line. Although there has been far less experience with 
asenapine than with other medications discussed in this section, a re-
cent open- label extension study suggests continual reduction in manic 
symptoms over 50 weeks (level 4).608 Further, a recent RCT in adults 
confirmed its efficacy in preventing relapse of mood episodes.374 
Although there have not been maintenance studies for quetiapine, 
risperidone, or ziprasidone in this population, clinical experience 
and open- label studies indicate that continuation and maintenance 
treatment with these medications is another option, particularly for 
those patients who have responded well to acute treatment (level 
4).591,609,610 Further, there is evidence that oral quetiapine and long- 
acting injectable risperidone monotherapy and adjunctive therapy and 
oral ziprasidone adjunctive therapy are effective in preventing mood 
episodes in adults with BD.369,370,383,384,387
Treatment of comorbid conditions
ADHD. Stimulants may also be used for comorbid ADHD in stable/
euthymic youth taking optimal doses of anti- manic medications. 
Adjunctive mixed amphetamine salts (level 3)611 and methylpheni-
date (level 3)612 have both been shown to be effective in address-
ing attention symptoms and have been well tolerated overall within 
the RCTs completed to date, theoretical and epidemiological data 
regarding risks of induction of mood elevation notwithstanding.613 
Although open trials suggest potential benefits of atomoxetine (level 
4),614,615 the possibility of inducing mania or hypomania remains,616 
suggesting the need for RCTs before clinical recommendations can 
be made.
Substance use. Comorbid substance use should be treated con-
currently to mood symptoms, with inpatient hospital or community 
residential treatment employed as clinically indicated. A small study 
suggests that lithium may be effective for reducing substance use in 
this population (level 3),617 and FFT should also be considered (Section 
2). Positive trials of N- acetylcysteine for cannabis use disorders among 
adolescents,618 smoking,619 and bipolar depression among adults 281 
suggest that N- acetylcysteine may benefit adolescents with comorbid 
bipolar and SUDs; however, studies examining this hypothesis have 
not yet been completed (level 4).
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7.3 | Management of bipolar disorder in older age
7.3.1 | Presentation and course
Because of the aging population in Canada and many countries around 
the world, knowledge of pertinent issues related to the management 
of older adults is becoming increasingly important. Approximately 6% 
of geriatric psychiatry outpatients and 10% of inpatients have BD,620 
and proportionally this population is one of the highest users of psy-
chiatric and physical health services.621 Approximately 25% of the pa-
tients with BD in the USA in 2005 were over the age of 60 years,622 
and by 2030 >50% of patients with BD are expected to be aged >60 
years.623
The lifetime prevalence of late- life BD is about 1%- 2% with a 1- 
year prevalence of 0.1%- 0.7% in the general population. About 90%- 
95% of older adults with bipolar disorder have their initial episode 
prior to age 50 years, although there is a minority who will have a 
later onset.624,625 Late onset is often related to neurological or physical 
comorbidity,626 and may carry a negative prognosis,627 although this is 
not a consistent finding.628
While symptoms of mania or hypomania are generally less prom-
inent in older adults, depressive and cognitive symptoms are more 
often observed, and hyperactivity, aggression, insomnia, impulsiv-
ity, and self- neglect may pose a significant risk to the patient and 
others.629,630 Psychiatric comorbidity is also generally lower than in 
younger patients, with anxiety and substance use being the most com-
mon.631 Compared to younger patients, older adults are less likely to 
utilize inpatient, outpatient, and emergency room services and more 
likely to use case- management and conservator services.632
Cognitive dysfunction is a significant concern for this population, 
with >30% showing significant deficits across all mood states, includ-
ing euthymia.633 This cognitive dysfunction is relatively stable, related 
to the number of mood episodes earlier in life, and does not appear 
to exceed normal aging in 2- 5- year follow- up.634-636 Lithium use has 
been associated with lower rates of cognitive disorders in BD,637 and 
higher lithium levels in drinking water may be associated with lower 
dementia risks,638,639 although prospective trials are required to de-
finitively assess this. Standardized instruments, such as the Montreal 
Cognitive Assessment (MoCA), should be used to quantify cognitive 
dysfunction. Because of the link between cognition and functioning 
in BD,634,640 the impact of medications (particularly those with a high 
anticholinergic burden) on cognition should be considered when mak-
ing treatment decisions. Furthermore, improvement of modifiable risk 
factors such as diet, exercise, and mental stimulation should also be 
promoted in order to further diminish the risk of cognitive decline.
7.3.2 | Medical comorbidity
Older adults with BD have an average of three to four medical co-
morbidities, with metabolic syndrome, hypertension, diabetes, car-
diovascular disease, arthritis, and endocrine abnormalities being the 
most common.631,641 Together, these contribute to a reduction in 
life expectancy of 10- 15 years in BD compared to non- psychiatric 
populations.642 Because of these high rates of comorbidities, assess-
ment of an older adult with BD should include a thorough physical 
and neurological examination, including clinical laboratory tests. 
Neuroimaging should also be applied as indicated, particularly in the 
presence of focal neurological signs and symptoms or abrupt late onset, 
or if the presentation is different from prior episodes. Coordination 
with other health care providers is also imperative, as this can optimize 
physical health,643 as can smoking cessation.
7.3.3 | Pharmacological treatment
The data supporting efficacy of medications in various mood states 
in this population are limited, with only a single RCT exclusively in 
geriatric patients completed to date, comparing lithium vs divalproex 
for the treatment of mania/hypomania.644 Despite this, open- label 
trials, naturalistic studies, and post hoc analyses of mixed aged RCTs 
suggest that medications efficacious in adults overall will also be ef-
fective in older adults, although additional considerations regarding 
medication tolerability and age- related changes in pharmacokinetics 
and pharmacodynamics must be taken into account. Because of the 
high number of medical comorbidities as well as physical changes 
related to the aging process, strict attention must be paid in these 
patients to potential pharmacokinetic issues, drug- drug interactions, 
side effects, and the need for ongoing monitoring (see Section 8).
Amongst other effects, lithium has been associated with adverse 
neurological effects645 and renal disease.646 Divalproex has been as-
sociated with motor side effects645 and metabolic effects (weight gain 
and diabetes mellitus).647 Carbamazepine induces cytochrome P450 
enzymes and can reduce the levels of divalproex and other medica-
tions.648 Regarding antipsychotics, which are now very commonly used 
for BD in older adults, dose reduction may be beneficial in some aging 
patients to lower the risk of motor, sedation, metabolic syndrome, and 
cognitive effects.649 There is an association between mortality and 
antipsychotics in patients with dementia650 but it is unclear how this 
should be managed for patients with BD. Recently there have also been 
data linking antipsychotics with acute kidney injury.651
In particular, when lithium is used in this population, lithium level 
and renal monitoring should occur at least every 3- 6 months, as well 
as 5- 7 days following a lithium dose adjustment or adjustment of non- 
steroidal anti- inflammatory drugs (NSAIDs), antiontensin II receptor 
blockers (ARBs), angiotensin- converting enzyme inhibitors (ACEIs), or 
thiazide diuretic dosing.652 Special consideration also needs to be given 
to dose selection. A post hoc analysis of the STEP- BD study found that 
while, on average, older patients required a similar number of med-
ications to younger patients to achieve recovery, lower doses were 
used. In that sample, over twice as many older patients as younger 
ones recovered using lithium alone (42% vs 21%, respectively).653 In 
general, starting at a lower dose (eg, 150 mg nightly for lithium) is rec-
ommended, with gradual adjustments to reach the lowest end of the 
therapeutic range for adults, with subsequent titration based on toler-
ability and effectiveness; keeping in mind that some older patients will 
require similar blood levels as the general adult population in order to 
achieve remission. Further discussion, including clinical guidance and 
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more detailed treatment recommendations, can be found in the ISBD 
Task Force report.654 In light of very limited international guidelines for 
maintenance treatment of older adults with BD, an ISBD Task Force 
is currently undertaking a Delphi survey of international experts, and 
clinicians are advised to consult this as results become available in the 
future (Shulman K, personal communication).
Pharmacological treatments have been evaluated using the cri-
teria for strength of evidence for efficacy (Table 1) in older adults 
as well as safety and tolerability (Section 8). Unfortunately, there 
is a dearth of literature for efficacy of treatments in older adults. 
However, clinical experience supports the notion that treatments 
known to work in general adult populations are also effective in older 
adults. Tolerability may be different and this is an important consid-
eration in treatment selection in older adults. General principles for 
management of acute episodes described in Sections 3 and 4 also 
apply to this population.
Acute mania
Monotherapy with lithium (level 2)644 or divalproex (level 2)644 is 
recommended as a first- line treatment. Quetiapine (level 2)655 can 
be considered as second-line. Asenapine (level 4),656,657 aripiprazole 
(level 4),658 risperidone (level 4),659 or carbamazepine (level 4)654 may 
be applied as third- line treatments. For treatment- resistant episodes, 
clozapine (level 4)660 and ECT (level 4)654 should also be considered.
Bipolar depression
There are no RCTs of any agents in older adults with acute bipolar 
depression. Post hoc analyses of RCTs suggest efficacy of quetiapine 
(level 2)661 and lurasidone (level 2)662 monotherapy and hence these 
are recommended as first- line options. However, in older adults, given 
the concerns about side effects of atypical antipsychotics, clinicians 
may wish to try lithium or lamotrigine first based on their efficacy in 
adult populations, although the evidence of efficacy is limited in older 
adults (lithium, level 4; lamotrigine, level 4).663,664 Divalproex (level 4), 
aripiprazole (level 4),658 and carbamazepine (level 4)665 are third- line 
options. ECT (level 4)654 is an important option that should be consid-
ered in treatment- resistant cases, for suicidal patients, or for patients 
with inadequate food or fluid intake.
While the use of antidepressants in BD remains controver-
sial260,426 and there have been no studies in older age BD; antide-
pressants are frequently used in this population (>40% of patients).666 
Antidepressants with lower manic switch potential (eg, SSRIs and bu-
propion)260 used in combination with mood stabilizers may be benefi-
cial in selected patients who cannot tolerate/do not respond to other 
agents with a stronger geriatric evidence base. Possible medication 
interactions with ongoing medications for non- psychiatric conditions 
must always be considered.
Maintenance
Choice of agents should be based on what has been effective in the 
acute phase, with recommended options with geriatric efficacy data 
being lithium (level 2),667,668 lamotrigine (level 2),668 and divalproex 
(level 3).667




Most patients diagnosed with BD will also have at least one comor-
bid psychiatric diagnosis. The most common comorbid conditions are 
substance use disorder, anxiety disorder, personality disorder, and im-
pulse control disorder (such as ADHD, ODD, and CD).45 Comorbidity 
impacts the course of BDs by increasing the likelihood of treatment 
resistance and suicide risk, and also by increasing the time spent with 
impairing symptoms.34,50,669,670
When treating comorbid conditions, determining which disorder 
to address first requires careful consideration. Some comorbid disor-
ders may be managed with the same treatment employed to manage 
bipolar symptoms (eg, quetiapine for comorbid anxiety and BD), while 
other comorbid disorders (eg, ADHD) may require distinct treatments. 
Importantly, some treatments for comorbid disorders may lead to 
bipolar symptom destabilization; for instance, an antidepressant em-
ployed to treat an anxiety disorder may provoke mood elevation.
Safely and effectively managing comorbid conditions often ne-
cessitates the implementation of a hierarchical approach, depend-
ing on each patient’s individual needs and preferences. In general, 
the disorder or symptom associated with the greatest morbidity 
and mortality—such as acute mania, psychosis, or suicidal ideation—
should be managed first. Substance use disorders may be addressed 
concurrently or sequentially, depending on severity and contribution 
to mood instability. Once mood stability is established, the treat-
ment of additional comorbid conditions, such as ADHD or metabolic 
disorders, should follow based on their impact and the patient’s 
preference.
There is a dearth of research to guide the best management of 
BD in the context of comorbid conditions. There have been few trials 
designed with comorbid symptoms as the primary target for mood- 
stabilizing treatments—evidence is mainly derived from secondary 
analysis of published data. Thus, the limited research informing the 
treatment of comorbidities constrains our ability to make definitive 
recommendations. However, because comorbidity is so common and 
burdensome for patients, appropriate management is a challenging 
daily reality in clinical practice. Therefore, CANMAT decided to pro-
vide a brief overview of relevant clinical issues and the evidence base 
for pharmacological treatments for treating comorbid populations. The 
reader is advised to consult the following references for the role of 
psychological treatments in managing comorbidity.671-673
Substance use disorders
Two recent reviews indicated that the prevalence rate of comorbid 
SUD in BD is about 33% in general population surveys674 and ap-
proximately 45% in clinical settings.675 SUD can negatively impact the 
course of BD, resulting in lower rates of remission,407 a higher number 
of hospitalizations,676,677 and an increased risk of suicide attempts429 
and perhaps suicide deaths.678
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Substance use should be addressed as early as possible, as it is 
likely to interfere with treatment for BD. However, the presence of a 
SUD should not preclude an attempt to treat BD, which might result in 
an individual being more amenable to treatment. As the directionality 
of the interaction between SUD and BD is rarely clear in the reality of 
clinical practice, it is recommended that the two conditions be treated 
simultaneously.
A more detailed discussion on the impact of and the general prin-
ciples of the treatment of substance use comorbidity can be found in 
a CANMAT Task Force publication,679 and other reviews673,681  and 
a meta- analysis680 published on the topic since 2012. Here we pro-
vide a brief update on the pharmacological treatments identified in 
the CANMAT Task Force publication. It is important to note that the 
criteria for level of evidence used here are more stringent than those 
applied to the Task Force report.
The levels of evidence for treatment of comorbid SUD are low. 
This is because of (i) the paucity of data, (ii) complexity of study de-
signs (given the fact that many patients will be using more than one 
substance), and, most importantly (iii) inconsistency of the outcome 
variables used in these studies; hindering direct comparison of results. 
Nevertheless, some evidence- based recommendations are available 
for clinicians, starting with general principles of treatment: if at all 
possible, avoid medications that could increase the risk of destabiliz-
ing the BD, and choose treatments that could help both conditions.
Alcohol use disorder
A combination of divalproex and lithium is the only treatment for al-
cohol use disorder comorbid with BD that meets criteria for level 2 
evidence.682,683 In a small RCT, there was a significant reduction in 
the number of drinks per drinking day, as well as per heavy drinking 
day, in the combination group compared to the group with lithium 
alone when adherence to treatment was added as a covariate. There 
is only level 3 evidence for lamotrigine,684 and divalproex mono-
therapy or add- on.685-687 While lithium may also show some benefits 
(level 3),617 it has to be used with caution in heavy drinkers because 
of potential electrolyte imbalance; and anticonvulsants warrant liver 
function tests and lipase levels before initiating treatment. Agents for 
primary alcohol use disorder may also show benefits in BD, such as 
disulfiram (level 3),688-691 naltrexone (level 3)692-695 and gabapentin 
(level 4).696,697 Furthermore, guidelines for pharmacotherapy in al-
cohol dependence alone can offer some guidance in the absence of 
comorbidity- specific trials.698
Quetiapine is not recommended for the treatment of alcohol 
use disorder comorbid to BD because of lack of efficacy. Quetiapine 
add- on therapy was not more effective than placebo add- on in reduc-
ing the number of drinks per day or other alcohol- related measures in 
patients with BDI699 or BDI and BDII with alcohol dependence (level 
1 negative).700 In another RCT, quetiapine monotherapy or add- on 
therapy to mood stabilizers was compared with placebo monotherapy 
or add- on therapy in patients with bipolar depression with comorbid 
anxiety and substance use disorders.701 No significant improvement 
was found in depressive or anxiety symptoms but alcohol or substance 
use- related outcomes were not reported separately.
No specific recommendations are given regarding acamprosate 
at this time. In a smaller RCT, acamprosate add- on was ineffective in 
improving drinking- related outcomes in BDI/BDII patients with alco-
hol dependence (level 3 negative)702 but a post hoc analysis showed a 
small decrease of the Clinical Global Impression scores for substance 
use severity towards the end of the trial. Further studies are needed.
Cannabis use disorder
About 20% of patients with BD have cannabis use disorder at some 
point in their life.675 Cannabis use disorder is associated with younger 
age, manic/mixed episode polarity, presence of psychotic features, 
and comorbid nicotine dependence, alcohol use disorder, and other 
SUDs.703 Cannabis use is also associated with more time in affective 
episodes and rapid cycling.704
There is limited research into treatment options for this frequent 
SUD. Lithium and/or divalproex have level 3 evidence.617,682,685-687 
Quetiapine failed to provide any benefit in terms of mood and anxiety 
symptoms in a small subsample of highly comorbid patients with BD. 
generalized anxiety disorder (GAD) and cannabis use disorder701 (level 
3 negative). The effect of quetiapine on specific cannabis use- related 
outcomes was not reported.
Stimulants: cocaine, amphetamine, and methamphetamine use 
disorders
Citicoline adjunctive therapy had a positive outcome in two RCTs in 
patients with BD with comorbid cocaine use disorder, although the 
benefits of citicoline decreased over time in the more recent study 
(level 2).705,706
Lithium or divalproex, either alone or in combination, were proven 
useful in small studies addressing cocaine use disorder682,685-687,707,708 
(level 4). Quetiapine in monotherapy or in combination with the ongo-
ing treatment shows evidence of efficacy for cocaine, amphetamine 
and methamphetamine use disorder709-711 (level 3). Risperidone has 
been studied alone and as an add- on agent for cocaine and for meth-
amphetamine use disorders with level 3 evidence for efficacy.711,712
Bupropion has anecdotal reports favouring efficacy in cocaine 
use disorders (level 4).713 Citicoline improved depressive symp-
toms in patients with methamphetamine use disorder and bipolar 
depression.714
Lamotrigine has been studied in a 10- week RCT of lamotrigine 
vs placebo added to ongoing medication. While results were nega-
tive for the a priori outcome variable (positive urine drug screens), 
they were positive on the secondary outcome of the amount of 
dollars spent per week on cocaine purchases (level 2 negative).715
Opioid use disorder
While methadone has the most evidence of efficacy in comorbid BD 
and opioid use disorder (level 3),716,717 because of the lack of research 
in this area and increasing concern related to risk of overdose, cli-
nicians should consult the Canadian Research Initiative in Substance 
Misuse (CRISM) national treatment guidelines on primary opioid use 
disorder when available (anticipated 2018) for further advice on man-
aging opioid use disorders in their patients.
     |  139YATHAM eT Al.
Others
Olanzapine add- on therapy was effective in decreasing manic symp-
toms and measures of substance use such as reduction in cravings in 
hospitalized inpatients (level 2).718 Aripiprazole has level 4 evidence to 
decrease craving of alcohol, but not consumption, and level 4 evidence 
to decrease cocaine use in polysubstance users.719
Anxiety disorders
Patients with BD frequently experience symptoms of anxiety and co-
morbid anxiety disorders (GAD, panic disorder, post- traumatic stress 
disorder and others). Clinical samples indicate that 24%- 56% of pa-
tients with BD meet criteria for one or more anxiety disorders, with 
the highest rates in women.720 Comorbid anxiety symptoms and anxi-
ety disorders are associated with a higher number of mood episodes 
and depressive symptoms, including suicidality and sleep disturbance, 
and greater impairment of psychosocial functioning and quality of 
life.721 The presence of a comorbid anxiety disorder is also associ-
ated with high rates of use of antidepressants,722 which should be 
employed with caution due to their potential for mood destabilization 
(Section 4).
While the CANMAT Task Force report720 described key studies 
and treatment recommendations in length, those recommendations 
have been updated below. However, it remains the case that there 
are few studies that have focused exclusively on anxiety symptoms or 
disorders comorbid with BD, whether for treatment efficacy or safety. 
While there are treatment options, the limitations resulting from a 
paucity of data prevent the development of clear guidelines or treat-
ment algorithms.
A “step- wise” approach was recommended in the 2012 CANMAT 
recommendations for managing comorbid anxiety. In general, mood 
stabilization is the priority before specific anxiety treatments are 
considered (Figure 9). Despite clinical experience, antidepressants, 
particularly serotoninergic agents, should be employed with cau-
tion due to their potential to provoke mood destabilization. While 
benzodiazepines are an important clinical tool because they can rap-
idly alleviate anxiety, clinicians should strive to prescribe them at the 
lowest possible dose for the shortest period possible, given the con-
cerns about suicide risk, abuse and dependence. CBT continues to be 
an appropriate first- line treatment for anxiety.
Generalized anxiety disorder and panic disorder
Quetiapine was superior to placebo and divalproex in improving anxi-
ety symptoms in patients with comorbid GAD and/or panic disorder 
(level 2).724 Further, secondary analyses from several RCTs indicate 
that quetiapine monotherapy significantly reduces symptoms of 
GAD and panic disorder in patients with bipolar depression.290,313,725 
Negative trials include risperidone versus placebo in patients with BD 
and comorbid GAD and/or panic disorder726 and ziprasidone versus 
placebo in a similar trial.727
For patients who are euthymic and treated with lithium, the addi-
tion of lamotrigine or olanzapine has demonstrated similar anxiolytic 
effects (level 3).728 In a secondary post hoc analysis, combinations of 
olanzapine and fluoxetine (level 3), and to a lesser extent olanzapine 
monotherapy, were effective in reducing anxiety in patients with bipo-
lar depression.314
Gabapentin employed as an adjunctive therapy in open- label 
studies reduced anxiety symptoms in patients with BD (level 4).696,729 
Given its relatively benign side effect profile and efficacy in other pri-
mary anxiety disorders, gabapentin is an appropriate strategy.
Obsessive compulsive disorder
Obsessive compulsive disorder was re- categorized in DSM- 5 and is 
no longer characterized as an anxiety disorder; however, anxiety is a 
cardinal feature. OCD is a comorbid condition in 10%- 20% of patients 
with BD730-733 compared with 2%- 3% in the general population.734 
However, the prevalence appears to vary widely, depending on the 
clinical setting and bipolar subtype.731 Comorbid OCD may be more 
common in children and adolescents with BD than in adults731 and has 
F IGURE  9 What is the role of primary treatments for anxiety disorders in treating co-morbid anxiety in bipolar disorder?  
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
Primary treatments for anxiety disorders: Should they be used to treat co-morbid anxiety in
bipolar disorder?
There are no large RCTs that examined the efficacy of SSRIs, SNRIs, pregabalin or lorazepam in treang anxiety symptoms in BD paents
with co-morbid GAD. However, several RCTs assessed the efficacy of these agents in paents with primary GAD and have been found to
be effecve (723). So,should clinicians employ these treatments in treang co-morbid anxiety symptoms in GAD? As with any clinical
decision, CANMAT recommends assessing risk-benefit rao. 
Pregabalin is effecve and is not associated with risk of mood destabilizaon and is well tolerated. Hence, pregabalin would be considered
an appropriate opon although this has not been tested in BD populaon with co-morbid anxiety. Lorazepam also does not cause mood
instability but given the potenal dependence with longer-term use, only short-term use of lorazepam may be appropriate.  In the case of
andepressants, especially with SNRIs, the risk of manic/hypomanic switch is likely higher. Therefore, if andepressants are being
considered for treang anxiety symptoms, it is recommended to primarily use SSRIs. Further, if SSRIs are used, it is important to ensure
adequate mood stabilizaon with one or more prophylacc anmanic agents (eg. lithium or divalproex or an atypical anpsychoc).
Lorazepam and clonazepam do not provoke mood instability, they are rapidly effecve for the acute management of anxiety and they may
address early warning signs of mania by inducing sleep. While inappropriate prescribing may result in misuse and dependence and cauon
must be exercised when prescribing benzodiazepines to elderly paents in parcular, the use of benzodiazepines may be appropriate for
treang anxiety associated with bipolar disorder. Short-term use is desirable but some paents are unable to tolerate other anxiety
treatments and experience significant symptomac relief and funconal improvement due to the judicious use of benzodiazepines. 
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been reported to co- occur more commonly with BD than other anxiety 
disorders,735 although other studies have not found that association.736
When diagnosed comorbidly with BD, OCD has been associated 
with an earlier onset of BD, a higher number of previous mood episodes, 
rapid cycling, seasonality, substance misuse, and lower overall function-
ing.732,737-742 Jeon et al recently conducted a comprehensive review of 
patients diagnosed with BD and comorbid OCD and found twice the 
rate of pharmacological switch to mania or hypomania, but suggested 
this could be due to the more frequent use of antidepressants in that 
population.732 Other authors have raised similar concerns.743
Symptoms of OCD may precede or follow mood symptoms and the 
severity of OCD symptoms tends to fluctuate with mood changes.744 
The high rate of co- occurrence and the many shared clinical features 
of OCD and BD suggest a shared neurobiology. Some researchers 
have posited that the high rate of co- occurrence might reflect a dis-
tinct bipolar phenotype rather than separate disorders.736,745
OCD symptoms may remit during effective treatment of BD; mood 
stabilizers alone or with atypical antipsychotics may be adequate to 
resolve comorbid symptoms of OCD and antidepressants might not 
be necessary for the majority of patients.730,736 If antidepressants 
are used, clinical experience suggests that SSRIs are preferred, but 
because of the potential risk of manic switch clinicians need to op-
timize prophylactic antimanic agents before initiation. The CANMAT 
Task Force 2012 report included several small case reports indicating 
the potential benefit of lithium,743 anticonvulsants,743,746 olanzap-
ine,747,748 risperidone,749,750 quetiapine751 and aripiprazole 752 for the 
treatment of comorbid OCD (all level 4 evidence).
Since the 2012 CANMAT publication, there has been very limited 
new evidence regarding the treatment of comorbid BD and OCD. Two 
published case reports described successfully employing aripiprazole 
once monthly753 and orally754 for patients with intractable bipolar and 
OCD symptoms. Another case report described benefits of ECT,755 and 
a small trial also found benefits with adjunctive topiramate (level 3).756
Personality disorders
A meta- analysis indicates that 42% of patients with BD also have 
a comorbid personality disorder, and this feature can be both a di-
agnostic confound and predictor of poorer treatment response. 
The most prevalent was obsessive compulsive personality disorder 
(18%), followed by borderline (16%), avoidant (12%) paranoid (11%), 
and histrionic (10%) personality disorders.757 Despite the high preva-
lence of these comorbidities, research assessing the effectiveness 
of treatments is sparse. The CANMAT Task Force recommendations 
describe key issues in the management of personality disorders, in-
cluding the relationship between personality and mood disorders, 
accurate diagnosis, and the effect on treatment response and clinical 
course.758
The 2012 CANMAT Task Force recommendations for comorbid 
personality disorder concluded that divalproex (level 3)466 and lamo-
trigine (level 4)759 may provide some symptomatic relief for comorbid 
borderline personality disorder. Psychoeducation might be of value, 
as one small RCT that included patients with any comorbid personal-
ity disorder (level 3)760 demonstrated. That study, along with another 
small trial that combined psychoeducation and skills training for pa-
tients with a mood disorder plus a personality disorder and suicidal 
ideation (level 3),761 showed a modest long- term benefit. Larger, more 
specific studies are needed. There are also data to support the utility 
of DBT for the treatment of BD, which has robust data for efficacy in 
the treatment of borderline personality disorder.75,762,763
Since those CANMAT recommendations were published in 2012, 
few new studies have significantly contributed to our understand-
ing of the appropriate treatment of these highly comorbid disorders. 
Alesiani and colleagues assessed the value of the Systems Training for 
Emotional Predictability and Problem Solving (STEPPS) program for 32 
subjects with personality disorder and mood disorder (half MDD and 
half BD, mostly BDII), and a history of suicide attempts or self- harm 
and emotional and behavioural dysregulation. Although results are 
preliminary due to small sample size and high drop- out rate, findings 
suggest that such group treatment may improve symptoms, as well as 
reduce suicide attempts and hospitalizations.761
ADHD
ADHD and BD co- occur far more commonly than would be expected 
based on their individual prevalences in the general population. 
Approximately 10%- 20% of patients with BD meet the criteria for 
adult ADHD and up to 20% of adults with ADHD also meet the cri-
teria for BD.764 BD and ADHD have a high degree of symptom over-
lap, making the comorbid diagnosis difficult and requiring careful 
attention to childhood history and lifetime course of illness. Patients 
with comorbid ADHD often experience a more treatment- refractory 
course, more mood episodes, greater functional impairment and a 
heightened risk of suicide.765
The treatment of ADHD presenting comorbidity with BD is dis-
cussed in detail in a previous CANMAT Task Force Recommendation 
paper.765 Recommendations were to treat bipolar symptoms first with 
mood stabilizers and/or atypical antipsychotics to stabilize mood be-
fore considering treatment for ADHD symptoms. Mixed amphetamine 
salts (level 3),611 methylphenidate (level 3),612 atomoxetine (level 4),615 
bupropion (level 4),766 or lisdexamfetamine (level 4)767 add- ons to 
mood- stabilizing treatments have been reported to be efficacious in 
improving ADHD symptoms.
In a s Swedish national patient registry study of patients with BD 
and ADHD, methylphenidate monotherapy significantly increased the 
risk of mania, while those patients treated concurrently with a mood 




While there is consistent evidence showing the high prevalence of comor-
bid medical conditions in BD768-774 and the negative impact these diagno-
ses have on longevity,775,776 these conditions frequently go undiagnosed 
or undertreated. In a large UK cross- sectional analysis of electronic data 
sets involving 1.7 million patients in primary care, those diagnosed with 
BD, when compared with healthy controls, had lower rates of diagnoses 
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(odds ratio [OR] 0.59, 95% confidence interval [CI] 0.54- 0.63) and treat-
ment of medical conditions, despite higher rates of one (OR 1.2, 95% CI 
1.16- 1.39) or multiple illnesses (OR 1.44, 95% CI 1.3- 1.64).769
Metabolic syndrome in particular is a highly prevalent comorbidity, 
present in 20- 65% of patients with BD.777 Defined as a cluster of clin-
ical and biochemical features, including abdominal adiposity, hyper-
tension, impaired fasting glucose, diabetes mellitus, and atherogenic 
dyslipidaemia,778 metabolic syndrome not only greatly increases an 
individual’s risk for cardiovascular disease, diabetes mellitus, and pre-
mature mortality779 but also worsens bipolar clinical outcomes.780,781 
Increased body mass index (BMI) is an important contributor to met-
abolic syndrome, although metabolic dysfunction is not always ac-
companied by overweight/obesity, and so patients with normal BMI 
should also receive regular monitoring (Section 8).
It has been hypothesized that BD and metabolic syndrome share 
a set of common risk factors and overlapping pathophysiology.782-784 
While medications used to treat BD, particularly atypical antipsy-
chotics, can also lead to metabolic dysfunction and weight problems 
(Section 8), insufficient access to primary and preventative health care, 
low socioeconomic status, habitual inactivity, insulin dysfunction, pe-
ripheral inflammation and neuroinflammation, oxidative stress, and 
childhood adversity are also important contributors.785
Principles of management
As noted in previously in these guidelines, older adults commonly have 
three or more medical comorbidities that contribute to the 10- 15 year 
lower life expectancy compared to non- psychiatric populations.642 
The most common medical comorbidities are metabolic syndrome, 
hypertension, diabetes, cardiovascular disease, arthritis, and endo-
crine disorders.631,641 This highlights the necessity for vigilance when 
treating all patients with BD, including regular assessments of their 
metabolic parameters.
Working collaboratively with other members of a patient’s health 
care team is as essential aspect of good clinical care. Comprehensive 
management of comorbid medical conditions should include a mul-
tidisciplinary team- based approach, including primary care, medical 
specialists, nurses, psychologists, and social workers as appropriate, 
with patients taking an active role in their care. Treatment strategies 
should focus both on the psychiatric symptoms and medical issues and 
risk factors.
A promising strategy for improving the medical care of people with 
BD is through “primary care- based medical homes” where those with 
a serious mental illness and at least one other chronic condition re-
ceive integrated care. While most studies do not separate BD from 
other major mental illnesses in analyses, matched samples in the North 
Carolina Medical Homes programme indicate that patients with BD 
(n = 13 406) in primary care medical homes had greater use of primary 
care and specialty mental health care compared with propensity- 
matched controls, and marginally lower use of emergency services. 
However, of three diagnostic groups studied (depression, schizo-
phrenia and BD), use of preventative services such as lipid screening 
and cancer screening was only greater in the subgroup with depres-
sion.786 At the same time, a cross- sectional Canadian study examin-
ing patient- centred medical homes in naturalistic practice found that, 
where rostering was elective, individuals with BD and psychosis were 
differentially excluded (relative risk [RR] 0.92, 95% CI 0.90- 0.93),787 
suggesting that concentrated efforts should be made to ensure appro-
priate access to these services.
Treatment recommendations
Treatment strategies that target metabolic disorders should include 
non- pharmacological lifestyle interventions. Replacing “high metabolic 
risk” psychiatric medications with medications that have a more fa-
vourable profile is highly recommended if the therapeutic advantage 
of the high- risk agent over the alternative is minimal and metabolic/
weight issues persist. Bariatric surgery should be considered following 
unsuccessful attempts at the aforementioned strategies if the individ-
ual	has	a	BMI	≥27	with	weight-	related	morbidity	or	a	BMI	≥30	without	
significant metabolic morbidity. Readers are referred to the CANMAT 
Task Force report785 for further detailed discussion on foundational 
principles for managing metabolic conditions in patients with BD.
While there is no evidence specifically regarding treatment of 
comorbid dyslipidaemia or hypertension in BD, it is noteworthy that 
many of the medications used to manage these comorbid medical dis-
orders have epidemiological or even clinical trial evidence that they 
may benefit mood. Examples include statins, aspirin and angioten-
sin antagonists.788-793 The implications are that clinicians should be 
actively engaged in the management of these disorders, and should 
select therapies from those agents that may have benefit in mood 
symptoms. This again is concordant with the notion of shared risk 
pathways for these non- communicable disorders.









Prothrombin time and partial thromboplastin time
Urinalysis
Urine toxicology for substance use
Serum creatinine
eGFR
24h creatinine clearance (if history of renal disease)
Thyroid- stimulating hormone
Electrocardiogram (>40 years or if indicated)
Pregnancy test (if relevant)
Prolactin
CBC, complete blood count; eGFR, estimated glomerular filtration rate; 
HDL, high- density lipoprotein; LDL, low- density lipoprotein; TC, total cho-
lesterol; TG, triglyceride; vLDL, very low density lipoprotein (Adapted from 
Yatham et al. 20062).
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7.4.3 | Other comorbid medical conditions
Two studies from a random sample of 1 million people, taken from a 
large population- based retrospective cohort in Taiwan, demonstrated 
a reduced risk of both stroke and cancer associated with lithium 
treatment for BD. The lithium group was compared with propensity- 
matched controls.
The first study reported hazard ratio for stroke over 11 years of 
0.39 (95% CI 0.22- 0.68) for those prescribed lithium, even when ad-
justing for the risks associated with typical and atypical antipsychot-
ics. The reduced risk was also correlated with a higher dose, longer 
treatment duration and a higher rate of exposure to lithium.794 In the 
second study, in a sample of 4729 patients diagnosed with BD, lith-
ium exposure was associated with a reduced risk of cancer, compared 
to a group prescribed anticonvulsant medications. (Lithium with or 
without anticonvulsant HR = 0.735, 95% CI 0.55- 0.97). The study 
also demonstrated a dose- response relationship.795 In a subsequent 
large BD cohort study (n = 9651) focusing on genitourinary cancer, 
however, lithium was not associated with any change in risk.796
A recent meta- analysis suggests increased risk of dementia in 
BD.797 There is some evidence that lithium in drinking water reduces 
the risk of dementia in the general population638 as does the use of 
lithium in patients with BD.798
8 | SAFETY AND MONITORING
8.1 | Medical evaluation and laboratory 
investigations
A complete medical history including assessment of BMI and base-
line laboratory investigations (Table 23) should be performed prior 
to initiating pharmacological treatment for BD or, in the case of an 
acute clinical situation, as soon as the patient is cooperative. For 
more detail, readers are referred to comprehensive guidelines for 
safety monitoring in BD.652 In women of childbearing age, preg-
nancy should be ruled out, and they should be counselled about 
the possibility of lamotrigine and carbamazepine affecting the ef-
ficacy of oral contraceptives before initiating pharmacotherapy.
For those on maintenance therapy with lithium, thyroid and 
renal function as well as plasma calcium799 should be assessed at 
6 months and at least annually thereafter or as clinically indicated. 
Menstrual history (to assess for polycystic ovary syndrome), hae-
matology profile, and liver function tests should be obtained at 
3- 6 month intervals during the first year, and yearly thereafter 
and as clinically indicated, in patients on maintenance treatment 
with divalproex. Patients initiated on lamotrigine or carbamazepine 
should be routinely educated about the risks of skin rashes and the 
potential for Stevens- Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN). They should be advised to contact the treating 
physician if they observe any type of skin rashes or mucosal ulcers 
as they require urgent medical evaluation to determine the nature 
of rashes/ulcers and implementation of most appropriate treatment 
options which might include discontinuation of these medications 
and instituting other therapeutic strategies to treat serious rashes 
and prevent destabilization of BD. Further, prior to commencing 
carbamazepine, patients with ancestry in genetically at- risk popu-
lations such as Han Chinese and other Asian patients should have 
genotyping performed to ensure that they do not have the human 
leucocyte antigen (HLA)- B*1502 allele, which confers a high risk for 
SJS/TEN with carbamazepine.800 In addition, those on carbamaze-
pine therapy should have serum sodium levels measured at least an-
nually and as clinically indicated given the risk of hyponatraemia with 
this compound. Patients on atypical antipsychotics should have their 
weight monitored monthly in the first 3 months and every 3 months 
thereafter. Blood pressure, fasting glucose and lipid profile should 
be assessed at 3 and 6 months, and yearly thereafter. Children under 
10 years of age, seniors, medically ill patients, and patients on com-
bination treatments should receive more frequent monitoring. Re- 
emergence of clinical symptoms, as well as signs of haematological, 
hepatic, cardiovascular, and neurological dysfunction, should also 
signal the need for additional investigations.
Patients receiving treatment should be regularly monitored for 
side effects, including weight changes and other adverse events such 
as extrapyramidal symptoms (EPS).
8.2 | Monitoring medication serum levels
Patients on lithium, divalproex, or carbamazepine need to have 
their serum medication levels monitored regularly. This is particu-
larly important for those who may be non- adherent to treatment. 
Measurement of serum levels should be repeated at the trough point, 
which is approximately 12 h after the last dose. It is recommended 
that two consecutive serum levels be established in the therapeutic 
range during the acute phase for lithium and divalproex, and then 
measurement be repeated every 3- 6 months or more frequently if 
clinically indicated. For carbamazepine, serum level monitoring is 
mainly done to ensure that the levels are not in the toxic range and 
to check for treatment adherence as there is no established relation-
ship between efficacy and serum level; thus, monitoring for serum 
carbamazepine levels may be done at 6- 12 monthly intervals and as 
clinically indicated.
The target serum level for lithium in acute treatment is 0.8- 
1.2 mEq/L (0.4- 0.8 mEq/L in older adults) while in maintenance treat-
ment, serum levels of 0.6- 1 mEq/L may be sufficient801,802; serum 
levels should be obtained about 5 days after the most recent dose 
titration. Clinicians may wish to consult the “lithiumeter” schematic 
for further guidance.803 It is important to avoid toxic levels as these 
are associated with an increased risk of kidney damage in the long 
term.804 The target serum level for divalproex is 350- 700 mM/L (50- 
100 ug/mL) in the acute phase and should be obtained 3- 5 days after 
the most recent dose titration. There is some evidence for a linear re-
lationship between serum divalproex level and therapeutic efficacy in 
acute mania, with higher levels associated with greater efficacy.805 It is 
currently unknown what levels of divalproex offer optimum efficacy in 
maintenance treatment as no study to date has systematically assessed 
the relationship between serum divalproex level and the maintenance 
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efficacy. Therefore, clinician are advised to maintain serum divalproex 
levels within the accepted laboratory range values during maintenance 
treatment and carefully monitor patients for emerging mood symp-
toms and tolerability and adjust the dose of divalproex as needed in 
order to achieve optimum efficacy and tolerability.
Patients who are treated with concurrent carbamazepine or other 
hepatic enzyme- inducing agents should have serum levels of all psy-
chotropic medications monitored, particularly in cases of inadequate 
response or non- response, to determine whether efficacy has been 
compromised because of reduced serum levels.
TABLE  24 Safety/tolerability concerns and risks of treatment- emergent switch with pharmacological agents indicated for use in bipolar 
disorder
Safety concerns Tolerability concerns Risk of treatment emergent switch
Acute Maintenance Acute Maintenance Mania/hypomania Depression
Lithium + ++ + ++ − −
Anticonvulsants
Carbamazepine ++ ++a + ++ − −
Divalproex − ++a + + − −
Gabapentin − − + + − −
Oxcarbazepine + + + + − −
Lamotrigine ++ − − − − −
Atypical antipsychotics
Aripiprazole − − + + − −
Asenapine − − + + − −
Cariprazine − − + − − −
Clozapine ++ +++ ++ +++ − −
Lurasidone − − + + − −
Olanzapine + +++ ++ ++ − −
Paliperidone − + + ++ − −
Quetiapine + ++ ++ ++ − −
Risperidone − + + ++ − −
Ziprasidone ++ ++ ++ + − −
Conventional antipsychotics
Haloperidol + +++ ++ ++ − ++
Loxapine + + + + − nk
Antidepressants (adjunctiveb)
Agomelatine + − − − + −
Bupropion + − + − + −
Ketamine IV ++ nk ++ nk nk nk
MAOIs ++ ++ + ++ ++ −
SNRIs − + + − ++ −
SSRIs − − + + + −
TCAs ++ ++ ++ ++ +++ −
Stimulants
Amphetamines − ++ + − +++ −
Modafinil − − − − ++ nk
Dopamine agonists
Pramipexole − + − − ++ nk
MAOIs, monoamine oxidase inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic 
antidepressants.
−,	limited	impact	on	treatment	selection;	+,	minor	impact	on	treatment	selection;	++,	moderate	impact	on	treatment	selection;	+++,	significant	impact	on	
treatment selection; nk, not known.
adivalproex and carbamazepine should be used cautiously in women of child bearing age (Section 7).
bAntidepressant monotherapy is not recommended in bipolar I disorder; for more information on bipolar II disorder, see Section 6.
144  |     YATHAM eT Al.
8.3 | Safety and tolerability of pharmacotherapy
Safety and tolerability issues, in addition to efficacy data, have been 
considered when determining recommendations for each phase of 
illness. The most notable concerns are described below and a sum-
mary of their potential impact on treatment selection is included in 
Table 24, as well as in treatment hierarchy tables in Sections 2- 4. As 
medication side effects are an important contributor to medication 
non- adherence, these potential concerns should be discussed with 
patients receiving or considering treatment with various agents to 
help inform decision making.
8.3.1 | Weight gain
As described in Section 6, despite normal weight at illness onset,806 
it is common for patients with BD to become overweight or obese, 
and several medications used to treat the illness may also exacer-
bate this effect. The likelihood of medications to cause weight gain 
should be carefully considered, as this is one of the most frequent 
treatment- related factors of non- adherence; contributing to upwards 
of 60% of cases.807 The medications most commonly associated with 
weight gain are olanzapine, clozapine, risperidone, quetiapine, gabap-
entin, divalproex and lithium; with carbamazepine, lamotrigine, and 
ziprasidone being the safer or options associated with less weight 
gain.808 Recent reviews further suggest that asenapine and aripipra-
zole (longer term use) 809 also may lead to weight gain, but the impact 
of lurasidone on weight is minimal.810 All patients should be regularly 
monitored for weight changes.
8.3.2 | Gastrointestinal symptoms
Both lithium and divalproex are commonly associated with nausea, 
vomiting, and diarrhoea, with 35%- 45% of patient experiencing these 
side effects.372,811 For lithium, this is particularly pronounced during 
treatment initiation, or rapid dose increases.812 Gradual dose titra-
tion, taking the medication at bedtime, taking medications with food, 
and slow release preparations may reduce nausea and other side 
effects.813
8.3.3 | Renal toxicity
Lithium has a well- recognized potential for renal toxicity, includ-
ing nephrogenic diabetes insipidus (NDI), chronic tubulointersti-
tial nephropathy, and acute tubular necrosis, with NDI reported 
in 20%- 40% of patients.814-816 Upwards of 70% of patients on 
chronic lithium treatment will experience polyuria, which can 
cause impairment in work and daily functioning. This side effect 
is commonly underreported, unless it is directly inquired about.817 
Long- term administration (ie, 10- 20+ years) is further associated 
with decreased glomerular filtration rate and chronic kidney dis-
ease.818 While long- term lithium administration is probably an 
important risk factor for developing chronic kidney disease, fac-
tors that may increase susceptibility include higher plasma lithium 
levels, multiple daily lithium doses (vs once daily), concurrent 
medications (eg NSAIDs, ARBs, ACEIs and diuretics), somatic ill-
nesses (eg, hypertension, diabetes mellitus and coronary artery 
disease) and older age.819,820 Instances of lithium toxicity will 
also greatly increase risk of renal dysfunction.821 Lithium use is 
associated with a two- fold higher risk of chronic kidney disease 
in older adults (>66 years).822 While the overall risk for progres-
sive renal failure is low, plasma creatinine concentrations and ide-
ally estimated glomerular filtration rate (eGFR) for these patients 
should be measured at least every 3- 6 months.652 Since 37% of 
patients aged >70 years have an eGFR <60 mL/min per 1.73 m2,823 
a strict eGFR cut- off for lithium discontinuation is difficult. The UK 
National Institute for Healthcare and Excellence (NICE) guidelines 
for chronic kidney disease (CKD) recommend nephrologist consul-
tation if there is rapidly declining eGFR (>5 mL/min per 1.73 m2 
in 1 year, or >10 mL/min per 1.73 m2 within 5 years), if the eGFR 
falls below 45 in two consecutive readings, or if the clinician is 
concerned.646,824
Because of its narrow therapeutic window, acute lithium intoxica-
tion is also a complication, which, though reversible, can lead to reduc-
tions in glomerular filtration rate.825,826 Drugs that alter renal function 
and general medical conditions characterized by decreased circulating 
volume all contribute to increased risk.827
8.3.4 | Haematological effects
Carbamazepine may be a risk factor for leucopenia,828-830 although 
this finding is not robust.831 This side effect is generally reversible 
with dose reduction or discontinuation. There is also some concern 
about rapidly developing bone marrow suppression resulting from hy-
persensitivity, particularly in older patients.831,832
Clozapine carries the greatest risk for drug- induced changes in 
white blood cell counts, with approximately 0.18% of patients expe-
riencing changes rated as probably or definitely drug induced.828 All 
patients started on clozapine should have a baseline haematological 
profile established and be enrolled in the clozapine monitoring pro-
gramme which requires regular monitoring of haematological param-
eters: weekly at first and then every 2- 4 weeks later in the course of 
treatment.833
8.3.5 | Cardiovascular effects
Lithium can increase the risk of abnormal QT prolongation or T- wave 
abnormalities,834 an impact more pronounced with age, as almost 
60% of older patients on lithium maintenance therapy have ECG 
abnormalities.835 Several antipsychotics, including risperidone, olan-
zapine, ziprasidone and asenapine, are also associated with arrhyth-
mias, QTc prolongation, and other cardiovascular adverse events. 
Clozapine may increase the risk of several rare but serious events 
such as dilated cardiomyopathy, myocarditis, and pericarditis. Of the 
antipsychotics, lurasidone and aripiprazole are considered safe from 
a cardiac perspective, although aripiprazole may increase the risk for 
hypotension.810
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8.3.6 | Endocrine effects
There is also a strong link between lithium maintenance treatment 
and hypothyroidism, which is also associated with increased risk of 
affective episodes, rapid cycling, and more severe depression.836,837 
Routine screening of thyroid function is therefore recommended for 
all patients on lithium treatment. Since lithium can also cause hy-
perparathyroidism, routine monitoring for serum calcium is recom-
mended, and, if elevated, further investigations should be performed 
to evaluate for hyperparathyroidisim.838 Hypothyroidism is ordinarily 
not an indication for lithium cessation in a patient with a good re-
sponse; rather, thyroid supplementation is recommended.
New onset oligomenorrhoea or hyperandronism is more common in 
divalproex users.839 While there are reports of an increased incidence 
of polycystic ovary syndrome (PCOS) in divalproex treatment, a recent 
meta- analysis did not support this.840 In those who develop PCOS on 
divalproex, there is evidence from a small sample that discontinuing 
divalproex results in remission of some of the aspects of PCOS.841
Hyperprolactinaemia is common with some antipsychotics, and 
can have short- term and long- term adverse effects. Risperidone, ami-
sulpride and paliperidone are more likely than other compounds to 
cause it.842 Hyperprolactinaemia can induce amenorrhoea, sexual dys-
function, and galactorrhoea, amongst other effects. In the long term, 
it can cause gynaecomastia and osteoporosis.843 When such effects 
are seen, it may advisable to reduce the dose or switch to a different 
medication.844
8.3.7 | Cognition
While many patients experience cognitive impairment, these deficits 
may be attributable to the disease itself, with more pronounced effects 
in those with more severe or chronic illness.845 While a small study has 
led to suggestions that medicated patients who are euthymic do per-
form similarly to those not receiving treatment,846 other naturalistic tri-
als point towards the potential negative impact of several medications, 
with the effects of antipsychotics being the most significant.845 Lithium 
can also lead to impairment in processing speed and memory, which 
patients may find distressing,847 although recent randomized con-
trolled data suggest lithium is superior to quetiapine in this regard.329 
Indeed, the effects of lithium on neurocognition are complex and fur-
ther research is needed to fully elucidate its neurocognitive impact.848 
Anticonvulsants, except for lamotrigine, are also linked to subjective 
cognitive impairment.847 Given the importance of cognition on a pa-
tient’s function and quality of life, further studies are needed in this area.
8.3.8 | Sedation
Sedation is a concern for many, and is reported by over half of patients 
as a reason for treatment non- adherence.807 Divalproex and atypical 
antipsychotics are most likely to lead to these effects, with 30%- 50% 
of patients on atypical antipsychotics experiencing sedation, com-
pared to 8%- 13% with placebo164,214,849-851 and 21%- 29% of patients 
on divalproex.852,853 This is not a concern with all antipsychotics, 
however; quetiapine, clozapine, and olanzapine will generally have 
higher rates of sedation compared to ziprasidone, risperidone, and ari-
piprazole.810 Lamotrigine and lithium have both been found to be less 
likely to cause sedation than divalproex.854,855
8.3.9 | Neurological effects, including EPS
Tremor can be a significant cause of frustration for many patients, 
and is experienced by up to 10% of those treated with lithium or di-
valproex.668,856,857 New onset neurological symptoms in patients on 
divalproex should raise suspicion of hyperammonaemic encephalopa-
thy, which, while rare, can be potentially fatal, and hence early detec-
tion and discontinuation of divalproex is critical to prevent morbidity 
and mortality858 Sustained release formulations and dose reductions 
may limit symptoms.802,859,860 While conventional antipsychotics such 
as haloperidol are often associated with EPS (including pseudoparkin-
sonism, akathisia, acute dystonia, and tardive dyskinesia),861 this risk is 
either absent or low with atypical antipsychotic agents.862,863 Among 
the atypical agents, risperidone, aripiprazole, cariprazine, ziprasidone 
and lurasidone are more likely to cause EPS, particularly at higher 
doses.810 In older patients, impaired swallowing function and dys-
phagia have also been linked to atypical agents, particularly at higher 
doses.864,865
Although rare, neuroleptic malignant syndrome (NMS) is a po-
tentially life- threatening adverse event associated with antipsychotic 
agents. The risk with atypical agents was considered negligible ini-
tially; however, while the risk is very low, several atypical agents have 
nevertheless been associated with NMS.866 While generally unpre-
dictable, the risk is greatest during the initial phase of treatment or 
change of dosage, with intravenous or intramuscular administration, 
with high dosages or polypharmacy, when the patient is physically 
restrained or dehydrated, in high ambient temperatures, in older 
patients and in patients with medical or psychiatric comorbidities. 
Patients with a previous history of NMS and/or a personal or family 
history of catatonia are also at higher risk.867 Antipsychotics may also 
impact thermoregulation, with case studies indicating the potential 
for both heat- related illnesses868 and hypothermia869; thus, patients 
should be made aware and monitored for these risks during periods 
of extreme temperatures.
8.3.10 | Dermatological reactions
Approximately 10% of patients being treated with lamotrigine will expe-
rience a non- serious rash, with 0.3%- 1% developing a serious rash such 
as toxic epidermal necrolysis and SJS,870 although for those initiated on 
a dose of 25 mg with a gradual titration increasing the dose by 25 mg 
biweekly, the risk of developing serious rash may be as low as 0.02% 
or 1 in 5000.871 In some cases, an even lower rate of titration may be 
used (ie 12.5 mg/day and then gradually increase as per instructions. 
Carbamazepine is also associated with increased risk of rash and SJS, 
especially in the first 8 weeks of therapy,872 although the baseline risk 
is extremely low. Similarly, while these can also occur with divalproex, 
the risk is extremely low. Nevertheless, it is important that patients be 
146  |     YATHAM eT Al.
informed of these risks and told to report any rash immediately, and 
these treatments should be discontinued if a serious rash is suspected.
Lithium is also linked with a variety of potentially distressing skin 
conditions, including acne, psoriasis, eczema, hair loss, hidradenitis 
suppurativa, nail dystrophy and mucosal lesions, with overall estimates 
ranging from 3% to 45% depending on the criteria applied. Most cases 
can be managed without treatment discontinuation.873
8.3.11 | Metabolic syndrome, hyperglycaemia, type 
2 diabetes and dyslipidaemia
As described in Section 6, patients with BD are already at elevated 
risk for these physical illnesses and this risk is further exacerbated by 
some atypical antipsychotic agents and mood stabilizers. Clozapine 
and olanzapine are associated with the greatest level of risk, followed 
by quetiapine (particularly in higher doses) and risperidone, with a 
more minimal impact of aripiprazole, ziprasidone, asenapine, and lu-
rasidone.810 Lithium and divalproex are also associated with weight 
gain.791 All patients on atypical antipsychotics should be monitored 
for changes in blood glucose and lipid profiles as indicated previously 
in this section, and if disturbances are detected, the atypical antipsy-
chotic should be discontinued if possible and appropriate treatment 
initiated if necessary.
8.3.12 | Fracture risk and osteoporosis
Some anticonvulsants, antidepressants, and antipsychotics may de-
crease bone mineral density and increase the risk of fracture in high- 
risk patients.874,875 This risk is increased by the presence of mood 
disorders, as well as known risks for mood disorders such as physical 
inactivity, smoking and poor diet quality.876 Thus, screening for this 
population may be indicated.877
9 | CONCLUDING REMARKS
The diagnosis and management of BD is complex, and effective, 
evidence- based care requires knowledge of current research as well 
as lessons gained from years of clinical experience. Members of the 
CANMAT guidelines committee hope this document does an effec-
tive job at providing an easy to understand narrative of both, thus 
aiding both specialists and primary care providers in delivering 
evidence- based care to their patients. As with previous editions of 
these guidelines, CANMAT will strive to provide regular updates cap-
turing emerging trends and evaluating new evidence; and readers are 
encouraged to consult those as they become available to stay up to 
date in the field.
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